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ABSTRACT 
 
ALEXIS WELLS CARPENTER: Synthesis of Hybrid Inorganic/Organic  
Nitric Oxide-Releasing Silica Nanoparticles for Biomedical Applications 
(Under the direction of Professor Mark H. Schoenfisch) 
 
 
 Nitric oxide (NO) is an endogenously produced free radical involved in a number of 
physiological processes.  Thus, much research has focused on developing scaffolds that store 
and deliver exogenous NO.  Herein, the synthesis of N-diazeniumdiolate-modified silica 
nanoparticles of various physical and chemical properties for biomedical applications is 
presented.    
 To further develop NO-releasing silica particles for antimicrobial applications, a 
reverse microemulsion synthesis was designed to achieve nanoparticles of distinct sizes and 
similar NO release characteristics.  Decreasing scaffold size resulted in improved bactericidal 
activity against Pseudomonas aeruginosa.  Confocal microscopy revealed that the improved 
efficacy resulted from faster particle-bacterium association kinetics.   
 To broaden the therapeutic potential of NO-releasing silica particles, strategies to tune 
NO release characteristics were evaluated.  Initially, surface hydrophobicity and NO release 
kinetics were tuned by grafting hydrocarbon- and fluorocarbon-based silanes onto the surface 
of N-diazeniumdiolate-modified particles.  The addition of fluorocarbons resulted in a 10x 
increase in the NO release half-life.  The addition of short-chained hydrocarbons to the 
particle surface increased their stability in hydrophobic electrospun polyurethanes.  Although 
NO release kinetics were longer than that of unmodified particles, durations were still limited
  iii 
to <7 days.  
An alternative strategy for increasing NO release duration involved directly 
stabilizing the N-diazeniumdiolate using O2-protecting groups.  O2-Methoxymethyl 1-(4-(3-
(trimethoxysilyl)propyl))piperazin-1-yl)diazen-1-ium-1,2-diolate (MOM-Pip/NO) was 
grafted onto mesoporous silica nanoparticles to yield scaffolds with an NO payload of 2.5 
µmol NO/mg and an NO release half-life of 23 d.  Doping the MOM-Pip/NO-modified 
particles into resin composites yielded antibacterial NO-releasing dental restorative materials.  
A 3-log reduction in viable adhered Streptococcus mutans was observed with the MOM-
Pip/NO-doped composites compared to undoped controls.   
The greater chemical flexibility of macromolecular scaffolds is a major advantage 
over LMW NO donors as it allows for the incorporation of multiple functionalities onto a 
single scaffold.  To demonstrate this advantage, dual functional particles were synthesized by 
covalently binding quaternary ammonium (QA) functionalities to the surface of NO-releasing 
silica particles.  The QA functionality proved more effective against Staphylococcus aureus 
than P. aeruginosa, and increasing alkyl chain length correlated with increased efficacy.  
Nitric oxide-releasing QA-functionalized particles were found to be more effective against S. 
aureus compared to monofunctional particles. 
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Chapter 1: 
Designing Silica Particles for the Delivery of Therapeutic Nitric Oxide  
  A wide range of nitric oxide (NO)-releasing materials have emerged as potential 
therapeutics  that  exploit  NO’s  vast  biological  roles.    Macromolecular scaffolds, such as silica 
nanoparticles, are particularly promising due to their ability to store and deliver larger NO 
payloads in a more controlled and effective manner compared to low molecular weight NO 
donors.  In this introductory chapter, the synthesis and design of silica particles for drug 
delivery is presented, followed by a discussion on the development of NO-releasing silica 
nanoparticles for therapeutic applications.  
 
1.1  Overview of silica nanoparticles for drug delivery 
  Over the past forty years, nanotechnology has revolutionized scientific research, 
impacting the world in ways that parallel the development of electricity, biotechnology and 
digital information.1  Drawn by the fascinating properties exhibited by materials in the 
nanometer regime (≤100 nm), research in nearly all area of science have directed some focus 
into using nanotechnology.  Drug delivery in particular has benefited from the use of 
nanomaterials as nanomedicine is poised to significantly change the future of healthcare and 
disease treatment.2  
Silica-based nanoparticles represent a significant area in nanomedicine research.3-5 
Although silica does not adopt exceptionally different properties on the nanoscale, its wide-
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spread use arises from well-defined and tunable structures that can be tailored towards a 
desired therapeutic application.  Indeed, any number of functionalities may be incorporated 
into the silica network through facile sol–gel chemistry.  Physical properties such as particle 
size, shape, and porosity can also be easily tuned, allowing researchers to investigate their 
influence on drug delivery (e.g., cellular uptake, clearance/fate, and aggregation).  
Furthermore, silica’s inherent biocompatibility and water-solubility provide two distinct 
advantages when designing practical drug delivery scaffolds.  
  
1.1.1  Sol–gel chemistry  
The sol–gel process to form silica-based materials involves the hydrolysis and 
condensation of silane precursors to form a solid network.6  In basic conditions, hydrolysis 
occurs with the displacement of a labile ligand on the silicon atom by a hydroxyl ion (Figure 
1.1A).  The hydrolyzed monomer then undergoes a condensation reaction with a second 
hydrolyzed molecule to form a siloxane bond (Figure 1.1B).  Hydrolysis and condensation 
continue, forming a colloidal suspension (sol) that cross-links to form a solid network 
suspended in a continuous liquid phase (gel).  Depending on the reaction conditions, the 
condensed products resulting from the sol–gel process can range from highly porous, 
nanocrystalline materials to dense amorphous networks.  In addition to synthetic control, 
other advantages of sol–gel chemistry include mild reaction conditions, low-temperature 
preparation, and easy purification.7   
The type of material that results from sol–gel processing is dependent on the type of 
precursor and the pH of the reaction.  Precursors can be mono-, bi-, tri- or tetrafunctional 
based on the number of hydrolyzable ligands present (Figure 1.2).  Silanes where one or
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Figure 1.1  (A) Hydrolysis and (B) condensation reactions involved in the sol–gel process 
under basic conditions.   
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more of the hydrolyzable groups have been replaced with a non-hydrolyzable organic ligand 
are called organosilanes.  The substituents on the central silicon atom govern the rate of 
hydrolysis and condensation through both steric and inductive effects.  Larger or branched 
ligands hinder the access of nucleophiles to the silicon atom, thereby slowing the rate of 
hydrolysis.  The incorporation of an electron-donating alkyl group also contributes to slower 
hydrolysis as the central silicon atom has a higher electron density and is therefore less 
electrophilic.   
An acid or base catalyst is used to promote hydrolysis and condensation as well as 
govern the structure of the condensed product.6  In acid-catalyzed reactions, the rates of 
hydrolysis are fast and the rates of condensation are slow.  Acidic conditions with low water 
to silane ratios favor the formation of linear and branched polymers that interpenetrate with 
each other to form films.  Alternatively, base-catalyzed sol–gel reactions with high water to 
silane ratios promote slow rates of hydrolysis and rapid condensation, leading to highly 
branched clusters that do not entangle.  The preparation of silica particles is thus usually base 
catalyzed.  Base-catalyzed hydrolysis and condensation of a single tetrafunctional silane, 
such as tetraethoxysilane (TEOS), represents the simplest synthesis of silica particles.  To 
broaden their applicability, it is often desirable to vary the chemical and physical 
characteristics of silica particles.  Thus, modified sol–gel techniques have been developed 
that allow for precise control over particle growth to result in materials with specific 
properties.  The two general classes of silica particles are nonporous silica particles, 
synthesized by the Stöber method or the reverse microemulsion technique, and mesoporous
silica particles, prepared via a surfactant-templated method.   
As shown in Figure 1.3A, the Stöber method involves the hydrolysis and
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Figure 1.2  Silane precursors for sol–gel chemistry can be  (A) monofunctional, (B) 
bifunctional, (C) trifunctional,  or (D) tetrafunctional.
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condensation of silane precursors in a solution of water, an alcohol solvent (typically ethanol) 
and a base catalyst.8  A short-chain alcohol solvent is necessary to create a homogenous 
reaction solution as the tetraalkoxysilane is immiscible with water.  The Stöber method yields 
monodisperse, spherical particles typically in the micron to submicron size range and is 
scalable  to  increase  throughput.    The  Stöber  method  can  be  conducted  in  a  “one-pot”  reaction  
where all reactants are combined simultaneously.  Alternatively, a seeded-growth method 
utilizes small particles that are initially grown and used as seeds upon which larger particles 
form following multi-step addition of more silane precursors.  Lastly, a semi-batch approach 
can be used where one reactant (e.g., silane or catalyst) is added at a constant (typically slow) 
rate to a vessel containing the other reactants.  As will be discussed in Section 1.3.1, each of 
these synthetic strategies allows for particle size to be tuned by changing the concentration of 
water or reactants, reaction temperature, and solvent type.  Particles with specific organic 
functionalities can be created by using a corresponding silane precursor, the details of which 
are discussed in Section 1.4.1.   
The growth of monodisperse particles via the Stöber method can be described using 
the LaMer theory.9,10  These models relate the concentration of hydrolyzed silane 
([monomer]) to reaction time and the number of particles formed.  As hydrolysis reactions 
occur, the [monomer] increases with time until it reaches a critical concentration 
([monomer]nucleation) where initial sites of particle formation (i.e., nuclei) form.  While 
[monomer]  ≥  [monomer]nucleation, hydrolyzed silanes can either react with each other to form 
new nuclei or add to already formed nuclei.  Eventually, [monomer] falls below that of the 
sequential addition of hydrolyzed monomers.  To achieve monodisperse particle populations 
in Stöber reactions, the duration of the nucleation phase should be short such that
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Figure 1.3  Synthetic techniques for synthesizing silica nanoparticles for drug delivery 
include (A) the Stöber method, (B) the reverse microemulsion technique, and (C) surfactant-
templated synthesis. 
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most nuclei are created at the same time and experience the same growth histories.  The 
Stöber method typically produces particles larger than 100 nm as the reaction conditions do 
not stabilize nuclei, causing them to aggregate and form larger particles.  
 The reverse microemulsion technique is a method to produce silica particles less than 
100 nm with improved monodispersity.11  In contrast to the Stöber method where the sol–gel 
process occurs throughout the bulk of the reaction solution, the reverse microemulsion 
confines particle formation to the aqueous interior of micelles stabilized in an organic solvent 
(Figure 1.3B).  Surfactants used to form the micelles can be cationic (e.g., 
cetyltrimethylammonium bromide), anionic (e.g., sodium bis(2-ethylhexyl) sulfosuccinate), 
or nonionic (e.g., Triton X-100 or polyoxyethylene nonylphenyl ether).  Typically a co-
surfactant, such as 1-hexanol, is employed to stabilize the micelles.  The interior of the 
micelles is composed of water and the base catalyst and act as nanoreactors for silica 
nanoparticle synthesis. 
In a reverse microemulsion system, particle formation is also described according to 
the LaMer theory but is believed to occur at a much slower rate.12  Upon addition to the 
reaction mixture, the unhydrolyzed silanes become dispersed throughout the organic phase.  
As they slowly come in contact with the micelles, the silanes are hydrolyzed and enter the 
micelle’s   aqueous interior.13  Nucleation occurs when [monomer] reaches the critical 
concentration (e.g., [monomer]nucleation) within the micelle.  Similar to the Stöber method, the 
decrease in [monomer] after the onset of the nucleation phase occurs mainly through the 
diffusion-controlled growth of particles and nuclei.  However, the diffusion-controlled 
growth occurs at a much slower rate in a microemulsion due to the micellar structure’s  effect  
on viscosity and diffusion coefficients.  As such, the nucleation period is longer, resulting in 
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a greater number of particles and smaller particle sizes.  Furthermore, the nuclei formed in a 
reverse microemulsion are believed to be stabilized by the surfactant molecules, thus the 
extent of nuclei aggregation is lower than in the Stöber method.  Particle growth is confined 
to the micelle, thus particle size can be finely tuned by controlling micelle size.  For example, 
the water to surfactant ratio, surfactant to solvent ratio, the type of organic solvent, and 
reaction time all affect the resulting particle size.  Functionalized particles can be obtained by 
the addition of organosilanes to the emulsion.  The major drawbacks to synthesizing silica 
particles via a reverse microemulsion are low yields and extensive purification steps.  
Particularly for biomedical applications, complete removal of the potentially cytotoxic 
surfactant is necessary and requires copious washing with a variety of alcohols.  The ability 
to achieve small particles with narrow size distributions is the main advantage over the 
Stöber method.   
The two previously discussed techniques for sol–gel chemistry result in nonporous 
silica particles.  More recently, mesoporous silica particles (MSN) have been designed as a 
strategy to achieve greater functionalization potential and drug-loading capacity.14  The 
surface area of MSNs is typically >900 m2/g, while that of Stöber and reverse 
microemulsion-prepared silica particles is typically 5–200 m2/g. The pores of MSNs typically 
have a large volume (>0.9 cm3/g) with tunable sizes of narrow distributions (2–10 nm).  
Mesoporous silica particles are synthesized via a surfactant-templated approach, as illustrated 
in Figure 1.3C.  Surfactants are used to form liquid-crystalline mesophases that act as 
templates for the condensation of silane precursors.  Ammonium hydroxide (NH4OH) and 
sodium hydroxide (NaOH) have both been employed as base catalysts, each also providing 
morphological control as NH4OH and NaOH favor long and short micelles, respectively.15  
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Once the siloxane polymerization is complete, the surfactant molecules are removed either 
by solvent extraction with acidic ethanol or by calcination to reveal empty channels 
throughout the silica network.   
 
1.1.2  Drug delivery 
Silica-based nanomaterials are a popular scaffold for drug delivery due to their low 
cytotoxicity, chemical stability and high capacity for functionalization.4  Compared to “soft”  
nanoparticles (e.g., dendrimers, polymers, and vesicles), silica exhibits increased stability at 
high temperatures and varied pHs and is more resistant to mechanical stresses and 
hydrolysis-induced degradation   
Ideally, a successful drug delivery scaffold would be biocompatible and capable of 
high drug loading.14  Delivery to a specific site (e.g., cell type, tissue, or organ) is a desirable 
trait for most therapeutic applications and can be achieved using targeting moieties, as will 
be discussed later.  The major challenge in developing drug-releasing nanoparticles is the 
need for a scaffold that exhibits zero drug release prior to arrival at the site of interest and 
then provides complete delivery of drug payload.  Furthermore, the rate of drug release from 
the nanoscaffold often governs its biological effect,16 thus triggerable release of therapeutics 
is also desirable.  In general, achieving these goals with soft nanomaterials is difficult due to 
uncontrollable leaching and limited functionalization ability.14   
The two strategies that are used to load drugs onto/into silica particles include
covalent incorporation and non-covalent encapsulation. Covalent incorporation provides a 
more secure drug storage method that decreases the chance of premature release; however, a 
release trigger is required to cleave the bond securing the drug to the scaffold.  The most 
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notable release triggers for covalently loaded drugs include redox chemistry, enzymatic 
cleavage, pH, photolysis and thermolysis.3  Redox chemistry is a common strategy for 
achieving intracellular drug delivery due to the reducing environment present inside cells.  
Drugs can be tethered to organically modified silica scaffolds via reduction-sensitive 
linkages such as disulfide17 or organometallic18 bonds.  Hydrolysable or enzymatically 
cleavable bonds such as esters, carbonates, carbamates, hydrazones and amides are also 
common methods of covalent incorporation into silica.19  Alternatively, pH-sensitive 
functionalities can be incorporated into the silica network that result in drug release once the 
scaffold enters an area of a certain pH.  For example, the interior of endosomes is 
characterized by a lower pH than that of extracellular fluid (pH 5–6.5 vs 7.4, respectively).  
Thus, incorporating groups that are labile at lower pH values allows for selective drug release 
within cells.  Light-responsive materials have been designed where the bond tethering the 
drug to the scaffold is photo-labile such that drug release can be triggered with light 
irradiation.  Gold nanoparticles can be also be used for drug release as they will absorb light 
and convert the energy to heat to trigger thermolytic cleavage.  While UV, visible, and near-
IR active materials have been developed, near-IR irradiation (650–900 nm) is the most 
promising photo-trigger as it is only minimally absorbed by skin and tissue.  When using 
covalent incorporation for drug delivery, one must ensure that the chemical modifications 
necessary to covalently incorporate the drug do not alter the  drugs’ efficacy or  the  scaffolds’  
cytotoxicity.   
Alternatively, drugs may be loaded non-covalently via an encapsulation strategy.  
Mesoporous silica nanoparticles offer an excellent option for drug encapsulation due to the 
presence of large, uniform, and continuous pores.  Drugs can be loaded through the use of 
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diffusion by placing the porous particles in highly concentrated drug solutions; however, the 
upper limit of loading is relatively low for this method.  Alternatively, electrostatic 
interactions between the negatively charged silica scaffold and positively charged drug 
molecules can be used to achieve higher loading.  Increased loading of neutral or negatively 
charged drugs proves more difficult.  Liu et al. reported a strategy to coerce negatively 
charged   drugs   into   MSNs   through   the   formation   of   “protocells”. 20  In this method, a 
positively charged liposome is fused around the negatively charged silica particle in a 
solution containing the drug.  The electrostatic interactions between the negatively charged 
drug and the positively charged liposome cause the drug to be forced into the MSNs as the 
liposome encapsulates the silica.   
When drugs are not covalently bound to the scaffold, premature release represents a 
major obstacle.14  Stability of the drug within the scaffold can be promoted through non-
covalent interactions such as electrostatic or hydrogen-bonding.  For example, increased drug 
loading efficiency and extended release profiles of ibuprofen-loaded MSNs were achieved 
with aminosilane-modified MSNs.21  The hydrogen-bonding interactions between the 
protonated primary amines (at pH 7) tethered to the scaffold and the carboxylate groups of 
ibuprofen aided in drug loading stabilization.   
Another method for inhibiting the release of encapsulated drugs from mesoporous 
particles   is   through   the   use   of   “gatekeepers”, whereby zero premature release of drug is 
achieved by “plugging”  the  entrances  of  pores  with protecting groups after drug loading.14, 22  
The aforementioned strategies for releasing covalently bound drugs have been translated to 
the gatekeeping concept.  For example, Lai et al. blocked the entrances to the channels of 
MSNs using cadmium sulfide (CdS) nanoparticles that were tethered to the silica scaffold 
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with disulfide linkages.23  Reduction of the disulfide bond released the gatekeeping particle 
from the pore, allowing the encapsulated drug to diffuse out.  Other metallic nanoparticles as 
well as dendrimers and bulky organic molecules have also been employed as gatekeepers 
with release stimuli ranging from light to oscillating magnetic fields.3, 22   
In summary, silica-based nanoparticles offer a stable and chemically flexible scaffold 
that can be loaded with high concentrations of drug. The numerous opportunities for drug 
loading and release mechanisms are unique to these materials as such functionalities are not 
easily incorporated into soft materials.  
 
1.1.3 Influence of nanoparticle properties on nanoparticle-cell interactions 
Efficient drug delivery is governed by the extent of direct interaction between the 
nanoparticle carrier and the targeted cells.  Although the release of drug into the environment 
surrounding the target may still result in some therapeutic effect, diffusion of the drug away 
from the cell would necessitate a higher dosage to elicit the same therapeutic response if the 
drug were delivered directly into the cell.  Additionally, some drugs may be unable to 
permeate the cell membrane unassisted, thus nanoparticle carriers aid in intracellular 
delivery.  Nanoparticle characteristics (i.e., size, shape, and surface chemistry) govern 
particle-cell interactions both in terms of association and uptake.  As such, much effort has 
been focused on modifying particles accordingly to enhance these interactions and improve 
drug delivery efficiency.    
The smart design of particles for drug delivery requires an understanding of the 
various mechanisms by which a particle may interact with a cell.  Both eukaryotic and 
prokaryotic cells are characterized by a net negative charge, thus electrostatic forces may 
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lead to nanoparticle association.  Indeed, positively charged particles generally exhibit 
greater association and subsequent internalization into mammalian cells than neutral or 
negatively charged particles.24  Similarly, the extent of association between positively 
charged particles and bacteria cells is greater than that of negatively charged particles.25  In 
addition to carrying a negative charge, the surface of both prokaryotes and eukaryotes also 
express hydrophobic character due to membrane lipids.  As such, cells have exhibited an 
affinity for particles expressing lipophilic ligands, such as fatty acids and fatty amines.26  Due 
to the lipid bilayer comprising the cellular envelope, hydrophobic effects will also regulate 
whether a nanoparticle simply adsorbs to the membrane or is capable of penetrating into the 
interior of the cell.27  Lastly, nanoparticle-cell association can be greatly enhanced by 
tethering molecules onto the particle that bind to cell surface receptors.  For example, the 
inclusion of carbohydrates onto nanoparticle surfaces was found to enhance association with 
Escherichia coli by  binding  to  the  FimH  adhesion  protein  in  the  bacterium’s  pili.28  To date, 
several targeting moieties have been designed to increase the association of nanoparticles 
with both prokaryotic and eukaryotic cells, the details of which are discussed in Section 
1.1.4.   
For eukaryotic cells, once an association event has occurred cellular uptake may 
ensue.  The process by which matter is taken into mammalian cells is called endocytosis.  
Phagocytosis and pinocytosis are the two most prominent endocytic mechanisms for 
eukaryotic cells.  Large particles are taken up by phagocytosis (“cell eating”), while small 
particles, fluids, and solutes are taken up by pinocytosis (“cell drinking”).  Phagocytosis 
mostly occurs with macrophages and polymorphonuclear neutrophils, as these immune cells 
are key in cleaning up cellular debris and removing pathogens.  Pinocytosis is a common 
  15 
internalization strategy for all types of mammalian cells and is the generally accepted method 
by which particles are internalized by eukaryotic cells.5, 14, 29  The four main mechanisms for 
pinocytosis include macrophinocytosis, clathrin-mediated endocytosis, caveolae-mediated 
endocytosis, and clathrin- and caveolae-independent endocytosis.29  Macrophinocytosis is an 
actin driven process where protrusions form, collapse, and then fuse onto the cell membrane 
to form large endocytic vesicles with diameters of 0.5–10 µm.  In clathrin-mediated 
endocytosis, a coated pit is created by an assembly of clathrin, forming a vesicle ~120 nm in 
size.  In caveolae-mediated endocytosis, flask-shaped invaginations are formed by the protein 
caveolin, and internalized vesicles (~60 nm) are directed to the endoplasmic reticulum and 
the nucleus.  Clathrin- and caveolin-independent endocytosis occur through cholesterol-rich 
microdomains on the plasma membrane called lipid rafts (40–50 nm).  In general, uptake of 
silica particles into eukaryotic cells occurs through clathrin-coated endocytosis pathways 
although the inclusion of certain ligands may direct other mechanisms of endocytosis.   
 Although endocytosis is a necessary function for eukaryotes, an endocytosis-like 
mechanism has not been identified for prokayrotes.30, 31  Yet, the presence of nanoparticles in 
the interior of bacteria cells has been observed.32-35  It is believed that the route of ingress of 
nanoparticles into uncompromised bacterial cells may be through pores present in the outer 
membrane.25 Since these pores are used to secrete large proteins, only particles of very small 
sizes could pass through the pores.  For example, ring-shaped pores formed by secretin 
proteins (GspD) in Psuedomonas aeruginosa are estimated to have a diameter as large as 9.5 
nm, thus only nanoparticles less than 9 nm could pass.36  Even so, the probability of 
nanoparticle internalization through these large pores is low as the channels are likely gated. 
Most often, the presence of nanoparticles is observed in bacteria with compromised cell 
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membranes.  Thus, it is hypothesized that the particles entered the cellular interior only after 
the membrane had been compromised.25   
The mechanism and extent of cellular uptake is greatly affected by the physical and 
chemical characteristics of the nanoparticle scaffold.  It is generally believed that efficient 
uptake by non-phagocytic cells requires that the particle must be on the submicron scale,14 
although some have reported the internalization of particles as large as 5 µm.29  Overall, 
smaller particles are able to accumulate in the cellular interior to a greater extent than larger 
particles.  For example, the uptake of 50 nm MSNs by HeLa cells was 4, 20, and 11 times 
greater than that of 110, 170, and 280 nm particles, respectively.37  Similarly, the uptake of 
nonporous silica particles also exhibited a size-dependency with 23 nm particles being 
uptaken to a greater extent than larger 85 nm particles.38  The kinetics of internalization was 
also observed to be size dependent, with larger sized particles experiencing a slower rate of 
uptake.  After 60 min incubation, the 85 nm nonporous particles mostly remained physically 
adsorbed to the cell surface, while the majority of the smaller 23 nm particles were 
distributed throughout the cytosol. 38  Similarly, a greater concentration of smaller metallic 
particles has been observed in the interior of bacteria cells compared to that of larger 
particles.39  Due to the lack of endocytic mechanisms in prokaryotic cells, this size 
dependence is likely the result of Brownian motion across a damaged membrane.  A 
dependence of bactericidal efficacy on particle size is evident and is the focus of Chapter 2.  
Particle shape has also been observed to impact drug delivery efficiency by affecting 
particle-cell adhesion strength, internalization rate, cytotoxicity, circulation time and 
biodistribution.29, 40, 41  For example, higher aspect ratio MSNs were found to be internalized 
by human melanoma cells to a greater extent and at a faster rate than spherical particles.40  
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Furthermore, high aspect ratio particles resulted in a greater impact on cell proliferation, 
apoptosis, cytoskeleton formation, adhesion and migration.  In vivo experiments revealed 
that particle shape also governs biodistribution as MSNs with an aspect ratio of 1.5 
accumulated in the liver, while those with an aspect ratio of 5 distributed in the spleen.41  
Furthermore, the lower aspect ratio MSNs experienced a more rapid clearance rate.  Lu et al. 
observed a similar trend with antimicrobial MSNs, where those of higher aspect ratio 
exhibited a greater therapeutic impact.42  It was hypothesized that higher aspect ratios allows 
for greater surface contact between MSNs and the microbes, which in turn allowed for more 
efficient drug delivery directly to the bacterial membrane. 
In addition to physical characteristics, different surface chemistries present on the 
particle scaffold may influence the mechanism of cellular uptake.  For example, amine and 
guanidinium-functionalized MSNs are reportedly taken up by clatherin- and caveolae-
independent mechanisms, compared to the usual clathrin-coated endocytosis of silica 
particles.43  The uptake mechanism greatly impacts the effectiveness of the drug as it dictates 
the localization of the internalized nanoparticle.  Drug delivery to the cytosol of the cell is 
most ideal, but typically internalized particles remain trapped in endosomes.  Methods for 
triggering endosomal release have been achieved by modifying the surface of the particle.43  
For example, Verma et al. found that particles modified with alternating anionic and 
hydrophobic groups in an ordered manner achieved endosomal release whereas particles 
modified with the same functionalities but in a random, unordered fashion remained
trapped in the endosomes.44 
When cellular uptake is undesirable, poly(ethylene glycol) (PEG) and other similarly 
structured polymers can be incorporated onto the particle surface to prevent blood serum 
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proteins from adsorbing to the particle.24  Minimal protein adsorption results in decreased 
phagocytic cellular uptake and increased circulation time.  PEG-modified particles are 
typically used for antitumor therapies where the passive targeting of tumor cells is achieved 
through the enhanced permeation and retention (EPR) effect.  
Uptake of nanoparticles is most commonly monitored by flow cytometry, 
transmission electron microscopy, and confocal fluorescence microscopy.45, 46  
Internalization versus external association can be differentiated via a number of analytical 
techniques.  In flow cytometry, the particles must be fluorescent in order to visualize their 
location on/in the cell.  Particle internalization can be identified by the presence of 
fluorescence after copiously washing the cells or by employing extracellular fluorescence 
quenchers.  The use of transmission electron microscopy (TEM) is advantageous as there is 
no need to modify the particles to allow for visualization.  The localization of particles can be 
elucidated with TEM by using a microtome to obtain 100 nm thin slices of the specimen that 
can be imaged individually.  Stains are normally used for TEM imaging to increase the 
contrast between different cellular compartments.  However, TEM imaging requires fixation 
of the specimen, which can lead to artificially increased uptake.  Alternatively, the use of Z-
stack imaging with confocal microscopy allows for photographic  “slices” to be taken along 
the z-axis of live cells in solution.   Thus, real-time uptake and localization information can 
be obtained.  The presence of particles in the interior or exterior of the cells is determined by 
identifying the location along the z-axis where fluorescence is the greatest.  For now, the 
resolution of the Z-stack method limits this technique to investigating internalization by 
mammalian cells only. 
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1.1.4  Targeting strategies 
 The efficiency of drug delivery can be enhanced by increasing the probability and 
rate of an interaction between the nanoparticle and the intended tissue or cell.  Targeted 
delivery of nanoparticles can be achieved passively through processes such as the enhanced 
permeability and retention (EPR) effect or actively through the use of targeting or directing 
moieties. 
The EPR effect has been used for targeting nanoparticles to tumor sites by taking 
advantage of the fact that solid tumors and inflamed tissue have a more leaky vasculature 
than healthy tissue.2  As nanoparticles circulate throughout the vasculature, they are more 
likely to extravasate into cancerous tissue than normal tissue.  This phenomenon represents a 
passive strategy for the selective delivery of nanoparticles to cancerous tissue over normal 
tissue.  Nanoparticles that utilize the EPR for selectivity must be between 100–300 nm and 
experience long circulation life-times.4, 47  Micron-sized particles are quickly cleared by 
active phagocytosis of the reticuloendothelial system, while particles with diameters below 
100 nm are insufficient due to rapid renal clearance.  Increased circulation times can be 
achieved by modifying particle surfaces with PEG, which prevents non-specific binding of 
proteins and macrophages.  While the EPR effect allows for passive targeting of 
nanoparticles to tumor sites, active targeting strategies allow for increased internalization and 
allow for targeted treatment of other diseases.   
Nanoparticles can be actively directed or targeted to specific cells by including 
specific functionalities into the silica scaffold.  The incorporation of magnetic materials, such 
as iron oxide nanoparticles, provides the ability to direct and concentrate the drug at the 
diseased site by applying an external magnetic field.48-50  For example, Gang et al. reported 
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that nanoparticles loaded with a chemotherapeutic agent and smaller magnetite (Fe3O4) 
nanoparticles could be magnetically directed to a tumor site and resulted in a 15-fold higher 
drug concentration at the tumor site compared to freely circulating drug.51  Additionally, 
once the nanoparticle carrier has reached the targeted site, the application of an oscillating 
magnetic field can be used for heat generation to trigger drug release.52, 53 
Other active targeting strategies involve incorporating ligands on the particle surface 
that may increase the affinity of the intended cell for the particle by seeking a particular 
aspect that is more present on the targeted cell than other cells.  The most direct method of 
active targeting is to employ molecules that bind to receptors on the targeted cell surface.47  
For example, proteins, such as antibodies and glycoproteins, have been tethered to particle 
surfaces for active targeting.  Transferrin and transferrin receptor antibodies have proven 
effective antitumor targeting moieties as the majority of cancer cells overexpress transferrin 
receptors.54  Conjugating nanoparticles with the secondary human immunoglobulin (IgG) 
that targets protein A on the bacteria cell wall resulted in a significant increase in binding of 
the nanoparticles to bacteria compared to unmodified controls.55, 56  Moreover, the addition of 
the glycoprotein D-mannose onto nanoparticles was also found to increase binding to the 
bacteria cell wall compared to unmodified controls.28, 57 Avidity, the strength of multiple 
bonding interactions, can be enhanced through the use of larger multivalent targeting 
moieties; however, sterics limits the number of groups that can be tethered to the particle 
surface.  Smaller biomolecules have been employed to increase the probability of binding to 
the target.  One such type of small biomolecules are aptamers, which are a recently 
developed targeting strategy composed of single-stranded oligonucleotides such as DNA or 
RNA.58  The advantage of aptamers is their ability to bind to a wide range of non-nucleic 
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acid targets including peptides, proteins, and even whole cells with high affinity and 
specificity.  Other small molecules such as carbohydrates, vitamins, or peptides can also be 
tethered to the particle surface to actively target tumor cells.5, 47  For example, the addition of 
folic acid ligands allows for high-affinity binding to the folate receptor that is overexpressed 
on numerous types of cancer cells compared to normal cells.59  The fusion of nanoparticles to 
the cell membrane (and subsequent uptake into the cytoplasm) can be further enhanced by 
incorporating cell-penetrating peptides such as RGD, allatostatin 1, PLL, and arginine-rich 
peptides.60  The active targeting of prokaryotic cells has also been investigated by tethering 
the clinically used antibiotic glycopeptide vancomycin to nanoparticles for targeting Gram-
positive bacterium.  Vancomycin binds to the terminal peptide (D-alanyl-D-alanine) on the 
cell wall of Gram-positive bacteria through five hydrogen-bonds, increasing the avidity of 
the bacterium for the vancomycin-modified nanoparticles.61, 62   
In addition to increasing the efficiency of drug-delivering silica particles, the 
incorporation of targeting strategies also lowers the potential toxicity associated with 
exposure of non-diseased tissue, decreasing side-effects.  For example, the addition of folic 
acid ligands to silica particles was shown to increase preferential uptake by cancer cells up to 
five times that of normal cells.63 
   
1.2  Silica nanoparticles for the delivery of nitric oxide 
 Thus far, the use of silica nanoparticles for drug delivery was discussed broadly to
introduce the advantages inherent to these materials.   At this point, the focus is narrowed to 
describe the use of silica particles for delivering nitric oxide (NO), a small gaseous 
endogenously produced diatomic radical at the center of a wide variety of physiological 
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processes.  First identified for its cardiovascular role,64-66 NO is now known to play key roles 
in  human physiology and pathophysiology, including cancer biology, the innate immune 
response, as well as the wound healing cascade.67-72  Due to the fastidious nature of NO 
chemistry   and   biology,   a   thorough   knowledge   of   NO’s   physiological   effects   is   vital   to  
designing successful therapies.   
 
1.2.1  The biological and therapeutic roles of nitric oxide  
In the vascular endothelium, NO is generated to maintain proper blood flow and 
pressure.73  When NO is produced from vascular endothelial cells, it influences the cellular 
activities of smooth muscle cells, platelets, and immune cells (Figure 1.4).  After generation, 
NO diffuses into vascular smooth muscle cells and reacts with the iron of soluble guanylate 
cyclase.  This activation of guanylate cyclase results in the production of cyclic guanosine 
monophosphate (cGMP), leading to relaxation of the smooth muscle cells and an overall 
dilation of blood vessels.   Deficiencies in NO occur when the endothelium is injured or not 
functioning properly as is the case for several cardiovascular conditions, including 
atherosclerosis, heart failure, hypertension, arterial thrombotic disorders, coronary heart 
disease, and stroke.72  The administration of exogenous NO or the upregulation of 
endogenous NO production has vasoactive effects for treating ischemic heart disease, heart 
failure, and hypertension.74  
In cancer biology, NO is  often  described  as  a  “double-edged sword”  serving  as  either 
a tumor progressor or suppressor based on concentration and duration of exposure (Figure 
1.5).75  High NO concentrations produce reactive nitrogen species, which along with reactive 
oxygen species can cause oxidative and nitrosative stress that lead to DNA base deamination,
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Figure 1.4  Schematic  of  nitric  oxide’s  role  in  the  vascular  endothelium  and  its  effects  on  
cellular activities.  
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nitrosylation of enzymes, impaired cellular function, enhanced inflammatory reactions, 
inhibited mitochondrial respiration and tumor cell apoptosis.76  Alternatively, low 
concentrations of NO present anti-apoptotic effects and promote angiogenesis thereby 
increasing nutrient delivery and facilitating tumor growth.  All three isoforms of nitric oxide 
synthase (NOS) have been found in human solid tumors and are typically at higher levels 
than in normal tissue, indicating that NO may be a mediator of tumor progression.77  
Alternatively, the production of NO is part of the innate antitumor immune response 
mechanism of macrophages.  This complex relationship between NO concentration and 
tumor development/regression has ignited much research into both pro- and anti-NO cancer 
therapies.  Anti-NO therapies are essentially NOS inhibitors, which have shown to decrease 
endogenous NO levels and subsequently decrease tumor growth.75  Use of NOS inhibitors 
requires long term, systemic administration that can cause hypertension and tumor regrowth 
if treatment is halted prior to complete eradication.78  Pro-NO cancer therapies aim to 
increase NO concentrations at the tumor site to cause apoptosis and/or necrosis of cancer 
cells.77   
Nitric oxide is also a potent antimicrobial agent, released from inducible nitric oxide 
synthase (iNOS) in macrophages to eliminate pathogens.79  As depicted in Figure 1.6, NO 
exhibits antimicrobial effects both alone and upon reaction with oxygen or reactive oxygen 
intermediates (e.g., superoxide and hydrogen peroxide) to form other antimicrobial species 
including peroxynitrite, RSNOs, nitrogen dioxide, dinitrogen trioxide, and dinitrogen 
tetroxide.79  These reactive species can then interact with microbial proteins, DNA and 
metabolic enzymes, ultimately disrupting vital cellular structures and functions and leading 
to  potent  antimicrobial   efficacy.     Evidence  of  NO’s  efficacy  against  Gram-positive, Gram-
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Figure 1.5 The dual role of nitric oxide in cancer biology. 
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Figure 1.6 The numerous antibacterial mechanisms of nitric oxide and its byproducts (A) 
lead to decreased bacterial viability and decreased adhesion on NO-releasing surfaces (B) 
compared to control surfaces (C). Images of bacteria were obtained using atomic force 
microscopy
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negative, and fungal microbes is well documented.79-84  Furthermore, NO is capable of 
eliminating not only planktonic bacteria but also biofilms,85 which contribute to the 
persistence of infections due to their protective exopolysaccharide matrix that resists 
penetration of immune cells and antibiotics.86  The broad spectrum and multi-mechanistic 
nature of NO suggest it may be the basis for a new paradigm of antimicrobials that decrease 
the chance of resistance.  
Nitric oxide is also active in each phase of the wound healing cascade, indicating that 
NO-based therapeutics would be advantageous for promoting proper wound healing.87, 88  
The wound healing cascade consists of blood coagulation, inflammation, cell proliferation, 
lesion contraction, and remodeling.  This process begins immediately following tissue injury 
and continues up to months after the initial wounding.  Coagulation occurs to limit further 
blood loss by platelet adhesion and clot formation.  The secretion of growth factors activates 
fibroblasts, endothelial cells, and macrophages in an attempt to regain normal homeostatis.87, 
88  During the inflammation phase, neutrophils, macrophages, and lymphocytes collectively 
defend against invading microorganisms and help to remove damaged tissue.  Proliferation 
involves fibroblast migration, angiogenesis and re-epithelialization, beginning three days 
following injury and lasting up to several weeks.  During lesion contraction, the area of 
damage is reduced to prepare for remodeling, the last phase of wound healing.  This final 
phase consists of changes in the extracellular matrix (ECM) composition, decreases in 
macrophage and fibroblast density, and reduction in growth factor migration.  Finally, 
avascularization occurs upon decreased metabolism of neovascular tissues to form a flat 
surface.   Rapid recovery with minimal scarring and maximal function are the ultimate goal 
of wound healing.  However, in the case of severe injuries or because of preexisting 
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conditions (e.g., diabetes), the cascade leading to proper wound healing is not achievable 
without therapeutic intervention.89  The therapeutic potential for NO in promoting normal 
wound healing is indicated by its pro-angiogenic and anti-inflammatory nature as well as its 
ability to promote cellular proliferation/differentiation and collagen deposition. 
Although   many   details   still   remain   to   be   elucidated   regarding   NO’s   role   in  
physiology, the positive role of NO in a variety of human diseases is widely accepted.90-92  
As described above, the application of exogenous NO can be used for blood pressure 
regulation, tumor regression, elimination of microbial infection, and promotion of proper 
wound healing.  However, the administration of NO for these applications is not a trivial task 
due to the highly reactive nature of NO.  Gaseous NO can be used for some medical 
applications, but control over dosage and location is difficult.  Thus, gaseous NO is mainly 
used topically or for inhaled pulmonary treatment.  More controlled NO administration is 
achieved via compounds that can reversibly bind NO and release it upon some stimuli (i.e., 
NO donors).   
A wide variety of NO donors exist including metal nitrosyls, S-nitrosothiols 
(RSNOs), organic nitrites and nitrates, and N-diazeniumdiolates (NONOates).  S-
nitrosothiols and N-diazeniumdiolates represent the most widely used classes of NO donors 
for biomedical applications due to their ability to release NO under physiological conditions.  
S-nitrosothiols are endogenous NO donors that may be formed exogenously by reacting 
thiols with nitrosating agents (e.g. alkyl nitrite, dinitrogen trioxide, or nitrous acid) (Figure 
1.7).93  The release of NO from RSNOs occurs via numerous mechanisms. The S–N bond 
may be cleaved photolytically or thermally to generate NO and a thiyl radical.  Alternatively, 
the reaction of an RSNO with Cu(I) generates a thiolate, NO and Cu(II).  Regeneration of 
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Cu(I) occurs when the thiolate reacts with Cu(II), leading to a catalytic decomposition of 
RSNOs.  If free thiols are present, transnitrosation may occur where the nitroso functionality 
is transferred and may subsequently decompose via the aforementioned pathways.   
As shown in Figure 1.8, N-diazeniumdiolates are formed on amine sites upon 
exposure to gaseous NO in the presence of a base via one of two proposed mechanisms.94  In 
one mechanism, an NO dimer (N2O2) is first formed that subsequently reacts with the amine 
resulting in the formation of the NONOate (Figure 1.8A).  Alternatively, the amine may 
serve as the nucleophile, attacking one molecule of NO to first form a nitrosoamine radical 
anion that undergoes electrophilic attack on a second molecule of NO (Figure 1.8B).  The 
NO dimer mechanism is the more accepted version.94  Typically, a strong base such as a 
metal alkoxide is added to the system to promote NONOate formation.  In the presence of a 
strong base, the proposed mechanisms are altered as the amine is likely first deprotonated to 
facilitate nucleophilic attack.  The decomposition of N-diazeniumdiolates occurs in the 
presence of a proton source (i.e., aqueous physiological conditions) to release two molecules 
of NO and regenerate the parent amine (Figure 1.8C).  The ability to store two moles of NO 
per binding site is an advantage of NONOates over RSNOs; however, NONOates are 
plagued by the possibility of forming carcinogenic nitrosoamines.  In aerobic conditions, 
N2O3 is an oxidative product of NO and can react with secondary amines to form 
nitrosamines.
 
1.2.2  Small molecule NO donors and their limitations 
A number of low molecular weight (LMW) compounds have been designed that employ NO 
donor functionalities as NO delivery compounds. Some LMW NO donors have
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Figure 1.7  Reactions for S-nitrosothiol formation and degradation.  
  31 
 
 
 
 
 
 
 
Figure 1.8  The two proposed mechanisms of N-diazeniumdiolate formation involve (A) the 
formation of the NO dimer or (B) the formation of nitrosamine anion.  (C) The 
decomposition of NONOates via proton-initiated decomposition. 
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found clinical success, such as the use of sodium nitroprusside for blood pressure regulation 
and glyceryl trinitrate and isosorbide mononitrate for treating angina, anal fissures, heart 
failure and pulmonary hypertension.67 Despite their clinical use, common LMW NO donors 
are plagued by significant drawbacks, including hypotension, headaches, and cyanide 
poisoning.  Furthermore, continued use and reduced bioconversion of NO prodrugs can lead 
to tolerance.  Most of these drawbacks could be alleviated with directed NO administration 
as LMW NO donors typically diffuse quickly requiring higher doses.  However, small 
molecule scaffolds do not lend themselves to the inclusion of the targeting moieties.   
Indeed, the major challenge in developing a clinically successful NO-based 
therapeutic is the need for effective and selective NO delivery.  The therapeutic consequence 
of any NO-based drug depends strongly on the concentration and duration of NO delivered.  
As discussed above, micromolar NO concentrations can inhibit the growth of tumor cells, 
while picomolar NO concentrations have an angiogenic effect leading to cell proliferation.75  
As a result, NO-based therapies must store and deliver a precise NO dose and exhibit specific 
durations to be effective.  In addition, NO delivery must be selective due  to  NO’s  short  half-
life (seconds) limiting its sphere of influence to ~100 µm from its origin.95  Thus, it is 
necessary that these parameters (i.e., delivery site, NO concentration, and rate of NO release) 
be controllable and tunable.   
 
1.2.3  The development of silica particles for NO delivery 
 One strategy for achieving effective and selective NO delivery is through the use of 
macromolecular scaffolds.96  Examples of such scaffolds include biopolymers (i.e., nucleic 
acids, proteins, lipids, carbohydrates), dendrimers, zeolites, metal-organic frameworks, 
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synthetic polymers and films, and nano- or microparticles.  Macromolecular NO-releasing 
therapies have many advantages, the most significant of which is greater chemical tunability 
to allow for targeting, tuning NO release characteristics, and improving biocompatibility. 
Furthermore,   given  NO’s   short  half-life, delivery of high NO doses at a localized site is a 
clear advantage over LMW NO donors.  As a result of targeted delivery, the effectiveness of 
the NO-releasing drug may be increased and the occurrence of side effects including 
tolerance and toxicity may be decreased.  Macromolecular scaffolds can also be modified to 
delay or stimulate NO release in order to achieve tunable NO release characteristics, as 
different disease states require certain NO levels.  With gaseous or LMW NO donors, control 
of these parameters is difficult to achieve.  In Section 1.1, numerous examples were provided 
illustrating the potential of silica nanoparticles for drug delivery.  As a result of promising 
preliminary research on silica-based nanomedicine, silica nanoparticles have also been 
developed for use as NO release vehicles.   
The first report of NO-releasing silica particles was by Zhang et al., where 
aminosilanes were grafted onto the surface of fumed silica and subsequently N-
diazeniumdiolated.97  This work proved the ability to significantly increase the duration of 
NO release through the use of a macromolecular scaffold, as the half-lives (t1/2) of the 
surface-grafted N-diazeniumdiolate-modified silica particles were much longer than the half-
lives of the corresponding N-diazeniumdiolated aminosilane monomers.  Inspired by this 
work, Frost et al. translated this chemistry to prepare S-nitrosothiol-modified particles by 
coupling N-acetyl-L-cysteine or N-acetyl-D,L-penicillamine to primary amines grafted onto 
fumed silica particles via amide chemistry.98  While these works pioneered future A 
homogenous particle design where sites for NO donor formation are incorporated
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throughout the entire particle would theoretically allow for significantly higher NO payloads.  
Motivated by this concept, Shin et al. synthesized hybrid particles by hydrolyzing and co-
condensing TEOS or TMOS with one of three aminosilanes (i.e., N-(6-aminohexyl)-
aminopropyltrimethoxysilane (AHAP), (N-(2-aminoethyl)-3-aminopropyl-trimethoxysilane 
(AEAP), or (aminoethylaminomethyl)phenethyltrimethoxysilane (AEMP)) (Figure 1.9).99  N-
diazeniumdiolates  were  subsequently  formed  on  secondary  amines  site  via  a  “post-formation 
strategy”.  The amount of aminosilane incorporated throughout the particle was varied from 
10–77 mol%, allowing for a range of NO release totals and nanoparticle sizes to be achieved.  
As expected, the amount and type of aminosilane greatly influenced the observed NO release 
payloads and kinetics. In general, increasing the amount of aminosilane added to the sol 
resulted in an increase in nitrogen content in the resulting particles.  Following particle 
formation, the chemical environment surrounding the amine sites was also observed to 
influence N-diazeniumdiolate formation and degradation. For example, the total NO payloads 
from TEOS-based particles with 10 mol% AEAP and AHAP were 0.145 and 0.380 µmol/mg, 
respectively.  Surprisingly, the 10 mol% AEAP had higher nitrogen content (3.39 wt%) than 
10 mol% AHAP (2.74 wt%), as determined by elemental analysis. The type of backbone 
silane was also found to influence the total NO payload.  Particles composed of 10 mol% 
AHAP and 90 mol% TMOS or TEOS released 0.101 or 0.380 µmol/mg, respectively.  For 
this system, elemental analysis showed that higher NO payloads were achieved due to higher 
nitrogen contents as the 10 mol% AHAP/TEOS particles contained 2.74 wt% N, while the 10 
mol% AHAP/TMOS particles contained only 1.45 wt% N.   
In addition to NO totals, the kinetics of NO release were also found to depend on the 
backbone silane.  Particles composed of 10 mol% AHAP co-condensed with TEOS were
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Figure 1.9 Aminosilanes (A-G) and tetraalkoxysilanes (H-I) used to synthesize hybrid silica 
particles. (A) N-(6-aminohexyl)aminopropyltrimethoxysilane (AHAP), (B) N-(2-
aminoethyl)-3-aminopropyltrimethoxysilane (AEAP), (C) (aminoethylaminomethyl)-
phenethyltrimethoxysilane (AEMP) (D) 3-methylaminopropyltrimethoxysilane (MAP), (E) 
N-(2-aminohexyl)-11-aminoundecyltrimethoxysilane (AEAUD), (F) (3-trimethoxysilane)-
diethylenetriamine (DET), (G) N-(6-aminohexyl)aminomethyl-trimethoxysilane (AHAM), 
(H) tetramethoxysilane (TMOS), and (I) tetraethoxysilane (TEOS). 
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characterized by a t1/2 of 0.9 h whereas 10 mol% AHAP co-condensed with TMOS had a 
shorter t1/2 of 0.2 h. Again, this is likely because lower AHAP incorporation with TMOS 
leads to lower NO loading and thus shorter release duration.  Varying the type of aminosilane 
also resulted in changes in NO release kinetics. Since NONOate decomposition is proton-
initiated, the kinetics of NO release directly related to the rate that the NONOates react with 
water.  As such, faster NO release kinetics were observed from smaller particle sizes as more 
of their functional groups are closer to the particle surface compared to larger diameter 
particles.  It also follows that aminosilanes with more hydrophobic character would lead to 
longer NO release kinetics. This was evidenced with the AEMP-containing particles, which 
exhibited long half-lives of 5.4–6.0 h due to the hydrophobic conjugated ring present in the 
silane structure.  Unexpectedly, the longest half-life was achieved with 10 mol% 
AEAP/TEOS, even though the AEAP precursor is not significantly more hydrophobic than 
AEMP or AHAP.  Clearly, the environment within the silica matrix has as great an effect on 
N-diazeniumdiolate stability as the properties of the silane precursors.   
While the homogenous particle design allowed for higher NO loading than the 
surface-grafted particle system, the maximum NO loading was still limited by the low 
porosity and limited mobility of amines within the silica network.  Hydrogen-bonding 
between amines and silanol groups was believed to limit the availability of amines to be
converted to N-diazeniumdiolates.  Thus, subsequent work by Shin and Schoenfisch involved 
forming N-diazeniumdiolates  on  the  aminosilane  precursors  prior  to  particle  formation  (“pre-
formation  method”)  to  achieve  higher  NO  payloads.100  By forming the N-diazeniumdiolate 
moiety on the aminosilane precursors prior to incorporation within a silica particle, NO donor 
sites were present throughout the entire particle and total NO payloads per particle were 
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increased.  In addition to the aminosilanes previously employed, the aminosilanes used to 
prepare particles via the pre-formation method were expanded to include N-(6-
aminohexyl)aminomethyltrimethoxysilane (AHAM), N-(2-aminohexyl)-11-aminoundecyl-
trimethoxysilane (AEAUD), and (3-trimethoxysilane) diethylenetriamine (DET).   
The pre-formation method yielded NO totals that were orders of magnitude greater 
than what was achieved by the post-formation method.  The largest conversion efficiency 
(i.e., number of N-diazeniumdiolates per secondary amines) via the post-formation strategy 
was 52%, while the pre-formation method resulted in particles where ~100% of amine sites 
were N-diazeniumdiolated.  Exceptionally large NO totals of up to 11 µmol/mg were 
achieved, while the highest NO total achieved with the post-formation method was 1.7 
µmol/mg.  Based on elemental analysis, the pre-formation method also allowed for greater 
aminosilane incorporation, which contributed to improved NO loading.  As a result of these 
higher NO loadings, the duration of NO release was also significantly increased.  For 
example, NO release durations of up to 101 h were achieved with N-diazeniumdiolated 
DET/TMOS particles, which is nearly 6 times longer than durations measured from post-
formation particles.  Unfortunately, the pre-formation strategy was burdened by a decrease in 
control over particle formation.  As a result of the instability of the N-diazeniumdiolate 
group, it is likely that both modified and unmodified aminosilanes were present in the sol.  
Just as the addition of one organosilane complicates particle formation compared to a sol 
containing only tetraalkoxysilane monomers, the addition of two types of organosilanes 
complicates the reaction further.  Moreover, excess base, salt and other possible byproducts 
from the N-diazeniumdiolate reaction make controlled particle formation significantly more 
difficult with the pre-formation strategy compared to the post-formation method. 
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The therapeutic utility of surface-grafted and homogenous NO-releasing particles was 
preliminarily evaluated for use as thromboresistant and antimicrobial therapies, 
respectively.97, 101, 102 Surface-grafted silica particles were doped into polyurethane coatings 
on the inner walls of excorporeal blood circulatory tubes to evaluate their ability to inhibit 
thrombosis on blood-contacting devices.97  The NO release from these polymers mimicked 
the NO flux from stimulated endothelial cells (i.e., ~7 pmol cm-2 s-1) and effectively 
decreased platelet adhesion and activation.  The homogenous NO-releasing silica particles 
capable of higher NO payloads were evaluated for their antimicrobial efficacy.  Hetrick et al. 
observed >99% killing of Pseudomonas aeruginosa, Escherichia coli, Staphylococcus 
aureus, Staphylococcus epidermidis, and Candida albicans biofilms.101   
 
1.2.4 Limitations of NO-releasing silica particles  
The work of Zhang and Meyerhoff97 and Shin, Hetrick and Schoenfisch99-102 
exemplified the therapeutic potential of NO-releasing silica particles.  Encouraged by these 
reports, much remains to be discovered in terms of what specific particle characteristics can 
be tuned to improve these materials.  As has been discussed in previous sections, the 
chemical and physical characteristics of silica nanoparticles greatly affect their therapeutic 
potential.  More precise control over the physical and chemical properties of NO-releasing 
silica particles would allow for investigations in nanoparticle-dependent therapeutic effects 
and broaden the impact of these materials.   
To pinpoint the effect of a certain aspect, all other chemical and physical parameters 
must remain constant, a synthetic feat that is not trivial.  For example, Shin et al. observed a 
change in particle size, amine content, NO storage capacity, and NO release kinetics merely 
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by changing the backbone of 10 mol% AHAP silica particles from TMOS to TEOS.99  As 
discussed above, the use of alternative synthetic techniques for sol–gel chemistry, such as the 
reverse microemulsion, might allow for greater size control while keeping other particle 
characteristics constant.  Additionally, the therapeutic impact of NO-releasing nanoparticles 
may be enhanced by modifying the particle surface chemistry (e.g., surface charge and 
hydrophobicity).  Furthermore, expanding the chemical flexibility of NO-releasing silica 
particles may enable the design of multifunctional scaffolds as combination strategies that are 
characterized by increased therapeutic efficacy.103, 104   
 
1.3 Modifying physical properties of NO-releasing silica nanoparticles  
The development of NO-releasing silica particles for therapeutic applications requires 
that the physical properties be optimized as these characteristics will greatly influence 
nanoparticle-cell interactions and drug delivery efficiency.  Efficient delivery is of the utmost 
importance given NO’s   reactive nature and concentration-dependent biological effects. 
Physical characteristics may govern NO release kinetics by influencing the rate of water 
diffusion into the network and subsequent NONOate degradation.  For example, smaller 
particles are characterized by significantly higher surface area to volume ratios compared to 
larger particles.  Thus, NO release may be faster for smaller particles as a greater percentage 
of the NONOates are closer to the particle surface where they will contact water more 
quickly.  Furthermore, NONOates present at the interior of nonporous scaffolds will be more 
protected from decomposition than those present at the interior of porous particles due to 
decreased water diffusion.  In this section, methods for tuning size, shape and porosity of 
silica nanoparticle systems are discussed.  
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1.3.1 Size 
A wide range of particle sizes can be achieved with the Stöber method by changing 
specific reaction parameters including solvent type, reaction temperature, and concentration 
of water or ammonia.  The use of larger molecular weight water-miscible alcohol solvents 
can result in an increase in particle size.  Hydrolysis is slowed in solvents with larger molar 
volumes and results in a lower overall number of nuclei formed.  As discussed in Section 
1.1.1, when fewer nuclei are formed the resulting particles are fewer in number and larger in 
size.10  Indeed, TEOS particles synthesized in methanol, ethanol, or propanol exhibited 
average sizes around 30, 200, and 300 nm, respectively.105  Decreased hydrolysis rates and 
increased particle sizes can also be achieved by decreasing the reaction temperature.10  
Lastly, the concentration of water and ammonia may be varied to control particle size in a 
Stöber reaction.  Increasing water concentration above 9 M results in a decrease in particle 
size by promoting hydrolysis.8, 106, 107 Conversely, decreasing water concentration below 9 M 
increases particle size as a result of greater nuclei aggregation.10, 106  Generally, an increase in 
ammonia concentrations results in improved particle morphology (i.e., spherical shape) as 
high ammonia concentrations are required to provide sufficient stability of the particles in 
solution.  Thus, non-spherical and aggregated particles are often observed at low ammonia
concentrations.107, 108 
With the reverse microemulsion technique, particle size is governed by the size and 
stability of the micelle, which is impacted by the type of organic solvent, the water to 
surfactant ratio, the water to solvent ratio, and the ammonia concentration.11, 38  The viscosity 
and polarity of the organic solvent, as well as the size and molecular structure, influence the 
intermolecular forces between the surfactant molecules and the organic phase.  As a result, 
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the identity of the organic solvent greatly impacts the micelle diameter and the resulting 
particle size.109  Smaller organic solvent molecules can penetrate deeper into the surfactant 
layer, decreasing the overall size of the water droplet.  As the size of the water droplet 
decreases, the resulting particle size decreases.38  The water to solvent ratio (R) in a reverse 
microemulsion also affects particle size.13  At low R values, most water molecules are bound 
to the surfactant molecules comprising the micelle. The mobility of hydroxide (OH-) is thus 
limited, and hydrolysis and nucleation are not favored.  Additionally, less water results in 
fewer TEOS monomers present per micelle, decreasing the probability of intramicellar 
nucleation.  At large R values, both hydrolysis and condensation are favored as most water 
molecules are unbound.  There are also more TEOS monomers per micelle, favoring 
intramicellar nucleation and the formation of particles with smaller diameters.  As ammonia 
catalyzes the hydrolysis of the silane precursors, its concentration in the micelles also has a 
great effect on particle size and morphology.13  At low water concentrations, increasing 
ammonia concentration promotes hydrolysis and nucleation resulting in smaller particle 
sizes. At larger water concentrations, increasing ammonia concentration causes an increase in 
particle size as particle agglomeration occurs within the micelle.  A loss in control over 
particle morphology can occur at too high of ammonia concentrations due to siloxane bond 
cleavage.  The last parameter affecting particle size in reverse microemulsion syntheses is 
reaction time.  Interdroplet percolation occurs when two micelles collide and transfer silica 
cores, which may fuse and form one larger particle.38  Thus, increasing reaction time leads to 
a greater probability of interdroplet percolation, ultimately resulting in larger particles. 
Analagous to non-porous silica particles, the size of MSNs is controlled by modifying 
the rate of nucleus formation and monomer condensation.14  Methods for tuning particle 
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morphology include tuning reactant (silane or base) concentrations and varying reaction 
temperature.  For example, increasing reaction temperature results in an increase in the 
length of mesporous silica nanorods.110  Additionally, changing the type and concentration of 
surfactant will result in a change in particle size.  For example, lower surfactant 
concentrations will lead to less particle aggregation and a narrower size distribution (300–
600 nm).111 Co-condensation of an organosilane along with a tetraalkoxysilane also affects 
the resulting MSN particle size.  Huh et al. found that the incorporation of hydrophobic 
organosilanes resulted in a decrease in particle size compared to the unmodified MCM-41 
counterpart.112   
 
1.3.2 Shape 
The ability to create silica particles of various shapes is generally only achievable 
with surfactant-templated MSNs because the Stöber and reverse microemulsion techniques 
inherently produce spherical particles.  Since MSN grow along the micelles, their shape may 
be tuned by changing the geometry of the micelle.   
As with solid silica particles, the addition of an organosilane during the silane 
polymerization greatly impacts particle morphology of MSNs.  For example, the co-
condensation of TEOS with 3-aminopropyltrimethoxysilane resulted in curved hexagonal 
tubular structures.14  Alternatively, co-condensing TEOS with a polyaminosilane N-(2-
aminoethyl)-3-aminopropyltrimethoxysilane or 3-[2-(2-aminoethylamino)ethyl]propyl-
trimethoxysilane yielded MSNs of twisted columns or micron spheres, respectively.112  The 
incorporation of ureidopropyltrimethoxysilane also yielded micron-sized spheres but with a 
raspberry-like surface.  The influence of silane type on the resulting particle morphology is 
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attributed to the orientation that the organosilanes adopt with respect to the surfactant 
molecules during polymerization.  Hydrophilic silanes will orient themselves with their 
nonhydrolyzable groups positioned away from the micelles, while hydrophobic silanes will 
align such that the nonhydrolyzable portions are associated towards the hydrophobic domains 
of the micelle.   
The type of surfactant used to template the growth of MSN can also be modified to 
gain morphological control over MSNs.  The structure and packing of the micelle is greatly 
affected by the characteristics of the surfactant.  Again, since particle growth occurs around 
the micelles, it follows that micelle geometries will affect particle geometries.  This was 
observed experimentally by Trewyn et al. who utilized a range of room-temperature ionic 
liquids including 1-tetradecyl-3-methylimidaxolum bromide, 1-hexadecyl-3-
methylimidazolium bromide, 1-octadecyl-3-methylimidazolium bormide and 1-
tetradecyloxymethyl-3-methylimidazolium chloride to achieve spheres, ellipsoids, rods and 
tubes, respectively.113   
 
1.3.3  Porosity 
By definition, porosity is the volume of the voids in a network per unit mass.  Pores
are classified according to size as nanopores (≤2  nm), mesopores (2–50 nm), and macropores 
(0.05–10 µm).114  As drug type and release rates are dependent on the porosity of the delivery 
scaffold, much effort has focused on developing methods to control the porosity of silica 
particles to accommodate drug delivery needs.  
Nanoporous silica particles can be achieved without the use of a surfactant through a 
modified Stöber synthesis where an n-alkyltrialkoxysilane is added to the reaction as a 
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porogen.115  The hydrophobic ligands of the organosilanes orient towards each other with the 
hydrolyzable groups directed out towards the aqueous reaction conditions.  As hydrolysis and 
condensation proceed, hydrophobic pockets are formed throughout the silica network.  After 
particle formation, the organic groups can be removed by calcination to reveal silica particles 
with hollow nanopores.  Similarly, primary alkyl amines have also been included in a 
modified Stöber reaction to form nanopores throughout the silica scaffold.116  However, 
nanoporous silica particles are limited in the size and amount of drugs that may be loaded 
within the small diameter pores. 
Silica particles with larger mesopores are created through the use of the surfactant-
templated method (Section 1.1.1).  The pore volume of MSNs can be increased with no 
change in pore diameter by decreasing the reaction temperature.117  Post-synthesis 
hydrothermal treatment in acidic conditions was also found to increase pore diameter.117  
Control of pore structure and dimensions has been exemplified with additives such as 1,3,5-
substituted benzenes, long chain alkyls, and alkylamines as well as co-surfactants.118 
Alternatively, control over pore structure can also be achieved through the use of polymer 
additives.  For example, the triblock copolymer Pluronic P-123 was used in addition to 
CTAB to create larger pore diameters of 8 nm.   
 
1.4  Modifying chemical properties of NO-releasing silica nanoparticles 
 As discussed in Section 1.1.3, particle surface charge and hydrophobicity will 
influence nanoparticle-cell interactions and in turn govern drug delivery efficiency.  For NO-
releasing silica particles specifically, chemical properties will have a considerable effect on 
drug delivery both in terms of NONOate formation and degradation rate as well as cellular 
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interactions.  Below, methods for tuning the chemical properties of NO-releasing 
silicaparticles are discussed.   
 
1.4.1 Particle architecture 
To create N-diazeniumdiolate-modified particles, the silica network must be modified 
to include secondary amine sites.  The location of the amines within the network impacts 
both N-diazeniumdiolate formation and degradation rates.  Organically modified silica 
particles can be constructed via surface-grafted, core-shell or homogenous particle designs.   
The surface-grafting method involves condensing organosilanes with silanols present 
on the surface of a preformed particle.  This method allows for control over the scaffolds’ 
physical properties because the preformed particles are generally made from TEOS alone.  In 
the case of nonporous particles, the amount of organic functionalities that can be surface-
grafted is constrained by the low number of silanol groups present on the particle surface.  
Theoretically, there is a maximum of ~8 µmol silanols per m2 of silica, and at most only 
~50% can be modified due to steric hinderance.119  Surface-grafting aminosilanes onto 
nonporous particles, typically 5–200 m2/g, does not allow for significant NO-loading.  
Conversely, surface-modifications of MSNs result in a greater degree of functionalization 
due to a significantly larger specific surface area (>900 m2/g).14  Large NO payloads thus can 
be achieved by surface-grafting aminosilanes onto MSNs.42  The external surface is 
selectively modified by functionalizing prior to surfactant removal.14  The internal surfaces 
may then be modified following external modification and surfactant removal to impart a 
second functionality.   
A core-shell particle design allows for larger organic content while still employing a 
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template particle for fine control of particle morphology.  In this design, a core particle is 
formed typically from a tetraalkoxysilane (i.e., TMOS or TEOS).  A silica shell containing 
additional tetraalkoxysilane and an organosilane is then condensed around it.5  Since particles 
synthesized from TEOS or TMOS alone are generally monodisperse, the core-shell design 
yields particles with well-defined sizes and morphologies while still allowing for greater 
organosilane incorporation compared to surface-grafting.   
A homogeneous particle design allows for the greatest degree of functionalization 
because the organic groups are present throughout the entire scaffold.  To achieve equal 
distribution, organically modified silanes are hydrolyzed and co-condensed with a 
tetraalkoxysilane.  Although this method allows for greater concentrations of specific 
functionalities, the inclusion of a second type of silane during the sol–gel process typically 
disrupts uniform particle formation.  As a result, the synthesis of hybrid particles often 
requires greater effort in optimizing reaction conditions to achieve control over particle 
monodispersity and size.  In general, methods to ensure that the rate of hydrolysis and 
condensation of the two silanes are similar aid in obtaining well-defined hybrid particles.  If a 
large disparity exists between the rates of hydrolysis of the two silanes, a pre-hydrolysis step 
can be used for the silane with a slower rate.  Immiscibility between the two silanes may also 
disrupt homogeneous mixing and subsequently complicate uniform particle formation.   
 
1.4.2 Particle composition  
 For NONOate-based materials, NO payloads are governed by both the total number 
of amines present and their accessibility to deprotonation and reaction with NO.  Clearly, the 
ability to incorporate larger aminosilane concentrations into nanoparticles will increase the 
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potential for greater NO payloads.  However, the immobility and steric hindrance of amines 
fixed within a solid silica network result in conversion efficiencies (%Econv) around 30%.97, 99  
As previously discussed, Shin and Schoenfisch obtained greater NO payloads (%Econv≈100)  
by synthesizing particles composed of N-diazeniumdiolate-modified aminosilane precursors 
and a backbone tetraalkoxysilane.  The efficiency of N-diazeniumdiolate formation is 
significantly greater on aminosilane monomers dissolved in solution compared to those 
immobilized in a solid network.100   
In addition to NO payload, the chemical composition of the particle will govern the 
NO release kinetics.  For example, the structure of the aminosilane has been shown to affect 
NO release kinetics by altering intra/intermolecular bonding stabilization and 
hydrophobicity.  The inclusion of primary amines that can participate in hydrogen-bonding to 
stabilize the NONOate structure will prolong NO release.  As such, particles composed of the 
mono-aminosilane 3-methylaminopropyltrimethoxysilane (MAP; one secondary amine) 
exhibit fast NO release kinetics, whereas those of the di-aminosilane N-(2-aminoethyl)-3-
aminopropyltrimethoxysilane (AEAP; one secondary, one primary amine) have longer NO 
release kinetics.  Furthermore, the accessibility of the NONOate to protons (i.e., water) will 
influence NO release kinetics.  Increasing the hydrophobicity of the particles to decrease the 
diffusion of water into the silica network will also extend NO release.  For example, particles 
composed of (aminoethylaminomethyl)phenethyltrimethoxysilane (AEMP), which contains a 
conjugated ring, or N-(2-aminohexyl)-11-aminoundecyltrimethoxysilane (AEAUD), which 
contains a long alkyl chain, are characterized by longer NO release kinetics than particles 
composed of MAP.      
Nitric oxide release can be tuned by both changing the structure of the amine to
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which the NONOate is bound and/or by modifying the structure of the NONOate group 
directly.  O2-Protected NONOates are synthesized upon reaction of N-diazeniumdiolates with 
alkyl halides, epoxides, alkyl sulfates and aryl halides.94   These modified NONOates were 
designed to undergo hydrolytic or enzymatic cleavage such that the protecting group is 
removed in physiological conditions.  These functionalities are stable in basic conditions and 
withstand high temperatures, making them amenable to a wide variety of processing or post-
synthesis modifications.   
 
1.4.3 Surface chemistry 
The chemistries present on the particle surface will influence drug delivery efficiency 
by affecting NO release and governing nanoparticle-cell interactions.   As discussed in 
Section 1.1.3, the hydrophobicity and surface charge expressed by a particle will govern a 
cell’s affinity for it.  This is particularly important for NO-releasing particles due to the 
reactive nature of NO as well as its concentration/duration-dependent therapeutic effects.   
The surfaces of NO-releasing particles may be modified by grafting functional silanes 
onto the particle or covalently binding ligands to reactive groups near the particle surface.  
Surface-grafting is limited by the number of surface silanols, especially with hybrid particles.  
Covalent modification via ring-opening reactions, Michael additions, or N-
hydroxysuccinimide/ethyl(dimethylaminopropyl)carbodiimide (NHS/EDC) chemistry with 
primary amines present on the particle surface provide facile methods to modify particle 
surfaces.  Hydrophobicity may be modified through the addition of long-chain alkanes or 
fluorinated groups as discussed in Chapter 3.  Positively charged particles can be achieved 
through the inclusion of primary amines or quaternary ammoniums.  Alternatively, the
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addition of carboxylates and phosphates yield negatively charged particles.  Lastly, particles
may be modified with targeting moieties (Section 1.1.4) to direct NO delivery. 
 
1.5  Summary of dissertation research 
 The goal of my dissertation research was to design and synthesize NO-releasing silica 
nanoparticles with physical and chemical properties that may influence their therapeutic 
consequence.  Specifically, my research aimed to:  
1. develop synthetic techniques to achieve control over particle size, monodispersity, 
amine-content and surface chemistry of silica nanoparticles; 
2.  evaluate the influence of particle size on the bactericidal efficacy of nitric oxide-
releasing silica nanoparticles; 
3.  achieve N-diazeniumdiolate-based silica particles with prolonged NO release 
duration; and, 
4.  synthesize NO-releasing quaternary ammonium-modified silica nanoparticles as 
dually functional antimicrobials. 
In this introductory chapter, I sought to explain and justify the development of silica 
nanoparticles as drug delivery scaffolds.  The inherent physical and chemical flexibility of 
these materials represent advantages over other macromolecular scaffolds.  For example, 
specific properties can be tuned to influence nanoparticle-cell interactions and drug delivery 
efficiency.  This introduction also serves to demonstrate the therapeutic potential of NO-
releasing silica nanoparticles and describe methods for improving their effectiveness by 
tuning both their physical and chemical properties.  In Chapter 2, the reverse microemulsion 
technique is used to achieve silica particles of three distinct size and equal amine-content.  
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These scaffolds allowed for the study of the influence of scaffold size of NO-releasing silica 
nanoparticles on the bactericidal efficacy against P. aeruginosa.  In Chapter 3, the surface 
hydrophobicity of silica particles was modified via surface grafting to yield tunable and 
prolonged NO release kinetics.  Modifying particle surface chemistry was also found to 
enhance the stability of the particles in porous hydrophobic polymer films.  In Chapter 4, O2-
protected N-diazeniumdiolates are employed to achieve NO-releasing silica particles with 
NO release kinetics longer than any other silica particle scaffold to date.  The extended NO 
release scaffolds proved effective at inhibiting adhesion of plaque bacteria to dental 
composites compared to materials with shorter NO release durations.  Lastly, the chemical 
flexibility of silica particles is demonstrated Chapter 5.  Specifically, NO release is combined 
with quaternary ammonium groups to achieve multi-mechanistic antimicrobial 
nanomaterials.  Finally, Chapter 6 provides an overall summary of my dissertation work and 
suggests future steps for designing more effective NO-release scaffolds. 
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Chapter 2: 
Influence of Scaffold Size on Bactericidal Activity of Nitric Oxide-Releasing Silica 
Nanoparticles 
2.1 Introduction 
The endogenous free radical nitric oxide (NO) is involved in numerous physiological 
processes, including neurotransmission, wound healing, blood pressure regulation, platelet 
adhesion, and the immune response.1-5  While the delivery of exogenous gaseous NO has 
been shown to elicit promising antimicrobial effects against Gram-positive and Gram-
negative bacteria, and even antibiotic-resistant strains,6 the utility of NO as an effective 
therapeutic has been limited due to its reactive and concentration-dependent behavior.  As a 
result, much research has focused on the development of NO donors that store and generate 
NO in a controlled manner.7-11  Examples of NO donors that reversibly bind NO include 
metal nitrosyls, S-nitrosothiols, N-diazeniumdiolates, and organic nitrates.  N-
Diazeniumdiolate NO donors, formed upon the reaction of secondary amines with NO under 
basic conditions, are of particular interest as they undergo proton-initiated decomposition in 
physiological solution (pH 7.4, 37 °C) to release two equivalents of NO per functional 
group.7   
Although useful as tools for studying the role of NO in biology, most low molecular 
weight (LMW) NO donors release NO indiscriminately with undesirable cytotoxicity to 
healthy cells.3, 12, 13  In Section 1.2.3, macromolecular NO-releasing silica particles
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synthesized via the Stöber method were introduced as a new class of NO release materials 
that store/release substantial levels of NO with great potential for future targeting strategies 
due to versatile surface chemistries for attaching cell targeting and/or tracking (i.e., 
fluorescent) ligands.14, 15  Employing a hybrid silica design allows for a wide range of NO 
doses and release kinetics by changing the type and concentration of the aminosilane 
precursor.  Silica particles have also proven effective at delivering NO to bacteria (i.e., 
Pseudomonas aeruginosa) with greater  bactericidal action than comparable small molecule 
NO donors.13 Other recent reports corroborate the utility of nanomaterials for delivering 
antimicrobial agents.16    Indeed, nanoparticles composed of silver,17-20 copper,21-23 zinc 
oxide,24-28 titanium dioxide,24, 29, 30 and magnesium oxide exhibit a broad range of 
bactericidal activity. As discussed in Section 1.1.3, the bactericidal efficacy of such materials 
is dependent on both the chemical composition and the particle diameter, with smaller 
diameters generally enhancing killing. For example, Morones et al. reported more effective 
Escherichia coli (E. coli) killing using smaller diameter (~1–10 nm) silver nanoparticles due 
to greater particle interaction with the bacteria.17  Likewise, Nair et al. observed tunable 
killing as a function of particle size for zinc oxide nanoparticles, with the greatest killing 
efficacy observed for the smallest particle system prepared.28  Since particle association with 
bacteria appears to be critical to antimicrobial activity,17, 31-33 we sought to study the 
influence of nanoparticle size on nanoparticle-bacteria interactions and the resulting 
bactericidal efficacy of NO-releasing nanoparticles.  In this chapter, a reverse microemulsion 
approach was used to synthesize monodisperse NO-releasing silica particles of three distinct 
sizes (50, 100, and 200 nm) with equal NO release.  The size-dependent antibacterial action 
of these particles against Pseudomonas aeruginosa was then evaluated.   
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2.2 Materials and methods 
Tetraethoxysilane (TEOS) and N-(6-aminohexyl)aminopropyltrimethoxysilane 
(AHAP) were purchased from Gelest (Morrisville, PA).  Triton X-100, 1-hexanol, heptane, 
pentane, sodium methoxide (NaOMe, 5.4 M solution in methanol), dimethylformamide, 
methanol, and rhodamine isothiocyanate were purchased from Acros Organics (Morris 
Plains, NJ). Ethanol, butanol, and 1-propanol were purchased from Fisher Scientific (Fair 
Lawn, NJ).  Tryptic soy broth, tryptic soy agar, and minimum essential media (MEM) were 
purchased from Becton, Dickinson and Company (Sparks, MD).  Pseudomonas aeruginosa 
(ATCC #19143) was purchased from American Type Culture Collection (Manasses, VA).  
L929 mouse fibroblasts were obtained from the UNC Tissue Culture Facility (Chapel Hill, 
NC).  Nitric oxide (99.5%), nitrogen (N2), and argon (Ar) gases were purchased from 
National Welders (Raleigh, NC).  Distilled water was purified using a Millipore Milli-Q UV 
Gradient A-10   system   (Bedford,  MA)   resulting   in   a   total   organic   content   of   ≤6   ppb   and   a  
final  resistivity  of  18.2  mΩ·∙cm. 
 
2.2.1 Reverse microemulsion synthesis of amine-functionalized silica nanoparticles  
Amine-functionalized silica nanoparticles of select sizes were synthesized by 
adjusting the type and volume of organic solvent used in the reverse microemulsion.34-36  
Initially, reverse micelles were formed by mixing 3.54 g Triton X-100, 3.6 mL 1-hexanol, 
and the appropriate amount and type of organic solvent for 30 min.  Then, 240 μL  water,  120  
μL   ammonium   hydroxide   solution   (28   wt%   in   water),   and   40   μL   TEOS   were   added  
sequentially in 30 min intervals.  Hydrolysis and condensation were allowed to proceed for 3 
or 18 h, depending on the desired particle size, to form a TEOS seed particle.  The organic 
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solvent type and volume as well as the reaction time for initial TEOS seed growth for each 
particle size are listed in Table 2.1. Following the formation of the TEOS core particle, an 
additional  40  μL   (0.179  mmol)  TEOS  was  added   to   the  microemulsion,   after  which  84  μL  
(0.335 mmol) AHAP was added 30 min later.  Hydrolysis and co-condensation of TEOS and 
AHAP were allowed to proceed for an additional 18 h to form the amine-functionalized shell.  
The emulsion was broken upon the addition of ethanol.  Silica precipitates were collected via 
centrifugation at 3645 g for 5 min.  The supernatant was removed, and the particles were 
washed by resuspension in 1-butanol, 2-propanol, and ethanol, sequentially.  To ensure 
removal of Triton X-100, particles were resuspended in 45 mL of a 50/50 ethanol/water (v/v) 
solution, sonicated for 5 min in chilled water, and collected via centrifugation (3645 g, 5 
min). This process was repeated three times before a final wash with ethanol to aid in drying 
of the particles.  The resulting surfactant-free particles (confirmed by UV-Vis) were dried in 
vacuo overnight. Product yields were typically between 10–20 mg per reaction.  
 
2.2.2 N-Diazeniumdiolation of amine-functionalized silica nanoparticles 
 The procedure for loading NO onto the core-shell particles was modified from a 
previously reported method.14, 37  Briefly, particles were suspended in a 1:9 mixture of DMF 
and methanol (5 mg mL-1) by sonication.  Sodium methoxide, the base catalyst (5.4 M in 
MeOH), was added in either a 2.5:1 for 50 nm particles or 5:1 for 100 and 200 nm particles 
molar ratio relative to the concentration of secondary amines as determined by elemental 
analysis.  Following thorough mixing of this solution (vortexed for 1 min), 3.5 mL aliquots 
were placed in vials equipped with a stir bar. The open vials were then placed in a 160 mL 
Parr general purpose stainless steel pressure vessel with magnetic stirring and connected to
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Table 2.1  Variable synthetic parameters for each amine-functionalized nanoparticle size. 
Particle 
Size 
(nm) 
Organic Solvent  TEOS Core Particle 
Reaction Time 
(h) 
Type Volume 
(mL) 
 
50 pentane 45.6  3 
100 heptane 15.2  3 
200 heptane 15.2  18 
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an in-house NO reactor.  Oxygen was removed from the solutions by purging with Ar three 
times rapidly, followed by three 10 min Ar purges at 8 bar. The vessel was then filled to a 
pressure of 10 bar with NO that had been scrubbed with KOH.  The pressure in the reactor 
was maintained at 10 bar for 72 by repressuring with fresh NO to accommodate loss due to 
reaction and/or gas leak.  After 72 h, the NO was released from the vessel, and the solutions 
were again purged with Ar to remove unreacted NO.  The resulting N-diazeniumdiolate-
modified silica nanoparticles were collected by centrifugation (3645g, 5 min), washed three 
times with ethanol, and dried in vacuo.  The NO donor-modified nanoparticles were then 
stored in a vacuum sealed package at -20 °C until further use (up to one week).  No loss in 
NO loading was observed for particles stored in this manner up to 8 d (the longest period 
investigated) as determined by chemiluminescence upon comparing NO release immediately 
following diazeniumdiolate formation to that measured on day 8. 
 
2.2.3 Nitric oxide release measurements 
Total amounts of NO released from each particle size were evaluated using the Griess 
assay.38 The NO-loaded particles were placed in oxygenated phosphate buffered saline (PBS) 
upon which the liberated NO is oxidized to nitrite (NO2-).  After removing the particles via 
centrifugation, the supernatant containing NO2- was reacted with 1 wt% solutions of 
sulfanilamide and N-1-naphthylethylenediamine to form an azo-compound. By detecting the 
absorbance at 540 nm and comparing the results to a calibration curve, the concentration of 
NO released from the particles is deduced.   While the Griess assay allows for the 
measurement of total NO concentrations, real-time diazeniumdiolate degradation and NO 
release kinetics were determined using a Sievers NOA 280i chemiluminescence NO analyzer 
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(Boulder, CO) in PBS (pH 7.4) at 37 °C, as described previously.39  The absence of nitrite 
byproducts was confirmed by equal total NO concentrations measured from the Griess assay 
and the NOA.  Prior to analysis, the NO analyzer was calibrated with air passed through a 
NO zero filter (0 ppm NO) and a 26.39 ppm NO standard gas (balance N2). 
 
2.2.4 Nanoparticle characterization 
The hydrodynamic particle diameter and zeta potential (i.e., surface charge) were 
measured using a Malvern Zetasizer Nano-ZS (Malvern Instruments, Ltd.; Worcestershire, 
UK) equipped with a 10 mW HeNe laser (633 nm) and a NIBS® detector at an angle of 
173°. All samples were prepared at 1 mg/mL concentrations in PBS (size) or phosphate 
buffer (zeta potential) and analyzed at 37 °C to mimic the media used for NO-release and 
bacteria assays.  Phosphate buffer (non-saline, pH 7.4) was employed for zeta potential 
measurements because the high ionic content of PBS was found to corrode the folded 
capillary electrodes.40  Particle size and morphology were also characterized using a JEOL 
100 CX II Transmission Electron Microscope (TEM) at 100 kV. 
Covalent incorporation of AHAP and TEOS within the silica network was confirmed 
using solid-state cross-polarization/magic angle spinning (CP/MAS) 29Si NMR with a Bruker 
360 MHz DMX spectrometer (Billerica, MA) equipped with wide-bore magnets (triple-axis 
pulsed field gradient double-resonance probes).  Samples were packed into a 4 mm rotor 
(double-resonance frequency of 71.548 Hz) and spun at a speed of 10 kHz.  Chemical shifts 
were determined in parts per million relative to a tetramethylsilane external standard. 
Elemental analysis was performed using a PerkinElmer CHN/S O Elemental Analyzer Series 
2400 (Waltham, MA) instrument.  
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2.2.5 Bactericidal assays   
Pseudomonas aeruginosa was cultured to a concentration of 108 colony forming units 
(CFUs) per mL, collected via centrifugation, resuspended in sterile PBS and adjusted to a 
concentration of 106 CFU mL-1.  This starting concentration was chosen to accurately show 
at least 3 logs reduction as the limit of detection for the plate counting method is 2.5x103 
CFU mL-1.41  Aliquots of the 106 CFU mL-1 bacteria suspension were added to pre-massed 
amounts of nanoparticles to obtain the following concentrations 0, 0.025, 0.05, 0.1, 0.2, 0.3, 
0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 mg/mL.  The nanoparticle/bacteria suspensions were vortexed 
for 30 s to adequately suspend the nanoparticles, then incubated at 37 °C with gentle 
agitation.  Aliquots were then taken from each suspension after 2 and 24 h and diluted 10- 
and 100-fold in PBS before plating on tryptic soy agar.  Bacterial viability was measured 
after incubating plates at 37 °C overnight by counting observed colonies.  
 
2.2.6 Confocal microscopy studies 
Nanoparticles were fluorescently labeled by covalent modification with rhodamine 
isothiocyanate (RITC).42  Briefly, 50 mg of particles were suspended in 100 mL ethanol and 
mixed with 5 mg RITC, protected from light, for 48 h.  The particles were then washed 
copiously with ethanol using the suspension/centrifugation method described above until a 
colorless supernatant was achieved.  All confocal images were obtained with a Zeiss 510 
Meta Laser Scanning Confocal Microscope.  Brightfield and fluorescent images (543 nm 
HeNe excitation laser) were collected at room temperature with a N.A. 1.2 C-apochromat 
water immersion lens with either a 40 or 63  objective as indicated for each image. 
Pseudomonas aeruginosa cultures (106 CFU mL-1) were placed in a glass bottom petri dish 
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and allowed to adhere for 45 min at 37 °C prior to imaging.  The slide was then rinsed with 
fresh PBS to remove loosely or unadhered bacteria.  Brightfield images of untreated bacteria 
were obtained as controls. For all experiments, suspensions of rhodamine isothiocyanate 
(RITC)-modified AHAP/TEOS nanoparticles (500 µL of 10 µg mL-1 in PBS) were added to 
the bacteria on the glass slide.  To observe association of NO-releasing particles with bacteria 
over time, fluorescence images were taken immediately following the addition of particles at 
20 s intervals for 40 min.  To compare the influence of particle size on the extent of particle-
bacteria association, fluorescence images were obtained of bacteria treated with 10 µg mL-1 
of 50, 100, and 200 nm particles for 10 min.  After the 10 min incubation period, the 
suspension was removed, and the bacteria were copiously washed with fresh PBS to remove 
unassociated particles.  Fresh PBS was then added, and the bacteria were imaged.   
 
2.2.7 Cytotoxicity assays    
In vitro cellular toxicity of both control (i.e., control AHAP/TEOS particles) and NO-
releasing particles of all three sizes was evaluated using L929 fibroblast cells. Briefly, the 
fibroblasts were cultivated in MEM supplemented with 10% fetal bovine serum (v/v, FBS) 
and 1% penicillin/streptomycin, then incubated in 5% CO2/95% air under humidified 
conditions at 37 C. After attaining confluency, the cells were trypsinized and then seeded 
onto tissue-culture treated polystyrene 96-well plates at a density of 3x105 cells mL-1. Three 
days later, cells were incubated with control and NO-releasing nanoparticles at a 
concentration range of 0–3.2 mg mL-1 for 2 h and 0–0.8 mg mL-1 for 24 h. Subsequently, the 
particles were aspirated, cells were  washed  with   sterile  PBS   three   times,  and  100  μL   fresh  
media was added to the cells. Cellular viability was assessed using the MTS assay (CellTiter 
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96 Aqueous Non-Radioactive Cell Proliferation Assay; Promega, Madison, WI). Briefly, the 
MTS  reagent  (20  μL) was added to each well until a purple formazan color was formed in the 
control  (untreated)  wells.  The  supernatant  (90  μL)  from  each  well  was  then  transferred  to  a  
new 96-well plate prior to reading the absorbance at 490 nm using a microplate reader 
(Thermoscientific Multiskan® EX; Waltham, MA). Untreated cells were used as controls and 
results were expressed as percent viability relative to the untreated controls.  
 
2.3 Results and discussion 
While metallic and metal oxide nanoparticles with diameters of 1 to 500 nm have 
been reported to exhibit toxicity towards both Gram-positive and Gram-negative 
microorganisms, nanoparticles of  diameters  ≤100  nm  are  generally  more  effective biocides.16 
As such, we set out to investigate the influence of particle size on the bacteria killing efficacy 
of NO-releasing silica particles with diameters above, below, and equal to 100 nm.  To 
achieve these specific sizes, the reverse microemulsion technique was used as it provides a 
method for synthesizing silica-based particles in the nanometer range with excellent control 
over size and particle composition by changing any number of synthetic parameters including 
the amount of water and ammonium hydroxide,43-45 reaction time, the type of organic 
solvent, and the ratios of water to surfactant, surfactant to co-surfactant, and surfactant to 
organic solvent.34, 45, 46  A clear benefit of this method is the ability to tune particle size while 
keeping the aminoalkoxysilane:alkoxysilane ratio constant.35, 43, 47, 48  In general, particles 
synthesized by the reverse microemulsion method have a smaller size and narrower 
distribution than those produced via the Stöber method.34, 49  Narrow size distributions are 
essential when investigating the influence of nanoparticle size on bacterial interactions.
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Furthermore, the use of the reverse microemulsion technique provides a facile method for 
core-shell particle designs such that a variety of functionalities are easily incorporated as part 
of the silica scaffold.34-36, 43, 47, 48 
 
2.3.1 Size-controlled synthesis of amine-functionalized silica nanoparticles   
Scheme 2.1 illustrates the reverse microemulsion approach used to obtain amine-
functionalized silica nanoparticles.  For the three sizes (50, 100, and 200 nm), the micelles 
were prepared using Triton X-100 (surfactant) and 1-hexanol (co-surfactant) suspended in 
pentane or heptane.  Following micelle formation, an aqueous phase was introduced by 
adding water and ammonium hydroxide, sequentially. Following the formation of a stable 
microemulsion as indicated by a clear and colorless solution (step 1 of Scheme 2.1), the 
amine-modified silica nanoparticles were synthesized.  N-(6-aminohexyl)aminopropyl-
trimethoxysilane (AHAP) and tetraethoxysilane (TEOS) were chosen for study based on 
prior work that demonstrated NO-releasing AHAP/TEOS particles to be effective against P. 
aeruginosa and not toxic to fibroblast cells.13  The addition of pure aminosilane to the 
microemulsion resulted in amorphous silica particulates at low yields (1–2 mg) (Figure 
2.1.E). Thus, it was necessary to include a tetraalkoxysilane backbone to promote 
condensation as was seen for our previously reported particle systems.14, 15  However, the 
simultaneous addition of both AHAP and TEOS resulted in particles of a wide size 
distribution, especially at high AHAP concentrations (Figure 2.1).  By adopting a sequential 
silane addition method, the monodispersity of the particles was greatly improved.  Thus, 
TEOS was added initially to the microemulsion to form monodisperse TEOS seed particles 
(step 2 of Scheme 2.1) prior to shell modification with 65 mol % AHAP
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Figure 2.1 Transmission electron micrographs of silica particles resulting from the 
addition of (A) 0, (B) 27, (C) 53, (D) 77, or (E) 100 mol% aminosilane (balance TEOS).  
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1. Micelle Formation                                 2.  TEOS Core Particle                             3.  AHAP/TEOS Shell
Synthesis                                                   Addition
TEOS
3 or 18 h
TEOS +AHAP
18 h
 
Scheme 2.1 Synthesis of amine-functionalized silica nanoparticles via a reverse 
microemulsion. Step 1 involves micelle formation.  Step 2 is the addition of 
tetraethoxysilane (TEOS) to the  emulsion  to  form  monodisperse  “seed”  particles.    Lastly,  
step 3 is the subsequent addition of TEOS and AHAP that co-condense to form the 
AHAP/TEOS silica nanoparticles. 
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(balance TEOS), as shown in step 3 of Scheme 2.1.  The reverse microemulsion process 
allowed for higher aminosilane incorporation than was previously achievable via the 
Stöber process (10 mol %, balance TEOS)14 due to diffusion controlled particle growth.  
Of note, adding AHAP alone to the microemulsion resulted in poor shell formation and 
low yield.  Due to the mismatched hydrolysis and condensation rates of the two silane 
precursors,50 TEOS was added 30 min prior to the addition of AHAP during shell 
modification to achieve monodisperse particle populations.   
To tune particle size, a variety of synthetic parameters were adjusted (Table 2.1).  
The viscosity, polarity and molecular structure of the organic solvent are known to 
influence the intermolecular forces between the surfactant molecules and the organic 
phase, and thus greatly impact the micelle diameter and the resulting particle size.51  
Smaller organic solvent molecules can penetrate deeper into the surfactant layer, 
decreasing the overall size of the water droplet and ensuing particles.34  For this reason, 
pentane was used to prepare the smallest AHAP/TEOS particles (50 nm), while heptane 
was used to form the larger diameter particles (i.e., 100 and 200 nm).  Thus, increasing 
reaction time can ultimately lead to larger particles.34  For example, a 3 h TEOS seed 
reaction resulted in 5 nm particles whereas 12 nm seed particles were achieved after 18 h 
under the same solvent conditions.  Additionally, increasing the volume of organic 
solvent decreases the occurrence of interdroplet percolation, resulting in smaller particles. 
The resulting particle sizes and surface charges of the three synthesized systems are 
provided in Tables 2.2 and 2.3.  While electron microscopy provided a means to examine 
particle morphology, dynamic light scattering (DLS) allowed for the measurement of the 
hydrodynamic diameter and solution behavior of the particles.52  When interpreting
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Table 2.2 Particle size as determined by transmission electron microscopy (TEM) and 
dynamic light scattering (DLS). 
 
 
Particle 
Size 
(nm) 
TEM  DLS 
Diameter 
(nm) 
 Z-Ave 
(nm) PDI 
Number  
PSD 
(nm) 
Volume  
PSD 
(nm) 
50 56 ±  7  80.0 ± 3.1 0.150 ± 0.041 52.7 ± 3.3 66.8 ± 3.4 
100 93 ± 14  129.5 ± 13.7 0.087 ± 0.042 98.4 ± 6.7 127.3 ± 11.9 
200 199 ± 27  209.0 ± 3.9 0.041 ± 0.029 191.0 ± 1.8 221.7 ± 8.8 
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Table 2.3  Zeta potential values of AHAP/TEOS and N-diazeniumdiolate AHAP/TEOS 
silica nanoparticles as determined by Laser Doppler Velocimetry.  
 
 
 
 
 
 
 
 
Particle 
Size 
(nm) 
          Zeta Potentialb 
R2NH 
(mV) 
R2N[N(O)NO]- 
(mV) 
50 +11.8 ± 1.2 -5.2 ± 3.9 
100 +12.5 ± 1.1 +5.9 ± 2.3 
200 +11.4 ± 1.1 +8.4 ± 0.3 
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nanoparticle size, both DLS and electron microscopy data must be considered together for 
proper size characterization as particle size measurements from DLS better represent the 
entire particle population and the actual size in solution.  The Z-average diameter, 
polydispersity index (PDI), and particle size distributions (PSD), and diameters as measured 
from transmission electron microscopy (TEM) are provided in Table 2.2.  Taken together, the 
parameters reported in Table 2.2 provide a comprehensive evaluation of the actual particle 
sizes present during bacteria assays.  Z-average diameters result from the cumulants analysis 
of the intensity of light scattered from the sample, thus it may only be compared between 
samples that were prepared in the same dispersant and measured by the same technique. The 
number PSD is a measure of the particle size distribution based on the number of particles 
that are a particular size within the sample. Alternatively, the volume PSD is a measure of the 
particle size distribution based on the volume of the sample that is occupied by certain sizes. 
Both the Z-average and the volume PSD are skewed to larger sizes as larger particles will 
scatter more light and account for significantly more signal/volume than smaller particles.  
The polydispersity index (PDI) is a width parameter of the mean size calculated from the 
cumulants analysis, and ranges from 0 to 1, with a 0 indicating a stable suspension and a 
perfectly monodisperse population. Although no official standard exists, a PDI of <0.2 is 
considered  to  be  monodisperse,  while  a  PDI  ≤0.1  is considered to be highly monodisperse.53  
With respect to the synthesized silica particles, we observed increasing PDI values as the 
particle diameter decreased, indicating that while all sizes were monodisperse and formed 
stable suspensions in PBS, decreasing particle size resulted in a slight increase in size 
distribution.  This monodispersity was further corroborated by TEM (Figure 2.2 and Table 
2.2).  Collectively, the DLS and TEM data indicate that these particle systems are suitable for
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Figure 2.2  TEM micrographs of (A) 200, (B) 100, and (C, D) 50 nm AHAP/TEOS silica 
nanoparticles.  Scale bar is 1 µm for A–C and 0.2 µm for D. 
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investigating the influence of particle size on particle-bacteria interactions based on their 
narrow size distribution and solution stability.  
Solid state 29Si nuclear magnetic resonance (NMR) confirmed the covalent 
incorporation of the aminosilane into the silica network.  Cross-polarization (CP) and magic 
angle spinning (MAS) techniques were used to enhance the sensitivity toward silicon atoms 
near CHx or OH groups and improve peak resolution.54, 55  As shown in Figure 2.3, the 
spectrum of each particle system contained both T- and Q-bands, representing silicon atoms 
that are bound to three (AHAP) and four (TEOS) oxygen atoms, respectively.  Changes in 
the neighboring oxygen environments surrounding the observed silicon atom were indicated 
by peak splitting within the T- and Q-bands denoted by superscripted numbers corresponding 
to the number of siloxane bonds.54  The 29Si NMR spectra therefore confirmed successful co-
condensation and incorporation of AHAP and TEOS into the scaffold for each particle size. 
Of note, the ratios of the T-band to Q-band intensities are not reflective of the actual ratios of 
AHAP to TEOS within the particle because the core particles are likely pure SiO2 and free of 
hydrogens. 
Elemental analysis allowed for a more quantitative investigation of AHAP 
concentration within each particle system.  We hypothesized that the amine content would 
remain constant regardless of particle diameter because the molar amounts of silane 
precursors (both TEOS and AHAP) were held constant for all three systems.  Furthermore, 
the wt% N measured from CHN analysis may be translated to AHAP concentration as it is 
the only nitrogen-contributing component within the silica network.   For the smallest 
particle system (50 nm), we measured a wt% N of 5.39, corresponding to 1.93 µmol AHAP 
per mg of particles.  While the nitrogen amount increased slightly for the 100 nm particles
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Figure 2.3  Solid state CP/MAS 29Si NMR of (A) 50 nm, (B) 100 nm, and (C) 200 nm 
AHAP/TEOS nanoparticles.  The T-band (ca. -70 ppm) represents silicon atoms that are 
bound to three oxygen atoms (i.e., AHAP).  The Q-band (ca. -100 ppm) indicates silicon 
atoms with four siloxane bonds (i.e., TEOS).   
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(6.64 wt% N or 2.37 µmol AHAP per mg of particles), the larger 200 nm particle system was 
characterized by a slightly lower nitrogen content (5.29 wt% N corresponding to 1.89 µmol 
N per mg of particles), indicating a similar amine content regardless of a change in particle 
size for the three systems synthesized here.   
 
2.3.2 N-Diazeniumdiolate NO donor functionalization  
Nitric oxide was loaded onto the silica scaffolds via N-diazeniumdiolate formation on 
the secondary amine sites of AHAP by exposing the particles to high pressure of NO in the 
presence of a base catalyst (NaOMe) (Scheme 2.2).14, 37  N-diazeniumdiolate formation was 
confirmed via NO release and zeta potential (i.e., surface charge) changes observed after NO 
loading (Table 2.3).  Initially, each particle system was characterized by a slightly positive 
charge of ca. +12 mV, an expected result due to the protonated primary amines at pH 7.4.  
Following NO loading, the zeta potential for each size became neutral (zeta potential 
between -10 and +10 mV)40 from the contribution of the zwitterionic N-diazeniumdiolate 
functionality (Scheme 2.2).  The particles regained their positive charge within 10 min as the 
result of N-diazeniumdiolate decomposition and regeneration of parent amines. 
As shown in Table 2.4, the total amount of NO released from the particles was 
1.49±0.29, 1.26±0.17, and 1.01±0.08 µmol mg-1 for the 50, 100, and 200 nm AHAP/TEOS 
particles, respectively.  Based on the AHAP content per mg particle (Table 2.4), NO donor 
loading efficiencies were determined to be 38.6, 26.6, and 26.7% for 50, 100, and 200 nm 
particles, respectively.  Such NO loading efficiency is consistent with previously reported N-
diazeniumdiolate-modified silica particles.14, 37  The greater conversion efficiency for the 
smallest particle size may be attributed to the increased surface area to volume ratio,
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Scheme 2.2  N-Diazeniumdiolate formation on aminosilane-modified silica nanoparticle. 
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resulting in a larger concentration of amines nearer to the particle surface and therefore more 
accessible to reaction.   These hybrid silica particles have low porosity with surface areas 
(SBET) of 4–20 m2/g and pore volumes of 0.008–0.989 cm3/g (at p/po = 0.99) as determined 
from nitrogen adsorption-desorption isotherms.  Indeed, the high density and low porosity 
resulting from the co-condensation method used to synthesize amine-modified hybrid silica 
materials have been previously observed.14, 15  As a result of low porosity, amine sites farther 
from the particle surface are less accessible to diazeniumdiolation.  To ascertain the dose of 
NO delivered from the particles over the course of the bactericidal assays, the total amounts 
of NO released over 2 and 24 h were measured and are provided in Table 2.4.  As expected, 
each particle system was depleted of NO by 24 h.  The NO release data indicates that over 
the course of 24 h, bacteria were exposed to similar amounts of NO regardless of 
nanoparticle size as there is no statistical difference in the total amount of NO released from 
each particle system.  Since NO release occurs upon protonation of the secondary amine of 
the N-diazeniumdiolate, it is inevitable that the kinetics of NO release differ slightly for each 
particle size based on the N-diazeniumdiolate groups’ proximity to the particle surface and 
therefore differing rate of contact with the aqueous solvent.  As shown in Figure 2.4, the 
instantaneous release of NO from the particles was characterized by an initial burst of NO 
due to immediate decomposition of surface N-diazeniumdiolate NO donors upon solution 
immersion.  This instantaneous maximum concentration of NO release is defined as  [NO]m. 
The particles exhibited a [NO]m of 49.7, 43.5, and 44.7 ppm mg-1 from the 50, 100, and 200 
nm particles, respectively.   
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Table 2.4 Nitrogen content, NO release properties, and extent of amine to N-
diazeniumdiolate conversion for the amine-functionalized silica nanoparticles.  
 
Particle 
Size 
(nm) 
µmol 
AHAPa 
per  
mg  
particle 
[NO]tb 
(μmol mg-1) 
% Cc [NO]m
d 
(ppm mg-1) 
tme 
(min) 
tdf 
(h) 
2 h total 
50  1.93 0.47 ± 0.02 1.49 ± 0.29 39 49.7 ± 16.8 0.8 ± 0.1 15.2 ± 2.1 
100  2.37 0.38 ± 0.01 1.26 ± 0.17 27 43.5 ± 5.2 0.6 ± 0.1 13.0 ± 3.8 
200  1.89 0.42 ± 0.01 1.01 ± 0.08 27 44.7 ± 8.0 0.7 ± 0.1 9.9 ± 1.6 
aDetermined by CHN elemental analysis of control particles, b[NO]t, total number of moles of NO released 
per mg of particle as measured by the Griess assay, c Percent conversion of secondary amines to N-
diazeniumdiolate based on assumption that 100% diazeniumdiolate conversion would result in 2 mol NO 
per 1 mol of AHAP in particle scaffold, d[NO]m, maximum concentration of NO released as measured with 
NOA. etm, time required to reach [NO]m, ftd, duration of NO release. 
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Figure 2.4 Real time NO release profile for 50 (black), 100 (red), and 200 (blue) nm NO-
releasing AHAP/TEOS particles from t=0 to t=24 h. Inset: NO release from t=0 to t=0.2 h, 
corresponding to the shortest time period at which particle-bacteria association was 
investigated with confocal microscopy. 
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 2.3.3 Effect of nanoparticle size on bactericidal activity against Pseudomonas aeruginosa   
Based on prior work suggesting particles less than 100 nm are more effective 
antimicrobial materials,16 we hypothesized that the 50 nm NO-releasing silica nanoparticles 
would be more effective at bacteria killing than the larger 100 and 200 nm particles.  
Minimum bactericidal concentration (MBC) assays were performed under nutrient-free 
conditions in phosphate buffered saline (PBS) to eliminate bacteria replication as our goal 
was  to  more  accurately  emphasize  the  role  of  size  on  the  particle’s  bactericidal  activity.    The 
MBCs listed in Table 2.5 were determined as a function of NO-releasing nanoparticle size 
against 106 colony forming units (CFU) mL-1 P. aeruginosa cultures.  The minimum particle 
concentrations required to achieve complete killing (3 log reduction) after short (2 h) and 
long (24 h) exposures were thus determined using bacteria in the healthiest state (i.e., mid-
log growth stage).41  As shown in Table 2.5, the smaller particles were notably more effective 
at killing P. aeruginosa after 2 h compared to larger particles (MBC2h of 0.8 mg mL-1 for 50 
nm versus 1.5 mg mL-1 for 100 and 200 nm NO-releasing AHAP/TEOS particles, 
respectively).  This two-fold difference in MBC2h is significant given that there is only a 
slight difference in total NO released after 2 h from each particle size (Table 2.4).  The total 
NO released from each particle size after 24 h was not statistically different, yet a two-fold 
difference in MBC24h was still observed.  Furthermore, the increased NO release exposure 
resulted in nearly a 4-fold decrease in the particle concentrations required to kill P. 
aeruginosa with MBC24h of 0.2 mg mL-1 for 50 and 100 nm and 0.4 mg mL-1 for 200 nm 
NO-releasing particles (Table 2.5).  Of note, the 100 nm particles exhibited similar 
bactericidal properties as the 200 nm particles at short incubation times, while at longer 
periods the bactericidal efficacy of the 100 nm particles resembled that of the 50 nm
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Table 2.5 Minimum bactericidal concentration of NO-releasing AHAP/TEOS of each 
size after 2 and 24 h incubation with P. aeruginosa. 
Particle Size MBC2h MBC24h 
nm mg/mL mg/mL 
50 0.8 0.2 
100 1.5 0.2 
200 1.5 0.4 
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Table 2.6 Viability of P. aeruginosa following treatement with blank (i.e., in PBS only) or 
control (i.e., non-NO-releasing control AHAP/TEOS particles).  Initial bacteria concentration 
is 106 CFU/mL. 
 
Dose Exposure Time Bacterial Viability 
 
mg/mL h CFU/mL 
Blank (PBS) 0 2 6.3(±0.5)x106 
 
0 24 8.6(±0.2)x106 
50 nm 0.8 2 1.2(±0.2)x106 
 
0.2 24 9.6(±2.3)x106 
100 nm 1.5 2 3.5(±0.4)x106 
 
0.2 24 2.7(±0.2)x106 
200 nm 1.5 2 1.27(±0.03)x106 
 
0.4 24 5.2(±1.5)x106 
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nanoparticles.  This data corroborates the well-known relationship between biocidal activity 
and materials in the nanoscale (i.e., materials with size measuring 100 nm or less in one 
dimension).  The considerable decrease in MBC over time indicates that the efficacy of the 
NO-releasing nanoparticles improves as more NO is released.  Neither blanks (i.e., in PBS 
only) nor control (non-NO-releasing) AHAP/TEOS particles at MBC concentrations affected 
P. aeruginosa viability (Table 2.6). 
Although the observed relationship between particle size and MBC may be expected, 
the mechanism for this phenomenon remained uncertain.  Confocal microscopy was thus 
used to qualitatively observe particle fate.  To allow for visualization using fluorescence 
imaging, the surface-accessible primary amines of the AHAP particles were chemically 
modified with rhodamine isothiocyanate (RITC).42 Although NO release was decreased 
slightly (by 9%), no change in particle size or particle surface charge was observed following 
RITC modification. Similar to the non-fluorescent particles, a slight decrease in zeta potential 
was noted following diazeniumdiolation of the RITC-modified particles (ca. +13 mV to ca. 
+7 mV for control and NO-releasing, respectively).  Initially, a time-based experiment was 
conducted where the bacteria were treated with RITC-modified NO-releasing AHAP/TEOS 
particles, and images were collected at 20 sec intervals over the course of 40 min.  The 
particles rapidly associated with the bacteria within 2 min (Figure 2.5), a favorable attribute 
given the bolus release of NO.  Immediately following this interaction, membrane 
degradation, cellular collapse, blebbing and decreased adhesion to the substrate were 
observed and attributed to the antimicrobial action of NO (e.g., lipid peroxidation) (Figure 
2.6).56  Such severe morphological changes hindered our ability to distinguish between 
individual bacteria cells.  Thus, the remaining confocal experiments were carried out using
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Figure 2.5 Scanning confocal images of P. aeruginosa treated with 50 nm RITC-modified 
NO-releasing AHAP/TEOS nanoparticles. Brightfield, fluorescence (RITC), and overlay 
images were acquired (A) 0 (addition of particles), (B) 2.4, (C) 6.4, (D) 19.5, and (E) 39 min 
after  addition  of  10  μg  mL-1 nanoparticles. Scale bars are 10 µm. 
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Figure 2.6 Scanning confocal images of P. aeruginosa treated with 50 nm RITC-modified 
NO-releasing AHAP/TEOS nanoparticles. Brightfield image (A) was acquired before 
addition of 10 μg mL-1 nanoparticles and fluorescence overlay image (B) was acquired after 
10 min incubation with nanoparticles. Scale bars are 5 µm.  
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RITC-modified control AHAP/TEOS particles to maintain bacteria viability and potentially 
glean information on particle-bacteria association.  Given that the size and surface charge are 
similar between the NO-releasing and control RITC-modified particles, particle-bacteria 
interactions that occur with control particles are an accurate representation of those that occur 
with NO-releasing RITC particles.  When P. aeruginosa were exposed to particles at 50 µg 
mL-1 for longer than 30 min, fluorescence was present in all bacteria regardless of the particle 
size.  By exposing the bacteria to decreased doses of 50, 100, and 200 nm RITC-modified 
nanoparticles (i.e., 10 µg mL-1) for shorter time (i.e., 10 min), a difference in the rate and 
extent of association was observed fluorescently (Figure 2.7).  The greatest RITC 
fluorescence was observed upon treatment of bacteria with the 50 nm nanoparticles (Figure 
2.7A).  Bacteria exposed to 100 nm nanoparticles exhibited some fluorescence but at a lower 
magnitude than the 50 nm treated cells (Figure 2.7B).  Finally, little fluorescence was 
observed from the cells treated with the 200 nm particles (Figure 2.7C).  Collectively, these 
results indicate that although all particle systems tested interact with the bacteria, the smaller 
diameter particles do so more rapidly.  As shown in the inset of Figure 2.4 and provided in 
Table 2.4, a large amount of NO is released within the initial 10 min.  Therefore, the rate of 
association governs the amount of NO delivered to the bacteria.  Greater association with 
decreasing particle diameter corroborates our finding that smaller particles were more 
bactericidal at lower concentrations than larger particles. Indeed, the faster diffusion rate of 
smaller particles allows for a more rapid association with bacteria.  As such, a larger portion 
of the stored NO is likely delivered to the bacteria from the 50 nm particles compared to the 
100 and 200 nm particles, thereby lowering the necessary particle and overall NO 
concentrations required for effective killing.   
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Figure 2.7 Overlay of fluorescence and brightfield scanning confocal microscopy images of 
P. aeruginosa treated with 10 µg mL-1 of (A) 50, (B) 100, and (C) 200 nm RITC-modified 
AHAP/TEOS silica nanoparticles for 10 min. Magnification is 63 , and scale bar is 5 µm. 
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2.3.4 Cytotoxicity against L929 mouse fibroblasts   
The use of NO-donor functionalized silica scaffolds is motivated by both the 
synthetic versatility and biologically inert qualities of silica.57  To be useful as a potential 
therapeutic, such materials must possess favorable toxicity to normal cells.  The cytotoxicity 
of both NO-releasing and control AHAP/TEOS particles was thus evaluated against L929 
mouse fibroblasts.  Fibroblast viability screening represents a first test for evaluating 
cytotoxicity of both systemic and topical antibacterial agents as these cells play a critical role 
in wound healing.58, 59 Although our lab has previously observed that AHAP/TEOS particles 
synthesized via the Stöber method exhibited no toxicity toward fibroblast cells,13 the 
cytotoxicity of the particles reported herein was not obvious due to the modified synthesis 
(i.e., reverse microemulsion). In addition, our prior report did not investigate the role of size 
on toxicity. The MTS assay was used to measure cell viability after exposure to both control 
and NO-releasing particles for 2 and 24 h to mimic the two exposure times of the bactericidal 
assays.  Particle concentrations up to double the MBC values for each time point were tested 
to evaluate cytotoxicity above the concentration required for bacteria killing. Theoretical 
total NO doses delivered from each particle concentration after 2 and 24 h were calculated 
from the NO release data and are provided in Table 2.7.   As shown in Figure 2.8A, no 
toxicity was observed after 2 h from the NO-releasing particles up to their respective MBC2h 
doses regardless of particle size.  Control particles of 50 and 100 nm were also not toxic at 
their respective bactericidal concentrations. However, the MBC2h dose of control 200 nm 
particles (1.6 mg mL-1) decreased fibroblast viability by 36%.  Although toxicity was 
observed at the highest concentration tested (3.2 mg mL-1) for control 50 nm and both NO- 
releasing and control 200 nm particles, we note that these concentrations were well above the
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Figure 2.8 Cytotoxicity of control and NO-releasing particles against L929 mouse fibroblast 
cells as measured using the MTS assay after (A) 2 h exposure at 0 (white), 0.4 (light grey), 
0.8 (grey), 1.6 (dark grey), and 3.2 (black) mg mL-1 and after (B) 24 h exposure at 0 (white), 
0.1 (light grey), 0.2 (grey), 0.4 (dark grey), and 0.8 (black) mg mL-1. 
  95 
 
 
 
 
 
 
Table 2.7 Concentration of NO corresponding to the particle concentrations tested in 
cytotoxicity assays.  
Particle 
Size 
(nm) 
Particle  
Dose 
Total NO Dose 
2 h 24 h 
(mg mL-1) (µmol) 
50  0.1 0.05 0.15 
 0.2 0.09 0.30 
 0.4 0.19 0.60 
 0.8 0.37 1.19 
 1.6 0.75 2.38 
 3.2 1.49 4.77 
100  0.1 0.04 0.13 
 0.2 0.08 0.25 
 0.4 0.15 0.50 
 0.8 0.30 1.01 
 1.6 0.61 2.02 
 3.2 1.22 4.03 
200  0.1 0.04 0.10 
 0.2 0.08 0.20 
 0.4 0.17 0.40 
 0.8 0.34 0.81 
 1.6 0.68 1.62 
 3.2 1.35 3.23 
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therapeutic doses required for complete bacteria killing (0.8 and 1.5 mg mL-1, respectively). 
As shown in Figure 2.8B for 24 h treatment, no significant toxicity was observed for either 
NO-releasing or control particles at concentrations up to 2x MBC24h for all three sizes. Taken 
together, these results indicate that increased treatment time with NO-releasing AHAP/TEOS 
particles has the combined advantage of lower therapeutic dose required for sufficient 
bacteria killing with negligible effect on fibroblast cell viability.    
 
2.4  Conclusions 
A reverse microemulsion synthesis was developed to prepare three sizes of highly 
monodisperse aminosilane-modified silica nanoparticles.  The particles were characterized by 
high amine-loading with surface accessible primary amines that allowed for straightforward 
coupling of fluorescent markers.  Conjugation of other biorecognition agents should be 
compatible in the same way, further expanding the potential therapeutic utility of these 
scaffolds.  By maintaining constant NO loading/release for each particle size, the relationship 
between nanoparticle size and bactericidal efficacy was probed.  At shorter exposure time, 
the smaller NO-releasing silica nanoparticles (50 nm) were found to exhibit the greatest 
bactericidal activity. Such behavior may be attributed to their increased rate of association 
and subsequent greater NO payload delivered directly to the bacteria.  We hypothesize that 
increasing the rate at which NO-releasing particles associate with bacteria may further 
improve their antibacterial properties. Future research should focus on how the amount and 
kinetics of NO delivered into bacterial cells influences the observed bactericidal efficacy.  
Although particles with both neutral and positive surface charges were shown to interact with 
the bacteria, the rate of particle association is likely influenced by particle surface charge as 
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bacteria are characterized by a net negative charge. More effective antibacterial nanoparticle 
therapeutics may be realized by understanding the role of particle-bacteria interactions on 
bactericidal activity. 
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Chapter 3: 
Surface Modification of Nitric Oxide-Releasing Silica Nanoparticles  
3.1   Introduction 
Nitric oxide (NO) is produced endogenously as a regulator of numerous physiological 
processes including angiogenesis, wound healing, vasodilation, and the immune response.1  
As such, much research has been devoted to designing methods for delivering exogenous NO 
in a manner that mimics its biological generation in order to treat medical conditions such as 
hypertension, ischemia/reperfusion injury, thrombosis, restenosis, and cancer.2  The major 
factor inhibiting the clinical success of NO-based therapeutics stems from the gaseous and 
reactive nature of NO that make it difficult to control its delivery both in terms of release 
kinetics and location.    
Improved control over NO delivery can be achieved by incorporating NO donors, 
such as N-diazeniumdiolates and S-nitrosothiols, into macromolecular scaffolds to achieve 
biologically relevant NO release activity.3  For example, Zhou et al. designed polymers 
doped with S-nitrosothiol-modified silica particles to achieve NO fluxes that mimicked NO 
generation by endothelial cells (i.e., 1–4x10-10 mol cm-2 s-1).4  The advantage of N-
diazeniumdiolate (NONOate)-based materials over other NO donor moieties (e.g., S-
nitrosothiols) is their ability to store two molecules of NO per amine site with subsequent 
controlled release under physiological conditions without the need for an external trigger. 
Unfortunately, the labile nature of the NONOate functionality in aqueous media often results 
in materials with relatively short NO release durations (i.e., less than 24 h).  While fast 
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release of large NO payloads (i.e., micromolar) are sufficient for some applications, such as 
eradicating tumor or bacteria cells, the release of lower levels of NO (i.e., picomolar) for 
extended periods are required for other therapies (e.g., wound healing and treatment of 
cardiovascular dysfunctions).1  Methods for extending the NO release duration of N-
diazeniumdiolate-based macromolecules are thus needed to broaden their therapeutic impact.    
Due to the proton-initiated decomposition of N-diazeniumdiolate NO donors, the 
chemical environment surrounding the NONOate governs NO release kinetics.5  The 
zwitterionic NONOate can be stabilized directly through hydrogen bonding.  For example, 
silica nanoparticles composed of the diamine N-(6-aminohexyl)aminopropyl-
trimethoxysilane (AHAP) exhibit slower release kinetics compared to particles composed of 
the monoamine N-methylaminopropyltrimethoxysilane (MAP) as the primary amine of 
AHAP can stabilize through  hydrogen bonding.6  Another strategy for prolonging NONOate 
lifetimes is to increase the hydrophobicity of the environment surrounding the NO donor, 
thus slowing water diffusion and protonation of the N-diazeniumdiolate-bearing amine.  Koh 
et al. doped N-diazeniumdiolate-based silica particles into polyurethanes of increasing 
hydrophobicity to achieve materials with prolonged NO release.7  Electrospun polyurethane 
fibers capable of NO release are particularly attractive for applications such as wound 
healing and implant coatings due to their porous nature.8  Unfortunately, silica particles can 
leach from the fibers in physiological conditions (i.e., pH 7.4, 37 °C), preventing their 
development as implant coatings.   
Based on the proton-initiated decomposition of N-diazeniumdiolates to release NO, 
we hypothesize that NO release durations from silica nanoparticles will be extended by 
modifying the particle surface with hydrophobic groups.  Increasing the surface
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hydrophobicity of the NO-releasing particles may further improve their stability in 
hydrophobic polymers.  In this Chapter, the surface hydrophobicity of NO-releasing silica 
particles was varied by grafting ethyl-, isobutyl-, octadecyl-, or 
heptadecafluorotrimethoxysilane onto the surface of particles synthesized by co-condensing 
AHAP with tetramethoxysilane (TMOS).  The influence of modifying the surface 
hydrophobicity on NO payloads and release kinetics was then evaluated, along with studies 
doping the hydrophobic particles into electrospun polymer fibers. Specifically, NO release 
and dopant stability were evaluated as a function of surface modification and polymer type. 
  
3.2   Materials and Methods 
 N-(6-aminohexyl)aminopropyltrimethoxysilane (AHAP), ethyltrimethoxysilane, 
isobutyl-trimethoxysilane, octadecyltrimethoxysilane, (heptadecafluoro-1,1,2,2-
tetrahydrodecyl)-trimethoxysilane, and tetramethoxysilane (TMOS) were purchased from 
Gelest, Inc. (Morrisville, PA).  Ethanol, aqueous ammonium hydroxide solution (28 wt%), 
anhydrous toluene, anhydrous N,N-dimethylformamide, anhydrous tetrahydrofuran, 
anhydrous methanol, sodium methoxide (5.4 M solution in methanol), and potassium tert-
butoxide (20 wt% in tetrahydrofuran) were purchased from Fisher Scientific (Fair Lawn, NJ).  
Sodium trimethylsilanolate was purchased from Sigma Aldrich (St. Louis, MO).  Nitrogen 
(N2), argon (Ar), and nitric oxide calibration (26.81 PPM, balance N2) gases were purchased 
from National Welders (Raleigh, NC).  Pure nitric oxide gas (99.5%) used for N-
diazeniumdiolate formation was purchased from Praxair (Sanford, NC).  Distilled water was 
purified using a Millipore Milli-Q UV Gradient A-10 system (Bedford, MA), resulting in a
total organic  content  of  ≤6  ppb  and  a  final  resistivity  of  18.2  mΩ·∙cm. 
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3.2.1   Stöber synthesis of amine-containing silica nanoparticles 
Hybrid inorganic/organic silica nanoparticles were synthesized via a modified Stöber 
method. Briefly, AHAP (1.173 mL) and TMOS (0.708 mL) were premixed and added to a 
mixture of ethanol (59.16 mL), water (27.84 mL), and 28 wt% ammonium hydroxide (9.8 
mL).  The reaction was stirred at room temperature for 2 h.  The resulting white particle 
precipitates were collected by centrifugation (3645g, 10 min, 4 °C) and washed thrice with 
ethanol to remove unreacted reagents.  The particles were then dried in vacuo and stored in a 
sealed container until further use. 
 
3.2.2   Grafting of organosilanes onto the surface of silica nanoparticles  
A suspension of AHAP silica particles (50 mg) in 10 mL toluene was prepared via 
sonication.  Pyridine (100 µL) and an organosilane (200 µL) were added, and the reaction 
was refluxed overnight.  An excess of organosilanes was used as the silanes were found to 
condense with silanols on the glassware.  The surface-modified silica particles were collected 
by centrifugation (3645 g, 10 min, 4 °C), washed twice with toluene, then twice with 
ethanol.  The particles were then dried in vacuo and stored in a sealed container until further 
use.   
 
3.2.3 N-diazeniumdiolate-modification of AHAP and surface-modified AHAP silica
nanoparticles 
Each particle composition was suspended in N,N-dimethylformamide or methanol via 
sonication at a concentration of 5 mg/mL. Sodium methoxide, potassium tertbutoxide (5 wt% 
in THF), or sodium trimethylsilanolate was then added in a 1:3 mol ratio of secondary amine 
to base.  The mixtures were vortexed, aliquoted into 4 mL glass vials, placed in a 160 mL 
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Parr general purpose pressure vessel, and connected to an in-house NO reactor.  The 
solutions were stirred magnetically with removal of oxygen by purging with Ar. The vessel 
was then filled to a pressure of 10 bar with NO that had previously been scrubbed with KOH.  
After 72 h, the NO was released from the vessel, and the solutions were again purged with Ar 
to remove unreacted NO.  The resulting N-diazeniumdiolate-modified silica nanoparticles 
were collected by centrifugation (3645g, 10 min, 4 °C), washed thrice with ethanol, and dried 
in vacuo overnight.  Particles were stored at -20 °C in a vacuum sealed container until use. 
 
3.2.4  Particle-doped electrospun polymer fibers 
 Electrospun fibers were prepared using a custom electrospinning apparatus previously 
described.9  Briefly, a Series 205B High Voltage Power Supply (Bertan Associates, Inc.) was 
used to apply a voltage of 6 kV to a stainless steel blunt-tip needle (22 gauge) on a syringe 
containing the particle/polymer suspensions.  A grounded steel plate covered in aluminum 
foil was positioned perpendicular to the direction of flow, 15 cm from the needle tip.  A 
syringe pump (Kent Scientific, Torrington, CT) was used to eject the particle-doped polymer 
solutions at a rate of 0.015 mL/min.  The particle/polymer solutions were prepared by first 
dissolving 40 mg of polymer into 1.6 mL of a 3:1 (v/v) mixture of tetrahydrofuran and N,N-
dimethylformamide, then adding 0.4 mL of a 40 mg/mL particle suspension in methanol.    
 
3.2.5  Materials characterization 
Particle morphology and size were evaluated using a Hitachi S-4700 Scanning
Electron Microscope (Pleasanton, CA).  Solid-state nuclear magnetic resonance (SS NMR) 
experiments were performed on an 11.7 T (500 MHz) spectrometer.  A 3.2 mm HCN Balun 
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probe was used for 13C detection with samples spun at the magic angle with a rate of 12 kHz.  
For 19F detection, a 1.6 mm HFXY FastMAS probe was utilized with samples spun at the 
magic angle with a rate of 25 kHz.  The direct polarization (DP) technique was applied for 
both 13C and 19F detection, and a solid state echo was incorporated to reduce background 
signal.  X-ray photoelectron spectroscopy (XPS) was performed on a Kratos Axis Ultra DLD 
X-ray Photoelectron Spectrometer with a monochromatic Al Kα   X-ray source (150 W).   
Electrons were collected at an angle of 90 degrees from the sample surface from a 300 x 700 
µm area on the sample with pass energy set to 20 eV for high resolution spectra.  All spectra 
were obtained with a step size of 0.1 eV and calibrated to the C 1s peak at 284.6 eV.  
 Particle-doped polymer fibers were visualized with an FEI Quanta 200 field emission 
gun environmental scanning electron microscope (ESEM) without additional coating.  
Stability of the particles within the polymer fibers was investigated by submerging the 
particle-doped fibers (10–40 mg) in 15 mL of phosphate buffered saline (PBS, pH 7.4) for 7 
d and performing silicon elemental analysis on the soak solutions using a Teledyne Leeman 
Inductively Coupled Plasma-Optical Emission Spectrometer (ICP-OES).  Metal wire was 
used to ensure the hydrophobic fiber mats remained submerged in the soak solution.  
Analysis was performed in the axial configuration at 251.611 nm calibrated with 0.01–50 
ppm silica particle standard solutions of the corresponding particle system in PBS.  
Real-time nitric oxide release was measured using a Sievers NOA 280i
Chemiluminescence NO Analyzer (Boulder, CO) connected to a customized reaction vessel.  
Briefly, NO-releasing materials (i.e., particles or particle-doped fibers) were submerged in 
deoxygenated PBS (pH 7.4) at 37 °C with NO carried to the analyzer by passing N2 through 
the solution at a constant rate of 70 mL/min.  The analyzer was calibrated with air passed
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through a NO zero filter (0 ppm NO) and a 26.39 ppm NO standard gas (balance N2).   
 
3.3   Results and Discussion 
3.3.1  Surface modification of amine-containing silica nanoparticles 
The hydrolysis and co-condensation of an organosilane and a tetraalkoxysilane under 
dilute, basic conditions produces spherical inorganic/organic hybrid silica particles.10  On the 
surface of the resulting particles are both nonhydrolyzable organic groups and hydrolyzable 
silanol groups.  Thus, additional silanes can be added through condensation with the surface 
silanols, in essence adding a third organic component for preparing hybrid silica 
nanoparticles (Scheme 3.1).  Using such surface grafting methods, organosilanes of varying 
hydrophobicity were coupled to the surface of amine-containing silica particles (Figure 3.1).  
As shown in Figure 3.2, the surface grafting method did not result in a change in particle size 
or morphology.  
The number of silanes grafted to the particle surface depends on both the particle and 
the ligand.  For example, increasing the surface area of the particle allows for a greater 
number of surface silanols to facilitate ligand attachement.  Neue described a relationship 
between  surface  area  and  silanol  coverage  (χ)  in  terms  of  µmol/m2 according to Eq 3.111  
         12
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where %C is carbon weight percent of modified particles as determined from elemental 
analysis, nC is the number of carbon atoms on the ligand, and MW is the molecular weight of 
the attached ligand.  As the molecular weight of the ligand increases, the number of ligands 
that can be added to the particle should decrease due to steric hinderance.  Theoretically, the 
(Equation 3.1) 
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Scheme 3.1 Organosilanes are grafted onto the surface of hybrid silica nanoparticles through 
a condensation reaction between surface silanols on the particle and methoxides on the 
organosilane.  
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A CB D  
Figure 3.1  Structures of silanes of increasing hydrophobic character: (A) ethyltrimethoxy-
silane, (B) isobutyltrimethoxysilane, (C) octadecyltrimethoxysilane, and (D) (heptadeca-
fluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane.  
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greatest χ   achievable is ~4 µmol/m2 when grafting a monofunctional amine onto TEOS 
particles in ideal conditions (i.e., anhydrous and singly hydrolyzable silane).11  This number 
is decreased for hybrid silica particles as the number of surface silanols is reduced compared 
to particles synthesized from a tetraalkoxysilane alone.  The %C as determined by CHN 
elemental analysis of unmodified AHAP, ethyl-AHAP, isobutyl-AHAP, octadecyl-AHAP, 
and heptadecafluoro-AHAP was 15.69, 15.14, 15.42, 15.66, and 15.35%, respectively.  The 
lack of significant changes in the %C following surface grafting appears to be the result of 
the larger carbon content of AHAP prior to surface modification.  Since the addition of 
organic groups to the particle surface did not significantly change their carbon content per 
mass, Eq 3.1 could not be used to calculate surface coverage for our particles.   
 Solid-state nuclear magnetic resonance (SS NMR) spectroscopy with direct 
polarization and magic angle spinning (DP/MAS) was used to confirm the presence of 
surface-bound ligands.  Previous reports have shown that organosilanes bound to the surface 
of silica nanoparticles can be observed using SS NMR.12  As shown in Figure 3.3A, the 
peaks obtained from SS 13C NMR of unmodified AHAP were broad and difficult to evaluate 
quantitatively.  In general, the peaks obtained from SS NMR are broader than those obtained 
from liquid samples due to the decreased mobility of ligands attached to a solid compared to 
those freely moving in solution.13  The rigid structure of the nonporous particles that result 
from the Stöber synthesis further limits the mobility of the ligands, resulting in the broad 
peaks shown in Figure 3.3.  The chemical shifts of carbon-bound carbons in AHAP were 
between 20–35 ppm, and silicon-bound carbons appeared at 12 ppm.  Carbons bound to the 
secondary amine appeared at 51 ppm, and carbons bound to the primary amine at 42 ppm.  
Unfortunately, the chemical shifts of the alkyl surface groups overlapped with those of
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Figure 3.2  Scanning electron micrographs of (A) unmodified AHAP (d=148±23 nm), (B) 
ethyl-AHAP (d=146±22 nm), (C) butyl-AHAP (d=144±18 nm), (D) octadecyl-AHAP 
(d=152±17 nm), and (E) heptadecafluoro-AHAP (d=152±22 nm).  Scale bar = 1 µm. 
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AHAP carbons, which were broader and of a larger intensity (Figure 3.3B–F).  Thus, no 
quantitative information could be gleaned from the DP/MAS experiments.  Of note, the 
presence of the surface groups was indicated by a decrease in the intensity of the AHAP peak 
at 21 ppm and broadening of the shoulder peak at 24 ppm.  Furthermore, the fluorine-bound 
carbons were apparent in the SS 13C NMR spectrum of heptadecafluoro-AHAP at 110 ppm.  
Solid-state 19F NMR of the heptadecafluoro-AHAP confirmed the addition of the fluorinated 
ligand (Figure 3.4).  The peaks in the 19F NMR were more narrow than those in the 13C 
spectra because the fluorinated ligands are only on the particle surface and therefore have 
greater mobility.  Fluorines attached at the terminal carbons were confirmed by the presence 
of peaks at -85 and -86.9 ppm, with fluorines at the C2 position appearing at -130 ppm and 
fluorines at the C3-C8 positions appearing at -125 ppm.   
X-ray photoelectron spectroscopy (XPS) was employed to more conclusively confirm 
the presence of the alkylsilanes (i.e., ethyl, butyl, and octadecyl) on the particle surface.  
Although XPS is traditionally used to observe chemical environments on flat surfaces, this 
technique has more recently been used investigate the surface modifications of silica 
particles.14  In addition to identifying the types of elements present in a sample, XPS analysis 
can also provide semi-quantitative data regarding the relative amounts of chemical species 
present on or near the surface.15  Table 3.1 lists the atomic concentrations obtained from XPS 
analysis of unmodified and surface-modified AHAP.  To more directly evaluate the addition 
of surface-bound ligands, the number of carbons was normalized to nitrogens, as the nitrogen 
concentration should not change with surface modification.  As expected, the C/N ratio was 
greater for all surface-modified particles compared to that of the unmodified AHAP.  The 
addition of ethyl- or isobutyltrimethoxysilane resulted in an increase in C/N from 5.91
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Figure 3.3  Solid state direct polarization-magic angle spinning (DP-MAS) 13C NMR 
spectrum of (A) unmodified AHAP and (B) ethyl-, (C) butyl-, (D) octadecyl-, and (E) 
heptadecafluoro-AHAP silica nanoparticles.  
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Figure 3.4 Solid state direct polarization-magic angle spinning (DP/MAS) 19F NMR 
spectrum of heptadecafluoro-AHAP silica nanoparticles. 
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 (AHAP) to 7.29 and 9.30, respectively.  The C/N ratio of the octadecyl-AHAP was slightly 
less than that of the isobutyl-AHAP, indicating that a fewer number of 
octadecyltrimethoxysilanes were condensed onto the particle surface, as predicted by Eq. 3.1 
for ligands of larger MW.  The heptadecafluoro-AHAP were characterized by the greatest 
C/N ratio (12.02), even though this ligand is also characterized by a large MW.  Thus, sterics 
alone are not the only ligand-dependent factor governing surface coverage.  The increased 
C/N of heptadecafluoro-AHAP suggests that solubility may also influence the extent of 
condensation onto the particle surface.  As fluorocarbons have a lower solubility in toluene 
compared to hydrocarbons,16 it may be more favorable for the fluorocarbon-based silane to 
condense on the particle surface than remain in solution. 
Dynamic light scattering (DLS) was used to evaluate the extent to which the 
hydrophobicity of the particles was affected by surface modification.  Traditionally, DLS is 
used to determine the hydrodynamic radius of particles by focusing a laser on a sample of 
particles in solution and detecting the scattered light;17 however, information regarding how 
particles behave in solution can also be elucidated from DLS analysis.18  For example, the 
extent to which particles aggregate or sediment in solution may be characterized using the 
sample count rate, a parameter extracted from the number of photons detected per second.17  
A decrease in count rate would result from particle sedimentation as fewer particles would be  
suspended in solution and scatter light.  Suspensions of unmodified and surface-modified 
AHAP were prepared at equal concentrations (0.5 mg/mL) in PBS to assess the impact of 
hydrophobicity on particle behavior.  The count rate of unmodified AHAP remained constant 
throughout the experiment, indicating the particles formed a stable suspension in PBS.  The 
addition of hydrophobic ligands to the surface of AHAP decreased the derived count rate,
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Table 3.1  Atomic concentrations (%) and C/N ratios of unmodified AHAP and surface-
modified AHAP silica nanoparticles as determined with X-ray photoelectron spectroscopy 
(XPS).  
 Atomic Concentrations 
C/N 
 C 1s N 1s O 1s Si 2p F 1s  
AHAP 41.74 7.06 34.10 16.50 - 5.91 
Ethyl-AHAP 42.64 5.85 32.6 16.26 - 7.29 
Isobutyl-AHAP 43.23 4.65 24.14 11.35 - 9.30 
Octadecyl-AHAP 46.62 5.85 29.39 16.32 - 8.12 
Heptadecafluoro-AHAP 34.39 2.86 16.82 10.28 34.65 12.02 
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indicating such particles were less stable in aqueous media (i.e., PBS) compared to control 
(unmodified) AHAP particles (Figure 3.5).  As expected, the relative hydrophobicity of the 
particles increased in relation to the hydrophobicity of the surface-grafted ligand as 
determined by decreasing count rates.  
 
3.3.2  N-diazeniumdiolate modification 
A number of solvents and bases were evaluated to determine the solution conditions 
that would allow for the greatest amine to NONOate conversion efficiency for the surface-
modified AHAP particles.  A stability test was initially conducted to select an appropriate 
solvent for N-diazeniumdiolate formation.  Each particle system was suspended via 
sonication in hexane, tetrahydrofuran, N,N-dimethylformamide, or methanol (5 mg/mL) and 
allowed to sit undisturbed for 30 min.  All particle systems were found to be most stable (i.e., 
remain suspended) in methanol (MeOH) or N,N-dimethylformamide (DMF), thus these two 
solvents were selected for N-diazeniumdiolate formation testing.  To facilitate NONOate 
formation, a strong organic base is added to deprotonate the secondary amine and improve its 
nucleophilic character.19  The three bases tested were sodium methoxide, potassium tert-
butoxide, and sodium trimethylsilanolate.  Each particle system was suspended in either 
MeOH or DMF at a concentration of 5 mg/mL with a 3.5:1 equivalent of base to secondary 
amine. Overall, the NO loading was lower when MeOH was used as the solvent compared to 
DMF (Table 3.2).  The Hildebrand solubility parameter of DMF is closer to those of alkanes 
and fluorocarbons than MeOH,20 suggesting increased swelling may occur  in DMF and 
allow greater diffusion of base and NO into the silica network.  Sodium methoxide facilitated 
the greatest conversion efficiency in DMF.  
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Figure 3.5  Derived count rate from dynamic light scattering analysis of unmodified and 
surface-modified AHAP particles (0.5 mg/mL) in phosphate buffered saline.  
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Table 3.2  Amine to N-diazeniumdiolate conversion efficiency of surface-modified AHAP 
particles using sodium methoxide in either a 1:9 mixture of MeOH in DMF or pure MeOH. 
 
  %Econv   
  1:9 MeOH/DMF MeOH 
Ethyl-AHAP/NO 5.6% 1.3% 
Butyl-AHAP/NO 5.4% 1.5% 
Octadecyl-AHAP/NO 3.0% 0.6% 
Heptadecafluoro-AHAP/NO 2.9% 0.1% 
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 The NO release properties of unmodified AHAP/NO and surface-modified 
AHAP/NO are provided in Table 3.3.  Each system reached a maximum instantaneous NO 
concentration ([NO]max) within the first few minutes upon solution immersion, as is 
characteristic of N-diazeniumdiolate NO donors.  This maximum NO level results from the 
initial, fast diffusion of water into the scaffold.  As would be expected, the addition of 
hydrophobic surface ligands decreases the observed [NO]max.  Effects of surface ligand on 
the NO release kinetics were also evident in the NO release half-life (t1/2) data.  As expected, 
the addition of the hydrophobic surface groups increased t1/2 as the diffusion of water into the 
silica scaffold slowed, and the average lifetime of the NONOate functionalities was 
prolonged.  For example, increasing the alkyl chain length of the surface ligand from ethyl to 
butyl and octadecyl caused an increase in t1/2 from 0.3 to 0.5 and 1.1 h, respectively.  
Heptadecafluoro-AHAP exhibited the longest t1/2 of 2.7 h due to the extremely hydrophobic 
properties of fluorocarbons.   
While the addition of hydrophobic groups to the particle surface allowed for tunable 
NO release kinetics, the NO payloads exhibited by the surface-modified AHAP/NO were 
lower than that of unmodified AHAP.  Decreased diffusion of the base into the silica network 
due to the increased surface hydrophobicity would result in decreased NO donor conversion 
efficiency.  These results corroborate those previously observed by Shin et al., in which silica 
particles composed of more hydrophobic aminosilanes exhibited lower amine to N- 
diazeniumdiolate conversion efficiencies.21  Moreover, the total NO payload delivered from 
heptadecafluoro-AHAP was nearly half that of the hydrocarbon-modified systems.  The low 
conversion efficiency suggests the access of the solvated base to amines is even more limited 
for fluorocarbon-modified particles compared to hydrocarbon-modified particles.  Increased
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Table 3.3  Nitric oxide release characterization of unmodified AHAP/NO and surface-
modified AHAP/NO silica nanoparticles, including maximum instantaneous NO 
concentration ([NO]max), time required to reach [NO]max (tmax), total amount of NO released 
([NO]T), and the time required for the systems to release half of [NO]T (t1/2). 
 
 
[NO]max 
ppb/mg 
tmax 
min 
[NO]T 
µmol/mg 
t1/2 
h 
AHAP/NO 1528±86 2.2±0.4 0.279±0.03 0.6±0.04 
Ethyl-AHAP/NO 2861±800 1.2±0.1 0.110±0.004 0.3±0.1 
Isobutyl-AHAP/NO 1624±318 1.4±0.1 0.106±0.02 0.5±0.1 
Octadecyl-AHAP/NO 474±174 2.6±0.3 0.120±0.036 1.1±0.1 
Heptadecafluoro-AHAP/NO 85±2 1.3±0.2 0.051±0.005 2.7±0.2 
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 NO loading with tunable NO release kinetics might be achieved by first forming the 
NONOate moieties throughout the network, then modifying the particle surface.  
3.3.3 Particle-doped electrospun fibers 
 Electrospun polymer fibers have been previously used as tissue engineering scaffolds, 
wound dressings, and implant coatings.8 Imparting NO release to such porous materials may 
further enhance their utility due to the positive role of NO in mitigating the foreign body 
response and improving tissue integration.22-24  Our laboratory has previously reported NO-
releasing electrospun polymer fibers by incorporating small molecule and macromolecular 
NO donors into the fibers.9, 25  While the use of silica particles allowed for a greater range of 
NO release payloads and kinetics compared to the small molecule NO donor, particle 
leaching was observed at levels up to 85% that incorporated within the fibers.25  We 
hypothesized that increasing the surface hydrophobicity of the particle dopants may enhance 
their stability in the hydrophobic Tecoplast fibers.   
The solvent and concentration of the polymer solution, as well as the particle 
concentration, needle diameter, feed rate, applied voltage, and collection distance used in 
these experiments were based on previously optimized experimental parameters.9, 25  
Scanning electron micrographs of the resulting particle-doped fibers are shown in Figure 3.6.  
Ethyl-AHAP/NO and butyl-AHAP/NO are more uniformly incorporated within the fibers 
compared to octadecyl-AHAP/NO and heptadecafluoro-AHAP/NO, which formed large 
aggregates within the fiber mats.  The diameters of octadecyl-AHAP/NO- and 
heptadecafluoro-AHAP/NO-doped fibers were similar to that of the fibers doped with 
unmodified AHAP/NO, which were also not uniformly dispersed throughout the fibers. 
Conversely, the diameters of the ethyl-AHAP/NO- and butyl-AHAP/NO-doped fibers were
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Figure 3.6  Scanning electron microscopy images of Tecoplast electrospun polymer fibers 
doped with 5 wt% (A,F) AHAP/NO (d=318±90 nm), (B,G) ethyl-AHAP/NO (d=353±185 
nm), (C,H) butyl-AHAP/NO (d=427±141 nm), (D,I) octadecyl-AHAP/NO (d=299±101 nm), 
and (E,J) heptadecafluoro-AHAP/NO (d=309±176 nm) silica nanoparticles.  Scale bars = 5 
µm for A–E and 2 µm for F–J. 
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slightly larger, suggesting more uniform particle incorporation increases fiber diameter.   
The stability of the NO-releasing particles within the Tecoplast electrospun fibers was 
evaluated by soaking the fibers in PBS at 37 °C and measuring silicon content in the soak 
solution with ICP-OES after 7 d.  As shown in Table 3.4, unmodified AHAP/NO-doped 
fibers were characterized by 40% particle leaching, which was slightly less than the 59% 
leaching previously reported with 100 nm AHAP silica particles.25  The decrease in particle 
leaching is likely the result of the larger particle diameters (d=150 nm), as increasing particle 
size is known to enhance the stability of particles within electrospun fibers.25  Fibers doped 
with ethyl-AHAP/NO and butyl-AHAP/NO exhibited increased stability, as particle leaching 
decreased to 15% and 11%, respectively.  The addition of the more hydrophobic octadecyl- 
and heptadecafluoro-trimethoxysilane ligands to the particle surface did not alter particle 
leaching from the fibers.  In fact, heptadecafluoro-AHAP/NO were less stable than 
unmodified AHAP/NO as indicated by 55% particle leaching.  These results corroborate the 
morphological data obtained by ESEM that indicated ethyl-AHAP/NO and butyl-AHAP/NO 
were better incorporated within the fibers compared to AHAP/NO, octadecyl-AHAP/NO, 
and heptafluoro-AHAP/NO. 
  Nitric oxide release from the particle-doped Tecoplast electrospun fibers was 
evaluated with chemiluminescent detection (Table 3.3).  In general, increasing the 
hydrophobicity of the particle dopant resulted in lower NO fluxes and prolonged NO release 
durations.  For example, Tecoplast fibers doped with heptadecafluoro-AHAP/NO exhibited 
the lowest [NO]max and longest td.   The total NO released ([NO]T) from the AHAP/NO- 
doped electrospun fibers was nearly double that of the surface-modified particle systems, as 
expected based on the higher NO payload of the unmodified AHAP/NO scaffolds.  The
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Table 3.4 Characterization of Tecoplast electrospun polymer fibers doped with unmodified 
and modified NO-releasing silica particles including nitric oxide release, and particle 
leaching.   
 
Particle Dopant [NO]T
 b
 
(nmol/mg) 
[NO]
 max
c 
(pmol mg-1s-1) 
t
d
d 
(h) 
Particle 
Leachinge  
(%) 
AHAP/NO 13.8±3.1 4.2±1.1 12.9±1.1 40.4±0.3 
Ethyl-AHAP/NO 2.6±0.5 2.7±0.2 10.1±4.1 15.5±0.3 
Butyl-AHAP/NO 2.1±0.2 1.3±0.3 9.0±5.1 11.5±0.9 
Octadecyl-AHAP/NO 8.7±0.2 4.1±0.8 15.3±8.8 42.2±1.5 
Heptadecafluoro-AHAP/NO 2.0±0.9 0.4±0.2 20.9±5.7 55.1±2.3 
a As measured by scanning electron microscopy; b Total nmol NO released per mg of particle as determined by 
chemiluminescent nitric oxide analyzer (NOA); c Maximum instantaneous concentration of NO release as 
measured by NOA; d Duration of NO release; eAs determined by ICP-OES. 
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heptadecafluoro-AHAP/NO-doped fibers had the lowest NO payload, an expected result 
based on the low NO loading of these particles.  Overall, the duration of NO release was not 
significantly influenced by changing particle hydrophobicity; however, heptadecafluoro-
AHAP/NO-doped fibers did exhibit prolonged NO release durations.  Of note, the NO 
release durations of the ethyl-AHAP/NO- and butyl-AHAP/NO-doped fibers were nearly as 
long as that of AHAP/NO-doped fibers even though the modified systems were characterized 
by less than one-fifth of the total NO storage.  The addition of ethyl and butyl groups to the 
particle surface may result in NO-releasing particle-doped electrospun fibers with enhanced 
stability and increased NO release durations.   
 
3.4 Conclusions 
 Due to the concentration dependence of NO’s  therapeutic  activity,  methods  for  tuning  
the NO release kinetics from macromolecular scaffolds are desirable as materials could thus 
be tailored to fit specific applications.  As described herein, the addition of hydrophobic 
ligands to the surface of silica nanoparticles allows for a wide range of NO release kinetics 
(t1/2 = 0.3–2.7 h) without affecting particle size or morphology.  Unfortunately, surface 
modifications with hydrocarbon- and fluorocarbon-based silanes decreased the amine to 
diazeniumdiolate conversion efficiencies.  Future studies should focus on investigating 
whether first forming the N-diazeniumdiolate prior to surface modification will improve NO 
payloads.  The ability to modify particle surface properties broadens the utility of these NO-
releasing systems, as demonstrated by their increased stability as dopants in electrospun 
polymer fibers.  The addition of ethyl and butyl groups to the particle surface improves their 
stability in the fibers with little influence on fiber diameter and NO release kinetics.  Further
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tuning of surface hydrophobicity using octadecyl and heptadecafluoro ligands did not 
enhance dopant stability, suggesting that an optimal hydrophobicity may exist for achieving 
stable polymer composites.  
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 Chapter 4: 
O2-Protected Diazeniumdiolate-Modified Silica Nanoparticles for Extended Nitric 
Oxide Release  
4.1 Introduction 
  Given the proven antimicrobial nature of nitric oxide (NO) and the use of silica 
particles in commercial oral-care products, NO-releasing silica nanoparticles may prove 
useful for combating the plaque bacteria infections that plague dental restorative treatments.  
Indeed, 50–60% of restorative treatments result in secondary caries that necessitate 
replacement of the restoration.1  While dental composites modified with antimicrobial agents 
have been proposed to prolong the life-time of restorative materials, sustained release over 
the course of days–weeks has yet to be achieved.2-4     
The gaseous and reactive nature of NO requires the use of NO donors (e.g., N-
diazeniumdiolates, S-nitrosothiols, and metal nitrosyls) to achieve controlled therapeutic NO 
delivery.5, 6  N-diazeniumdiolate (NONOate) are among the most widely used NO donors as 
they are comprised of two molecules of NO covalently bound to an amine site, thus allowing 
for greater NO payloads compared to donors that store only one molecule of NO per donor 
site (e.g., S-nitrosothiols).  Moreover, the NONOate functionality results in the spontaneous 
generation of NO in physiological solutions via a highly efficient proton-initiated 
decomposition.  While advantageous, the labile nature of N-diazeniumdiolates often hinder 
the preparation of materials with prolonged release durations necessary for promoting 
implant integration.  Modifying macromolecular scaffolds, such as silica nanoparticles, with
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NO donors allows for more localized NO-release payloads and greater tunability of NO-
release kinetics by controlling water diffusion into the scaffold.6  Unfortunately, NO release 
from NONOate-based silica particles remains limited to only days at best.7, 8  The stability of 
the NONOate can be increased by adding a protecting group at the O2-position.  Release of 
NO then requires hydrolytic or metabolic cleavage of the protecting group prior to N-
diazeniumdiolate decomposition.9, 10  Indeed, O2-protected NONOates bound to LMW 
structures exhibit half-lives on the order of days compared to seconds or minutes for 
unprotected analogs.  O2-substituted diazeniumdiolate NO donors have previously been used 
to covalently modify proteins and polymers to yield materials with extended NO release.9, 11, 
12  To date, these structures have not been used to modify silica nanoparticle scaffolds, which 
hold great promise in a wide range of biomedical applications as discussed in Chapter 1.   
The lifetime of dental composites is often shortened due to the formation of plaque 
biofilms that degrade the material, increasing surface roughness and promoting further 
bacterial adhesion.13  Given that silica particles are a major component of commercial dental 
resin composites for strength and abrasion resistance,14 functionalized silica particles are 
excellent candidates to impart antimicrobial properties to the composite. We hypothesize that 
replacing the non-functionalized silica filler particles with silica particles capable of 
sustained NO release may result in improved antimicrobial dental composites with longer 
lifetimes.   
Herein, mesoporous silica nanoparticles were functionalized with an O2-substituted 
N-diazeniumdiolate-modified organosilane synthesized by coupling an alkyl halide 
organosilane with O2-methoxymethyl 1-(piperazin-1-yl)diazen-1-ium-1,2-diolate.  After 
evaluating the release from the resulting scaffolds, the particles were doped into a dental 
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composite resin to yield a new class of antimicrobial restorative materials.  The ability of 
these materials to decrease adhesion and viability of Streptococcus mutans over a 24 h period 
was evaluated in vitro.  
 
4.2 Materials and Methods 
 Tetraethoxysilane, chloropropyltrimethoxysilane, bromopropyltrimethoxysilane, 
iodopropyltrimethoxysilane, N-(6-aminohexyl)aminopropyltrimethoxysilane, and 
tetramethoxysilane were purchased from Gelest, Inc. (Morrisville, PA).  N,N-
dimethylformamide (anhydrous), methanol (anhydrous), acetonitrile (anhydrous), 
tetrahydrofuran (anhydrous), ethanol, and ammonia solution (30%) were purchased from 
Fisher Scientific (Fair Lawn, NJ).  1-Ethoxycarbonylpiperazine, 5.4 M sodium methoxide in 
methanol, anhydrous sodium carbonate, chloromethyl methyl ether, sodium sulfate, 
magnesium sulfate and cetyltrimethylammonium bromide were purchased from Sigma 
Aldrich (St. Louis, MO).  Nitrogen (N2), argon (Ar), and nitric oxide calibration (26.81 PPM, 
balance N2) gases were purchased from National Welders (Raleigh, NC).  Pure nitric oxide 
gas (99.5%) used for N-diazeniumdiolate formation was purchased from Praxair (Sanford, 
NC).  Reagents for the Griess assay (sulfanilamide, N-1-naphthylethylenediamine, and nitrite 
standard) were purchased from Sigma Aldrich (St. Louis, MO).  Distilled water was purified 
using a Millipore Milli-Q UV Gradient A-10 system (Bedford, MA), resulting in a total 
organic   content   of   ≤6   ppb   and   a   final   resistivity   of   18.2   mΩ·∙cm.  Streptococcus mutans 
(ATCC # 25175) was received from American Type Culture Collection (Manasses, VA).  
Estelite   Σ   Quick   (Tokuyama   Dental)   resin-based dental composite was a gift from UNC 
Dental School. 
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4.2.1 Synthesis of mesoporous silica nanoparticles 
Cetyltrimethylammonium bromide (290 mg) was added to 50 mL of a 5 mM solution 
of ammonium hydroxide in Milli-Q-purified water.  The mixture was stirred for 1 h and 
heated to 40 °C to allow micelle formation.  An initial 110 µL aliquot of tetraethoxysilane 
(TEOS) was added to the solution, with subsequent stirring for 5 h.  A second 600 µL aliquot 
of TEOS was then added, and the solution was stirred for an additional 2 h.  The particles 
were then allowed to age without stirring at 40 °C for 24 h.  The resulting mesoporous silica 
nanoparticles were collected by centrifugation at 16,770 g for 20 mins, washed thrice with 
ethanol and dried in vacuo.  The surfactant was removed by stirring the particles in 50 mL 
acidic ethanol (1:9 HCl:EtOH) at 60 °C overnight.   
 
4.2.2 Synthesis of O2-methoxymethyl 1-(4-(3-(trimethoxysilyl)propyl)piperazin-1-yl)diazen-
1-ium-1,2-diolate 
 
O2-Methoxymethyl 1-(piperazin-1-yl)diazen-1-ium-1,2-diolate (MOM-Pip/NO) was 
prepared as previously described.9  Briefly, 10 g of 1-ethoxycarbonylpiperazine was 
dissolved in 30 mL of methanol with 1.167 mL 5.4 M sodium methoxide in methanol.  The 
solution was placed in a Parr stainless steel pressure vessel connected to an in-house NO 
reactor, purged thoroughly with Ar, then pressurized to 10 bar with NO that had been 
scrubbed with KOH.  The pressure was maintained at 10 bar for 2 d, after which it was 
released and the solutions were again purged with Ar to remove unreacted NO.  Cold ether 
was added, and the resulting white precipitate (1) was collected by filtration, washed with 
cold methanol followed by ether and dried in vacuo.  To a slurry of 1 (2.2 g) and anhydrous 
sodium carbonate in tetrahydrofuran (100 mL) was added 0.75 mL chloromethyl methyl 
ether and 1 mL methanol simultaneously and dropwise under nitrogen at 0 °C.  The mixture 
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was then brought to room temperature and stirred overnight.  The reaction was then filtered, 
evaporated to dryness, and taken up in dichloromethane.  The product (2) was dried over 
sodium sulfate, filtered through magnesium sulfate, and evaporated to dryness.  The 
ethoxycarbonyl protecting group was then removed by heating 2 to reflux in 10% ethanolic 
sodium hydroxide for 1 h.  After cooling to room temperature, the ethanol was removed and 
the residue was extracted in dichloromethane, filtered, extracted with aqueous hydrochloric 
acid, washed with dichloromethane, and then made basic with aqueous sodium hydroxide.  
Lastly, the product was extracted with dichloromethane, dried over sodium sulfate and 
filtered through magnesium sulfate.  Removal of dichloromethane yielded MOM-Pip/NO, 
which was further purified by Flash 40 chromatography using a 4x15 cm KP-Sil column and 
an eluent of 10:1 dichloromethane/methanol. 
Hünig’s  base  (0.79  mmol) was added to a solution of MOM-Pip/NO (0.53 mmol) in 1 
mL anhydrous N,N-dimethylformamide.  Chloro-, bromo-, or iodopropyltrimethoxysilane 
(0.58 mmol) was then added, and the reaction was allowed to proceed for 24 h at 60 °C to 
yield O2-methoxymethyl 1-(4-(3-(trimethoxysilyl)propyl)piperazin-1-yl)diazen-1-ium-1,2-
diolate (MOM-Pip/NO-TMS).  N,N-dimethylformamide was removed by vacuum and the 
residue was taken up in THF.  The insoluble HI   salt   of   Hünig’s   base   was   removed   by  
filtration, and the solvent was removed.  The percent yields from chloro-, bromo- and 
iodotrimethoxysilane were 58, 81 and 94% as determined by 1H NMR.  1H NMR (CD3CN)  δ 
0.61 (t, SiCH2), 1.64 (m, SiCH2CH2CH2), 2.57 (t, Si(CH2)2CH2N), 2.83 (t, NCH2CH2N), 3.41 
(s, OCH2OCH3), 3.51 (s, Si(OCH3)3), 3.55 (t, NCH2CH2N), 5.16 (s, OCH2OCH3) ppm.  13C 
NMR (CD3Cl)   δ   6.46   (SiCH2CH2), 12.08 (SiCH2CH2), 50.56 (SiOCH3), 50.97 (CH2NCH-
CHN), 54.48 (OCH2OCH3), 57.07 (CH2NCH2CH2N), 59.94 (SiCH2CH2CH2N), 97.88
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(OCH2OCH3) ppm.  ESI/MS (in CH3CN): 353.08 m/z. 
 
4.2.3  Synthesis of O2-protected diazeniumdiolate-modified silica nanoparticles  
MOM-Pip/NO-TMS was dissolved in 1 mL tetrahydrofuran and added to a 
suspension of 10 mg of MSNs in 9 mL tetrahydrofuran.  The mixture was refluxed overnight, 
and the resulting MOM-Pip/NO-modified MSNs were collected by centrifugation (3645 g, 
10 min), washed twice with tetrahydrofuran, then twice with ethanol.  The particles were 
then dried in vacuo overnight, and stored in a vacuum-sealed container protected from light 
at -20 °C until further use.  
 
4.2.4 Synthesis of unprotected diazeniumdiolate-modified silica nanoparticles 
 Silica nanoparticles composed of N-(6-aminohexyl)-aminopropyltrimethoxysilane 
(AHAP) and tetramethoxysilane (TMOS) were synthesized via a modified Stöber method as 
previously described.15  Briefly, AHAP (1.173 mL) and TMOS (0.708 mL) were mixed and 
added to a solution of ethanol (59.16 mL), water (27.84 mL), and ammonium hydroxide (9.8 
mL).  After 2 h reaction at room temperature, the resulting particles were collected by 
centrifugation (3645 g, 10 min, 4 °C) and washed three times with ethanol.  After drying in 
vacuo, 20 mg of AHAP particles were suspended by sonication in 4 mL of a 1:9 mixture of 
methanol and N,N-dimethylformamide with 50 µL 5.4 M sodium methoxide in methanol.  
The particles suspensions were then purged with Ar and exposed to NO in the same manner
as described above.  After 3 d, the resulting N-diazeniumdiolate-modified silica nanoparticles
 (AHAP/NO) were collected by centrifugation (3645 g, 10 min, 4 °C), washed three times
with ethanol, and dried in vacuo.  
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4.2.5 Characterization 
Total amounts of NO released from the particles were evaluated using the Griess 
assay.  MOM-Pip/NO-modified particles were suspended in oxygenated phosphate buffered 
saline (PBS, pH 7.4) and liberated NO was converted to nitrite (NO2-).  Aliquots of the 
particle suspension were taken at the time points indicated in Figure 4.5.  The particles were 
removed by centrifugation, and 50 µL aliquots of the supernatant were reacted with equal 
volumes of 1 wt% solutions of sulfanilamide and N-1-naphthylethylenediamine.  The 
formation of an azo compound was detected by measuring the absorbance at 540 nm and 
comparing the results to a calibration curve constructed using nitrite standards to determine 
the total NO released from the particles.  Real-time nitric oxide release was monitored using 
a Sievers NOA 280i Chemiluminescence NO Analyzer (Boulder, CO) connected to a 
customized reaction vessel.  Nitric oxide-releasing materials were placed in deoxygenated 
media at 37 °C with NO carried to the analyzer by passing N2 through the solution at a 
constant rate of 70 mL/min.  The analyzer was calibrated with air passed through a NO zero 
filter (0 ppm NO) and a 26.39 ppm NO standard gas (balance N2).   
 Particle size and morphology were characterized using a Hitachi S-4700 Scanning 
Electron Microscope (Pleasanton, CA).  Covalent incorporation of MOM-Pip/NO-TMS onto 
the MSNs was confirmed using solid-state cross-polarization/magic angle spinning 
(CP/MAS) 29Si NMR with a Bruker 360 MHz DMX spectrometer (Billerica, MA) equipped
with wide-bore magnets (triple-axis pulsed field gradient double-resonance probes).  Samples
were packed into a 4 mm rotor (double-resonance frequency of 71.548 Hz) and spun at 10
kHz.  Chemical shifts were determined in parts per million relative to a tetramethylsilane 
external standard.  Nitrogen adsorption/desorption isotherms were obtained using a 
  139 
Micromeritics Tristar II Porosimeter (Norcross, GA) after outgassing the particles at 110 °C  
for 18 h.  The specific surface area was calculated using Brunauer-Emmet-Teller theory.  
Carbon, hydrogen and nitrogen content were determined on a Perkin Elmer CHN/S elemental 
analyzer operated in CHN mode.   
 
4.2.6 MOM-Pip/NO-MSN-doped dental composites 
  Particle-doped resins were prepared by mixing 1.4 mg particles into 138.6 mg resin 
with a spatula.  Particle-doped resins were pressed between glass slides into uniform disks 
with a diameter of 1 cm and a thickness of 0.1 cm.  The composites were cured using a 
Translux Power Blue dental curing light (440–480 nm) from Heraeus Kulzer (South Bend, 
IN). 
 
4.2.7  Bacterial adhesion assay 
 Streptococcus mutans was grown to 108 CFU/mL in BHI broth, centrifuged (3645 g, 
10 min), resuspended in PBS, and diluted to 106 CFU/mL in 10% (v/v) BHI in PBS.  
Particle-doped composite resins were placed in 1.0 mL of 106 CFU/mL and incubated at 37 
°C with gentle shaking.  After 24 h, the composites were removed and rinsed with distilled 
water to remove loosely adhered bacteria.  The composites were then placed in 1.0 mL of 
fresh PBS.  Adhered bacteria were removed by sonication (60 kHz, 10 min).  Complete
removal of adhered bacteria was confirmed by imaging the composites with atomic force
microscopy (AFM).  Aliquots (100 µL) were taken from the resulting bacteria suspensions,
plated on BHI agar nutrient plates, and enumerated after incubating for 48 h at 37 °C.     
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4.2.8  Atomic force microscopy imaging of composites 
Prior to imaging, substrates were gently rinsed in sterile water and allowed to dry 
under ambient conditions.  AFM images were collected in contact mode using an Asylum 
MFP-3D AFM (Santa Barbara California) and Olympus TR400PSA silicon nitride probes.  
At least three 10 µm2 images of each substrate were taken at a resolution of 1024x1024 
pixels and scan speed of 1 Hz.  Root-mean-squared (rms) roughness of substrates was 
determined using MFP-3D software over four 2 µm2 scan regions. 
 
4.3  Results and Discussion 
4.3.1  Synthesis of MOM-Pip/NO-modified mesoporous silica nanoparticles 
While the therapeutic utility of NO-releasing macromolecular scaffolds has been 
proven both in vitro and in vivo,5 the need for prolonged NO release scaffolds (i.e., weeks to 
months) remains a major hurdle.  O2-protected diazeniumdiolates are a promising class of 
NO donors as the functionality is still labile in physiological conditions but with significantly 
increased NO release lifetimes.  Previously, Saavedra et al. described the preparation of 
piperazine-based methoxymethyl (MOM)-protected diazeniumdiolates that could be coupled 
to macromolecular structures through reaction with the free secondary amine on the 
piperazine ring.9  Since this seminal report, piperazine-based MOM-protected scaffolds with 
half-lives up to 3 weeks have been developed.9, 11, 12  Based on the advantages of silica 
nanoparticles for drug delivery, we sought to design a new class of extended NO release 
scaffolds by modifying silica particles with methoxymethyl-protected diazeniumdiolate-
based silanes. 
 The incorporation of O2-protected NONOates into silica nanoparticles first required
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the synthesis of an O2-protected NONOate-modified organosilanes.  As shown in Scheme 
4.1, ethoxycarbonyl piperazine was first N-diazeniumdiolated and subsequently alkylated 
with chloromethyl methyl ether.  Removal of the ethoxycarbonyl group revealed MOM-
Pip/NO with a free secondary amine.  Full details of this synthesis have been previously 
described.9  A methoxymethyl protecting group was selected as it hydrolyzes slowly under 
physiological conditions (pH 7.4).  Other protecting groups have been designed that require 
enzymatic cleavage; however, such methodologies are not suitable for polymer dopants 
where access to enzymes would be low.   
As shown in Scheme 4.2, the MOM-protected NONOate silane was synthesized by 
coupling MOM-Pip/NO with an alkylhalide trimethoxysilane.  Initially, 
chloropropyltrimethoxysilane was chosen as the alkylhalide trimethoxysilane based on a 
previous report describing the coupling of MOM-Pip/NO to poly(vinyl chloride).9  
Acetonitrile, N,N-dimethylacetamide and N,N-dimethylformamide (DMF) were tested as the 
reaction solvent, as each is aprotic and has a dielectric constant sufficient for promoting SN2 
reactions.  After 24 h reaction time at 60 °C, DMF proved to be the best solvent as indicated 
by 1H NMR analysis.  The successful formation of MOM-Pip/NO-TMS was indicated by a 
shift in the piperazine protons alpha to the secondary amine from 3.04 to 2.83 ppm. The 
protons alpha to the halide also shifted from 3.57 to 2.57 ppm upon formation of MOM-
Pip/NO-TMS.  However, the reaction of chloropropyltrimethoxysilane and MOM-Pip/NO 
under these conditions only proceeded to 58% completion.  Thus, the more reactive bromo-
and iodopropyltrimethoxysilanes were tested under the same reaction conditions (DMF, 24
h, and 60 °C).  The reaction of MOM-Pip/NO with bromopropyltrimethoxysilane went to 
81% completion, while reaction with iodopropyltrimethoxysilane resulted in a near complete
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Scheme 4.1 Synthesis of O2-methoxymethyl 1-(piperazin-1-yl)diazen-1-ium-1,2-diolate 
(MOM-Pip/NO).9 
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Scheme 4.2  Synthesis of O2-methoxymethyl 1-(4-(3-(trimethoxysilyl)propyl)piperazin-1-
yl)diazen-1-ium-1,2-diolate (MOM-Pip/NO-TMS).  
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 reaction (94%) due to the superior leaving group ability of the iodo group.  The successful 
formation of MOM-Pip/NO-TMS was also confirmed with ESI mass spectrometry.  Excess 
Hunig’s  base  was  used   to   stabilize   the  MOM protecting group, which is unstable in acidic 
solutions.  The stability of the MOM protecting group was confirmed by monitoring the 
singlet at 5.16 ppm that corresponds to the protons of the terminal methyl group.   
As discussed in Section 1.1.1, the incorporation of organic functionalities onto silica 
nanoparticles can be achieved via a modified Stöber or a surface grafting method.  Although 
the Stöber method results in particles with the organosilanes incorporated throughout the 
entire particle, large organosilane concentrations often result in less control over particle size 
distribution and morphology.  Moreover, large sterically hindered organosilanes restrict the 
polycondensation reactions required for uniform particle formation.7  Alternatively, the 
surface-grafting method involves condensing organosilanes with surface silanols on 
preformed particles.16  Typically, the preformed particles are synthesized from 
tetraalkoxysilane precursors, allowing for more uniform particles to be easily achieved.  
Particles with large organosilane concentrations can be prepared using mesoporous silica 
nanoparticles (MSN) due to their large specific surface area.  Mesoporous silica 
nanoparticles are synthesized using micellular structures as templates for silica 
polymerization (Figure 4.1).17  Upon hydrolysis, the silicate species bind to the surfactant 
molecules at the micelle interface through electrostatic interactions.  Condensation of silicate 
species ensues, ultimately resulting in particle formation.  The surfactant molecules are then 
removed using an acid wash to yield mesoporous silica particles.  Numerous reports have 
demonstrated the ability to modify particle morphology by altering reaction conditions such 
as pH, temperature, and silane concentration.18, 19  For example, increasing reaction
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Figure 4.1  Synthesis of mesoporous silica nanoparticles (MSNs) involves the condensation 
of silane precursors around micelle structures to yield porous silica nanoparticles.  Following 
surfactant removal, organosilanes can be condensed onto the MSNs through reaction with 
surface silanols. 
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temperature has been found to increase the aspect ratio of the resulting silica particles, while 
increasing alkalinity results in increased aspect ratio and improved monodispersity.20  The 
reaction conditions used here (i.e., pH 11 and 40 °C) resulted in monodisperse rod-shaped 
silica nanoparticles with an aspect ratio of 3 (Figure 4.2).  Using Brauner-Emmett-Teller 
analysis of nitrogen adsorption-desorption isotherms, the MSNs were found to have a 
specific surface area of 1145 m2/g.  
 O2-protected diazeniumdiolate-modified silica particles were subsequently prepared 
by condensing MOM-Pip/NO-TMS onto the MSNs (Figure 4.1).  The successful addition of 
the MOM-Pip/NO-TMS into the silica network was confirmed using solid state 29Si nuclear 
magnetic resonance spectroscopy (SS 29Si NMR) with cross polarization and magic angle 
spinning (CP/MAS).  As shown in Figure 4.3, the resulting SS 29Si NMR spectra consisted of 
two peaks at -110 and -60 ppm corresponding to the Q-band and the T-band, respectively.  
The Q-band results from 29Si bound to four functionalizable groups, representing silicon 
atoms originating from the TEOS precursor.21  The T-band results from 29Si bound to three 
hydrolyzable groups, corresponding to the MOM-Pip/NO-TMS precursor.21  Elemental 
analysis further confirmed MOM-Pip/NO-TMS modification as indicated by an increase in 
the carbon wt% from 8.97 to 17.26% and nitrogen wt% from 0.31 to 6.77%.  Of note, the 
small carbon content present within the particle prior to modification is likely due to 
unreacted ethoxy ligands.  The elemental analysis results indicate that 1.2 µmol MOM- 
Pip/NO-TMS were incorporated per mg of MSNs, which is comparable to the organosilane
concentrations of previously reported amine-modified silica nanoparticles prepared via the 
Stöber method.7  The stability of the MOM-Pip/NO moiety during the functionalization step 
was confirmed by the presence of an absorbance maximum in the UV-Vis spectrum at ca.
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Figure 4.2 Scanning electron micrographs of mesoporous silica nanoparticles synthesized 
via a surfactant templated approach.  
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Figure 4.3  Solid state CP/MAS 29Si NMR spectrum of MOM-Pip/NO-modified MSNs.  The 
T-band (ca. -60 ppm) indicates silicon atoms bound to three oxygens (i.e., MOM-Pip/NO-
TMS), and the Q-band (ca -100 ppm) represents silicon atoms bound to four oxygens (i.e., 
TEOS). 
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 220 nm (Figure 4.4), which is within the range of that reported for O2-protected 
diazeniumdiolates.9  The addition of MOM-Pip/NO-TMS did not affect particle size or 
morphology as determined by SEM. 
Nitric oxide storage and release from the MOM-Pip/NO-modified particles were 
evaluated by elemental analysis and the Griess assay, respectively.  The MOM-Pip/NO-
modified particles were characterized by a total NO payload of 2.4 µmol NO/mg.  As shown 
in Figure 4.5, the rate of NO generation from the MOM-Pip/NO-modified particles was slow 
and continued for several weeks at 0.5–1.0 pmol mg-1 s-1.  The half-life of NO release was 
ultimately determined to be 23 d, which is significantly longer than any other NO-releasing 
silica particle to date.6  The longest previously reported NO release half-life from silica 
nanoparticles was 4.2 h from Stöber silica particles containing N-diazeniumdiolate-modified 
(3-trimethoxysilyl)diethylenetriamine.8  Thus, NO-releasing silica particles with sustained 
NO release was achieved by covalently incorporating an O2-protected N-diazeniumdiolate 
NO donor within the silica network.   
 
4.3.2 Inhibition of bacterial adhesion 
 Nablo et al. previously showed that the release of NO from xerogel-coated silicon 
rubber implants significantly decreases subcutaneous Staphylococcus aureus infections in 
vivo.22  A number of subsequent studies have demonstrated the ability of NO-releasing 
surfaces to decrease the adhesion of both Gram positive and Gram negative bacteria.23-26  To 
date, most evaluations have employed short exposure periods (0.5–2 h) in non-nutrient
conditions, which are less representative of the complex environment present in vivo.  To
assess the utility of MOM-Pip/NO-modified particles as dopants for antimicrobial dental
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Figure 4.4  UV-Vis absorbance spectrum of MOM-Pip/NO-modified particles with an 
maximum absorbance at 220 nm indicating the presence of the MOM-protected 
diazeniumdiolates. 
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Figure 4.5 Nitric oxide release from MOM-Pip/NO-MSNs. Total NO storage is 2.5 µmol/mg 
as determined by elemental analysis. 
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 restorative materials, we sought to evaluate the ability of these materials to resist bacterial 
adhesion over 24 h exposure times under nutrient conditions (10 vol% BHI in PBS).  
Streptococcus mutans was chosen as the test microbe as it has been implicated as a causative 
cariogenic bacterium.27   
To evaluate the advantage of the sustained NO release scaffolds, composites doped with 
faster NO-releasing unprotected N-diazeniumdiolate-modified AHAP/NO particles were also 
prepared.  Nitric oxide release from the particle-doped composites was evaluated in 10 vol% 
BHI in PBS over 24 h to mimic the bacterial adhesion assays.  The total NO released from 
MOM-Pip/NO- and AHAP/NO-doped composites in this media was 6.7±0.1 and 19.2±0.04 
nmol, respectively.  As shown in Figure 4.6, the NO release flux from the composites was 
low (0.1–0.4 pmol cm-2 s-1).  This result was attributed to NO scavenging by proteins present 
in the nutrient broth and was not unexpected.28  The NO release from MOM-Pip/NO-doped 
composites continually increased during the 24 h exposure period due to the slow 
decomposition rate of the protected N-diazeniumdiolate.  Conversely, the AHAP/NO-doped 
composites reached a maximum NO flux within the first few minutes, and the NO levels 
gradually decreased over the 24 h exposure time.  Both NO-releasing composites exhibited 
NO fluxes below that previously reported to be the minimum required in inhibit adhesion of 
Gram negative Psuedomonas aeruginosa.23, 24 Despite the low NO release, composites doped 
with 1 wt% MOM-Pip/NO particles were characterized by a 3-log decrease in viable adhered   
bacteria compared to control and AHAP/NO-doped composites (Figure 4.7).  No significant 
decrease in bacterial adhesion was observed between the
undoped control and AHAP/NO-doped composite resins.  Hetrick et al. reported a minimum
flux of 20 pmol cm-2 s-1 required to inhibit adhesion of P. aeruginosa to xerogels films.24  
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Figure 4.6  Nitric oxide release in 10 vol% BHI in PBS from dental composites doped with 1 
wt% AHAP/NO (squares) and MOM-Pip/NO (triangle) particles.  
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 However, Dobmeier and Schoenfisch previously noted a 50% reduction in adhesion of P. 
aeruginosa to xerogel microarrays with lower NO fluxes (1.0 pmol cm-2 s-1).23  Both prior 
studies were conducted in nutrient-free media at <2 h exposure times.  The results presented 
here indicate that the NO flux required to decrease the number of viable bacteria adhered to a 
surface is dependent on the substrate, bacterial strain, and exposure conditions (e.g., time and 
media).  
Atomic force microscopy images were obtained for each composite to ensure that 
differences in adhesion were not a result of changes in surface roughness due to the particle 
dopant (Figures 4.8A–C).  The filler silica particles present in the composite were visible in 
each trace and clearly the major contributor to the surface roughness.  Figure 4.8D provides a 
single 10 µm height trace, illustrating that the surface of each composite is similar regardless 
of the presence or absence of a functionalized particle dopant.  Surface roughness 
measurements also confirmed that the addition of MOM-Pip/NO and AHAP/NO particles did 
not significantly alter the surface topography (Figure 4.8E).  These results suggest that the 
reduction in viable S. mutans adhered to MOM-Pip/NO-doped composites was a result of 
their unique NO release.     
 
4.4   Conclusions
While silica nanoparticles have distinct advantages for the therapeutic delivery of 
NO, limited NO release durations remains a major hindrance for their use in many 
biomedical applications.  Herein, we demonstrated that NO-releasing silica particles with 
sustained NO release could be achieved by employing O2-protected N-diazeniumdiolate 
chemistry.  Indeed, O2-protected N-diazeniumdiolate silane-modified silica particles
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Figure 4.7  Viability of adhered S. mutans to control and particle-doped composites 
following 24 h incubation in 10 vol% BHI in PBS. 
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Figure 4.8  Atomic force micrographs of (A) control, (B), AHAP/NO-doped, and (C) MOM-
Pip/NO-doped composites, (D) representative height trace from center section of each image 
(indicated by horizontal red line), and (E) rms surface roughness determined from four 2 µm2 
areas. 
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exhibited an NO release half-life of 3 weeks, the longest duration achieved from a silica 
particle scaffold to date.  As a result, the potential applications of NO-releasing silica 
nanoparticles can be expanded to those requiring long durations of low NO fluxes. 
The therapeutic utility of MOM-Pip/NO-modified silica nanoparticles was 
preliminarily demonstrated by preparing novel antimicrobial dental composites.  The release 
of NO from the MOM-Pip/NO-doped composites effectively decreased the number of 
adhered viable S. mutans compared to control (undoped) composites.  To evaluate the full 
potential of NO-releasing dental composites, future studies should evaluate longer bacterial 
exposure times and whether NO inhibits plaque biofilm formation.  The effectiveness of 
composites doped with MOM-Pip/NO-modified particles in environments mimicking the 
oral cavity should also be evaluated as the lower pH will result in faster NO release, thus 
potentially influencing bacterial adhesion/viability.  Greater NO payloads may be achieved 
by forming composites with larger NO-releasing silica nanoparticle concentrations.  Indeed, 
unmodified silica particles comprise 70–90 wt% of commercial dental composites to provide 
increased modulus, strength, and abrasion resistance.29  Designing new composites composed 
completely of NO-releasing silica particles may yield improved composites with respect to 
resistance to biofilm formation. The effect of the NO-releasing particle dopants on the 
properties of the polymer composites must be evaluated.  Ultimately, a mixture of
unmodified and modified particles may prove necessary to maintain composite integrity.  
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 Chapter 5: 
Dual-action Antimicrobials: Nitric Oxide Release from Quaternary Ammonium-
Functionalized Nanoparticles 
5.1  Introduction 
With increasing occurrences of microbial antibiotic resistance,1 alternative 
approaches for fighting infections have become necessary.  Co-administering two 
antimicrobials that act via different mechanisms has been shown to significantly reduce 
microbial resistance and often results in synergy where the two agents are more effective in 
combination than when administered alone.2, 3 As such, researchers are developing strategies 
to modify macromolecular scaffolds (e.g., dendrimers, particles, polymers) with multiple 
antimicrobial agents.4-6 For example, macromolecular scaffolds have been designed to 
consist of a permanent antimicrobial characteristic that remains after the depletion of the 
releasable agent.7 
  Long chain quaternary ammoniums (QA) are a popular non-depleting antimicrobial 
component due to their broad-spectrum efficacy, simple structure, and ability to kill bacteria 
with no affect on the QA structure.8  The positively charged ammonium group promotes 
direct interaction with the negatively charged bacterial membrane, causing chemical 
imbalances by replacing essential metal cations.  Simultaneously, the long alkyl chain of 
QAs inserts into the membrane and cause physical damage.  The simple structure of the QA 
functionalities allows for straight forward integration into polymers,9, 10 films,11-13 
dendrimers,14 and particles,8, 15, 16 while still retaining their antimicrobial properties.  
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Unfortunately, tethering QAs to polymers or particles limits their action to only those 
bacteria that come in direct contact with the macromolecule.  Thus, coupling QA 
functionalities  with  a  second  releasable  agent  may  increase  the  materials’  sphere  of  influence  
and benefits from the advantages of the combination therapies discussed above.  Indeed, QA-
functionalized polymers impregnated with releasable silver ions (Ag+) exhibited a wider zone 
of inhibition than QA polymers alone.7, 17  Similarly, Wong et al. reported improved efficacy 
of QA-functionalized layer-by-layer coatings that leached gentamicin against biofilm 
formation.18   
To date, most combination strategies have only been applied to polymeric coatings or 
films.  Silica nanoparticles are well-poised as scaffolds for combination therapies due to their 
high surface area to volume ratio, chemical flexibility, and limited toxicity to mammalian 
cells.19  Our laboratory has demonstrated the broad spectrum bactericidal efficacy of silica 
nanoparticles that actively release nitric oxide (NO),20-22 a gaseous molecule produced 
endogenously as part of the innate immune response.23  Nitric oxide and its reactive 
byproducts decrease bacterial viability via both lipid peroxidation and reaction with 
membrane proteins, DNA, and metabolic enzymes.23  The key advantage of employing NO 
over other releasable   agents   (e.g.,   silver   and   antibiotics)   involves   NO’s   multimodal  
antimicrobial activity and low toxicity to mammalian cells at concentrations necessary for 
antimicrobial action.24  Furthermore, initial studies suggest the inability of bacteria to 
develop resistance to nanoparticle-derived NO.25  To date, the potential of NO-based 
therapeutics is evident in the immense research efforts focused on designing NO-releasing 
macromolecular scaffolds for biomedical applications.26,27  
The storage of exogenous NO within silica nanoparticles is achieved by forming N-
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diazeniumdiolate NO donors on secondary amine sites incorporated within the silica network 
(Scheme 5.1).22, 28  Upon exposure to physiological solution (pH 7.4, 37 °C), the N-
diazeniumdiolates undergo proton-initiated decomposition to release two molecules of NO 
per secondary amine site.  Moreover, the rate of NO release is dependent on the NO donor 
structure and chemical environment. We hypothesize that the incorporation of long chain 
quaternary ammoniums onto the surface of NO-releasing silica nanoparticles may result in 
increased efficacy compared to singly functionalized particles (i.e., QA or NO release alone).  
Herein, we investigated the role of QA alkyl chain length and NO release capability on the 
bactericidal efficacy against Gram-positive Staphylococcus aureus and Gram-negative 
Pseudomonas aeruginosa.  
 
5. 2 Materials and methods 
Tetramethoxysilane and N-(6-aminohexyl)aminopropyltrimethoxysilane were 
purchased from Gelest (Morrisville, PA).  Glycidyltrimethylammonium chloride, 
epichlorohydrin, dimethylbutylamine, dimethyloctylamine, dimethyldodecylamine, 
trimethylsilanolate, and propidium iodide (PI) were purchased from Sigma Aldrich (St. 
Louis, MO).  N,N-dimethylacetamide, methanol (anhydrous), ethanol, ammonia solution 
(30%) and tetrahydrofuran (anhydrous) were purchased from Fisher Scientific (Fair Lawn, 
NJ).  Media and reagents for bacteria and mammalian cell assays were purchased from 
Becton, Dickinson and Company (Sparks, MD).  Pseudomonas aeruginosa (P. aeruginosa) 
(ATCC #19143) and Staphylococcus aureus (S. aureus) (ATCC #29213) were obtained from 
American Type Tissue Culture Collection (Manassas, VA), and L929 mouse fibroblasts were 
obtained from the UNC Tissue Culture Facility (Chapel Hill, NC).  4,5-Diaminofluorescein
 164 
 
 
 
 
 
Scheme 5.1 Quaternary ammonium (QA) epoxides were synthesized via reaction of 
epichlorohydrin with a dimethylalkylamine and subsequently reacted with the primary 
amines on the surface of AHAP/TMOS particles to yield QA-functionalized silica 
nanoparticles. 
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diacetate (DAF-2 DA) was purchased from Calbiochem (San Diego, CA).  Nitrogen (N2), 
argon (Ar), and nitric oxide calibration (26.81 PPM, balance N2) gases were purchased from 
National Welders (Raleigh, NC).  Pure nitric oxide gas (99.5%) used for N-diazeniumdiolate 
formation was purchased from Praxair (Sanford, NC).  Distilled water was purified using a 
Millipore Milli-Q UV Gradient A-10 system (Bedford, MA), resulting in a total organic 
content  of  ≤6  ppb  and  a  final  resistivity  of  18.2  mΩ·∙cm. 
 
5.2.1 Synthesis of amine-functionalized silica nanoparticles 
The Stöber method was used to form monodisperse, spherical silica nanoparticles 
with amine functionalities throughout the particle scaffold as previously described.29  Briefly, 
a premixed solution of N-(6-aminohexyl)aminopropyltrimethoxysilane (AHAP) (1.173 mL) 
and tetramethoxysilane (TMOS) (0.708 mL) was added to a solution of ethanol (59.16 mL), 
water (27.84 mL), and ammonium hydroxide (9.8 mL).  The reaction was stirred at room 
temperature for 2 h.  The resulting white particle precipitates were collected by centrifugation 
(3645g, 10 min, 4 °C) and washed thrice with ethanol to remove unreacted reagents.  The 
particles were then dried in vacuo and stored in a sealed container at room temperature until 
further use.  
 
5.2.2 Synthesis of quaternary ammonium-functionalized silica nanoparticles 
The addition of QA functionalities to the particle surface involved the synthesis of 
quaternary ammonium epoxides (QA-epoxides) that were then subsequently reacted with 
primary amines on the particle scaffold via a ring opening reaction (Scheme 5.1).  To form 
the QA-epoxides, 0.04 mmol epichlorohydrin was reacted with 0.01 mmol N,N-
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dimethylbutylamine, N,N-dimethyloctylamine, or N,N-dimethyldodecylamine at room 
temperature overnight.  The mixture was added dropwise to cold ether while sonicating, and 
the solid/viscous liquid QA-epoxides were collected via centrifugation (810g, 5 min).  The 
supernatant containing excess epichlorohydrin and unreacted trialkylamines was decanted, 50 
mL fresh cold ether was added, and the QA-epoxides were sonicated extensively.  This 
washing procedure was repeated three times, followed by drying of the QA-epoxides in 
vacuo.  The removal of unreacted epichlorohydrin and trialkylamines was confirmed with 1H 
NMR.  Glycidyldimethylbutylammonium chloride (butylQA) was a viscous liquid: 1H NMR 
δ  0.98  (t,  3  H),  1.41  (m,  2H),  1.70  (m,  2H), 2.79 (dd, 1H), 2.98 (t, 1H), 3.24 (dd, 1H), 3.44 (s, 
6H), 3.52 ppm (m, 1H), 3.63 ppm (dt, 2H), and 4.62 ppm (dd, 1H); 13C  NMR  δ  13.8,  19.9,  
25.5, 45.5, 45.3, 53.1, 65.4, and 66.9 ppm; ESI/MS m/z 158.09. 
Glycidyldimethyloctylammonium chloride (octylQA) was a tacky solid; 1H  NMR  δ  0.87  (t,  3  
H), 1.29 (m, 10 H) 1.71 (m, 2H), 2.74 (dd, 1H), 2.98 (t, 1H), 3.10 (dd, 1H), 3.49 (s, 6H), 3.54 
(m, 1H), 3.67 (dt, 2H), and 4.96 ppm (dd, 1H); 13C  NMR  δ  14.2,   22.9,   23.71,   26.6,   29.4,  
32.02, 45.3, 45.5, 53.1, 65.8 and 66.9 ppm; ESI/MS m/z 214.16. 
Glycidyldimethyldodecylammonium chloride (dodecylQA) was a waxy solid; 1H   NMR   δ  
0.87 (t, 3 H), 1.27 ppm (m, 18H), 1.70 ppm (m, 2H), 2.74 ppm (dd, 1H), 2.98 ppm (t, 1H), 
3.08 ppm (dd, 1H), 3.54 ppm (s, 6H), 3.58 ppm (m, 1H), 3.65 (dt, 2H), and 4.97 ppm (dd, 
1H); 13C  NMR  δ  14.2,  23.1,  23.7,  26.5,  29.5,  29.7,  29.8,  29.9,  32.38,  45.3,  45.5,  53.1,  65.4,  
and 66.9 ppm; ESI/MS m/z 270.25. The IR spectra were similar for all QA-epoxides with the 
exception of the intensity of the saturated C-H absorbance at 2919 and 2850 cm-1, which 
increased with increasing alkyl chain length. IR (neat): 3019 cm-1 (methyl C-H), 2920 cm-1 
(saturated C-H), 2850 cm-1 (saturated C-H), 1468 cm-1 (methyl C-H), 1267 cm-1 (epoxy ring),
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972 (quaternary ammonium), 909 cm-1 (epoxy ring).   
A ring opening reaction was subsequently performed between the QA-epoxides and 
the primary amines on the surface of the particle scaffolds (Scheme 5.1).  The amine-
containing silica particles (AHAP, 100 mg) were suspended in 2.5 mL N,N-
dimethylacetamide via sonication, and 20 µL triethylamine was added.  The QA-epoxides 
were dissolved in 5 mL N,N-dimethylacetamide and added in excess to the particle 
suspension.  Dissolution of glycidyltrimethylammonium chloride required heating while all 
other QA-epoxides dissolved readily. The reaction was heated to 110 °C and allowed to 
proceed overnight.  The resulting QA-modified particles were collected via centrifugation 
(3645g, 10 min, 4 °C), washed thrice with ethanol and dried in vacuo.  
 
5.2.3  N-Diazeniumdiolation of silica nanoparticles  
Silica particles were loaded with NO by forming N-diazeniumdiolate NO donors on 
secondary amine sites (Scheme 5.2).  Briefly, 20 mg of AHAP/TMOS or QA-modified 
AHAP/TMOS particles were suspended by sonication in 4 mL of tetrahydrofuran, and 
trimethylsilanolate was added in a 3.5-fold excess relative to secondary amines, as 
determined with elemental analysis.30, 31  The particle suspensions were then placed in a 160 
mL Parr general purpose stainless steel pressure vessel with magnetic stirring and connected 
to an in-house NO reactor.  The solutions were flushed 6 times with Ar to remove oxygen 
from the system, then pressurized to 10 bar with NO that had been scrubbed with KOH.  The 
pressure was maintained at 10 bar for 3 d, after which it was released and the solutions were 
again purged with Ar to remove unreacted NO.  The resulting N-diazeniumdiolate-modified 
silica nanoparticles were collected by centrifugation (3645g, 10 min, 4 °C), washed twice
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Scheme 5.2  N-Diazeniumdiolate NO donors were formed on secondary amines within the 
particle scaffold upon exposure to high pressures of NO in the presence of a base (e.g., 
NaOSiMe3).  In the presence of a proton source (e.g., H2O), these NO donors breakdown to 
regenerate the parent amine and two molecules of NO. 
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with a 50:50 (v/v) mixture of 5 mM NaOH and methanol to remove unreacted base and 
byproducts from the particle suspension.  The NO-loaded particles were then washed twice 
with ethanol and dried in vacuo.   
 
5.2.4 Nitric oxide release measurements 
Real-time NO release in deoxygenated PBS (pH 7.4) at 37 °C was monitored using 
Sievers NOA 280i chemiluminescence NO analyzer (NOA, Boulder, CO) connected to a 
customized reaction cell as described previously.32  The absence of nitrite byproducts was 
confirmed by ensuring that total NO concentrations measured from both the Griess assay and 
the NOA were equal.33  Prior to analysis, the NO analyzer was calibrated with air passed 
through a NO zero filter (0 ppm NO) and a 26.39 ppm NO standard gas (balance N2). 
 
5.2.5 Nanoparticle characterization 
The   particles’   zeta   potentials   (i.e.,   surface   charge)  were  measured   using   a  Malvern  
Zetasizer Nano-ZS equipped with a 10 mW HeNe laser (633 nm) and a NIBS® detector at an 
angle of 173°. All samples were prepared at 0.5 mg/mL concentrations in either 10 mM 
NaOH or 10 mM phosphate buffer, sonicated briefly and analyzed at 37 °C.  Phosphate 
buffer (non-saline, pH 7.4) was employed for zeta potential measurements to mimic the 
media used for bactericidal assays because the high ionic contents of phosphate buffered 
saline were found to corrode the folded capillary electrodes.34  Particle size and morphology 
were characterized using a Hitachi S-4700 Scanning Electron Microscope (Pleasanton, CA).  
Carbon, hydrogen and nitrogen content were determined on a Perkin Elmer CHN/S elemental 
analyzer operating in CHN mode.  X-ray photoelectron spectroscopy (XPS) analysis was 
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performed on a Kratos Axis Ultra DLD X-ray Photoelectron Spectrometer with a 
monochromatic  Al  Kα  X-ray source (150W).   Electrons were collected at an angle of 90 
degrees from the sample surface from a 300 x 700 µm area on the sample.  The pass energy 
was set to 20 eV to allow for high resolution spectra to be obtained.  All spectra were 
obtained with a step size of 0.1 eV and calibrated to the C1s peak at 284.6 eV. 
 
5.2.6 Bactericidal assays 
P. aeruginosa and S. aureus were cultured in tryptic soy broth to a concentration of 
108 colony forming units per mL (CFU/mL), collected by centrifugation, and resuspended in 
PBS or 1% glucose, 0.5% TSB in PBS, respectively.  Of note, S. aureus was not viable in 
PBS alone after 24 h.  Each bacteria was diluted to 106 CFU/mL and treated with the 
appropriate concentration of QA-modified, NO-releasing, or NO-releasing QA-
functionalized silica nanoparticles.  The samples were briefly sonicated and vortexed in order 
to suspend the particles.  After 24 h of incubating at 37 °C, the particle-treated bacteria were 
spiral plated at 10- and 100-fold dilutions on tryptic soy agar plates.  Bacterial viability was 
assessed by counting the number of colonies formed on the agar plate using a Flash & Go 
colony counter (IUL, Farmingdale, NY). 
 
5.2.7  Confocal microscopy for detection of intracellular NO and cell death 
S. aureus was cultured in TSB to a concentration of 1 × 108 cfu/mL, collected via 
centrifugation (3645g, 10 min), resuspended in sterile PBS, and adjusted to 1 × 106 cfu/mL in 
PBS  supplemented  with  10  μM  DAF-2  DA  and  30  μM  PI.  Aliquots  of  the  S. aureus solution 
were incubated in a glass bottom confocal dish for 45 min at 37 °C. A Zeiss 510 Meta 
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inverted laser scanning confocal microscope with a 488 nm Ar excitation laser (2.0%) and a 
BP 505–530 nm filter was used to obtain DAF-2 (green) fluorescence images. A 543 nm 
HeNe excitation laser (25.3%) with a BP 560–615 nm filter was used to obtain PI (red) 
fluorescence images. The bright field and fluorescence images were collected by a N.A. 1.2 
C-apochromat water immersion lens with a 40× objective. Suspensions (1.5 mL) of 
AHAP/NO (1 mg/mL) or dodecylQA-AHAP/NO (1 mg/mL) particles in PBS (supplemented 
with  10  μM  DAF-2  DA,  30  μM  PI)  were  sonicated  and  immediately  added  to  the  S. aureus 
solution (1.5 mL) in the glass confocal dish. Images were collected every 5 min to observe 
intracellular NO concentrations and bacteria cell death. 
 
5.2.8 In vitro cytotoxicity 
L929 mouse fibroblasts were grown in DMEM supplemented with 10% (v/v) fetal 
bovine serum (FBS) and 1 wt% penicillin/streptomycin, and incubated in 5% (v/v) CO2 
under humidified conditions at 37 oC. After reaching 80% confluency, the cells were 
trypsinized, seeded onto tissue-culture treated polystyrene 96-well plates at a density of 
3×104 cells/mL and incubated at 37 oC for 48 h. The supernatant was then aspirated and 
replaced  with  200  μL  fresh  DMEM  and  50  μL  of  either  control  (AHAP,  methylQA,  butylQA,  
octylQA, dodecylQA) or NO-releasing (AHAP/NO, methylQA/NO, butylQA/NO, octylQA 
/NO, dodecylQA/NO) nanoparticle suspensions in PBS at the determined MBCs against P. 
aeruginosa or S. aureus. After incubation at 37 oC for 24 h, the supernatant was aspirated and 
120  μL  mixture  of  DMEM/MTS/PMS  (105/20/1,  v/v/v)  was  added  to  each  well.  After  1.5  h  
incubation at 37 oC, the solution in each well was transferred to a microcentrifuge tube and 
centrifuged for 2 minutes to remove the silica particles.  Ninety microliters of the supernatant 
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was then added to a clean microtiter plate, and the absorbance of the colored solutions was 
quantified at 490 nm using a Thermoscientific Multiskan EX plate reader. The mixture of 
DMEM/MTS/PMS and untreated cells were used as blank and control, respectively. The cell 
viability was calculated by taking the ratio of the absorbance of treated cells to the 
absorbance of untreated cells after subtracting the absorbance of the blank from both. 
 
5.3 Results and discussion 
5.3.1 Nanoparticle synthesis and characterization 
We have previously reported the synthesis of amine-functionalized silica particles 
capable of variable NO storage and release characteristics.22, 28, 35   For this study, particles 
were synthesized by hydrolyzing and co-condensing N-(6-
aminohexyl)aminopropyltrimethoxysilane (AHAP) and tetramethoxysilane (TMOS) via a 
modified Stöber process.  N-(6-aminohexyl)aminopropyltrimethoxysilane was selected as the 
NO-donor precursor due to its suitability for tethering QA functionalities via primary amines.  
The AHAP particles employed in this study were characterized by a spherical morphology 
and diameters of 180±26 nm as determined by scanning electron microscopy (Figure 1A).  
Dynamic light scattering (DLS) analysis indicated that the particles were monodisperse with 
a polydispersity index (PDI) of 0.07±0.02 and a measured Z-average (190±7 nm), consistent 
with diameters observed with SEM.  Employing a monodisperse particle system is important  
for studying antimicrobial efficacy as particle size has been shown to impact bactericidal 
activity.22 
The AHAP silica particles were modified with QA functionalities via a ring-opening 
reaction between surface primary amines and QA-epoxides (Scheme 5.1).  While
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Figure 5.1  Scanning electron micrographs of (A) AHAP (d=180±26 nm), (B) methylQA 
(d=181±27 nm), (C) butylQA (d=187±23 nm), (D) octylQA (d=185±26 nm), and (E) 
dodecylQA (d=187±24 nm) nanoparticles. Scale bar = 500 nm.  
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glycidyltrimethylammonium chloride is commercially available, earlier work demonstrated 
optimal bactericidal efficacy with long chain QAs.9, 36, 37  Quaternary ammonium-epoxides 
containing longer alkyl chains were thus synthesized by reacting epichlorohydrin with 
dimethylbutylamine, dimethyloctylamine, or dimethyldodecylamine (Scheme 5.1).  The 
formation of the QA epoxides was confirmed with 1H and 13C NMR, IR spectroscopy, and 
ESI mass spectrometry (Appendix B).  A shift in the 1H NMR resonances corresponding to 
the protons alpha to Cl/N and those of the nitrogen-bound methyl groups confirmed the 
formation of the QA epoxide.  Infrared absorbance bands indicating the QA-epoxide 
structure were also observed at 970 cm-1 (QA),38 1267 cm-1 (epoxide ring), and at 2920 and 
2850 cm-1 (saturated CH).  The intensity of the saturated CH absorbance increased with the 
increase in the length of the alkyl chain.   
The addition of QA groups to the particle surface was confirmed by monitoring 
changes in the nitrogen environments (N 1s) using X-ray photoelectron spectroscopy (XPS).  
As shown in Figure 5.2A, the N 1s peak for unmodified AHAP particles was fit with two 
component peaks at binding energies of 399 and 400 eV, corresponding to primary and 
secondary amines, respectively.  The N 1s peak of QA-functionalized particles consisted of a 
third component at 402 eV, representing the quaternary ammonium (Figure 5.2B–E).39  The 
R4N+ peak was most intense for the methylQA-modified particles.  The presence of a peak at 
399 eV for all QA-functionalized particles indicates that not all primary amines at the particle 
surface were functionalized. As expected, the synthetic strategy for QA surface modification 
did not influence particle size or morphology (Figure 5.1B–E).   
Quaternary ammonium functionalization was also verified by observing changes in 
the zeta potentials between AHAP and QA-modified AHAP particles using laser doppler
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Figure 5.2  X-ray photoelectron (XPS) spectra of the N 1s peak of (A) AHAP, (B) 
methylQA, (C) butylQA, (D) octylQA, and (E) dodecylQA nanoparticles.  The presence of 
primary (blue), secondary (green) and quaternary (red) amines are indicated by fitted curves 
at binding energies of 399, 401, and 402 eV, respectively. 
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velocimetry (LDV).  In 10 mM phosphate buffer PB, both unmodified AHAP and QA-
modified particles exhibited a positive zeta potential due to the presence of protonated 
primary amines or positively charged QAs, respectively.  In contrast, the zeta potential for 
the unmodified AHAP particles became negative in basic media (10 mM NaOH), whereas 
the QA-functionalized particles remained positively charged (Table 5.1), indicating the 
presence of a permanent, pH-independent positive charge.  A slight decrease in the zeta 
potential for longer chained QA-modified particles was observed with increasing pH, which 
was also accompanied by a decrease in the derived count rates.  Since all samples were 
prepared at the same concentration using similarly sized particles, the decrease in the derived 
count rate indicates sedimenting particles,40 an expected phenomenon for more hydrophobic 
particles.  Of note, the derived count rate and zeta potential of methylQA particles did not 
change regardless of pH.  Overall, the larger count rates for the QA-modified particles in 10 
mM NaOH suggest the positively charged particles are more stabilized in basic solution due 
to an abundance of negatively charged ions supporting the Stern layer.40   
 
5.3.2 Nitric oxide release analysis 
The silica particles were exposed to high pressures of NO in the presence of a base to 
form N-diazeniumdiolates NO donors (i.e., NONOates) on the secondary amines.  As shown 
in Figure 5.2, NONOate formation was confirmed by an absorbance maximum at 253 nm.20  
Figure 5.2 also depicts the absorbance from non-NO-releasing dodecyl-QA-modified AHAP, 
indicating the absence of the peak at 253 nm prior to exposure to NO.  Of note, no 
absorbance maximum is present at 450 nm following exposure to NO, indicating the 
scaffolds are free of cytotoxic nitrosamines.41   
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Table 5.1  Zeta potential measured from AHAP and QA-modified AHAP particle solutions.  
 
Zeta Potential 
(mV) 
 10 mM NaOH 10 mM PB 
AHAP  -9.4±0.6 20.5±1.0 
MethylQA  24.6±1.9 23.7±1.7 
ButylQA  20.9±0.9 16.8±1.1 
OctylQA  23.0±1.4 11.6±1.4 
DodecylQA  22.8±0.6 19.8±0.6 
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Figure 5.3  UV-Vis absorbance spectra of N-diazeniumdiolate-modified AHAP and QA 
silica nanoparticles.  Unmodified dodecylQA is shown for comparison.  
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Nitric oxide storage and delivery was evaluated by monitoring NO production in real 
time via chemiluminescence.  The addition of QA-functionalities did not influence the amine 
to NONOate conversion as each scaffold released similar NO payloads of ca. 0.3 µmol/mg 
(Table 5.2).  As such, the role of QA alkyl chain length on bactericidal efficacy could be 
elucidated since NO release remained constant.  The Griess assay was used to confirm that 
no nitrite was formed during the NONOate reaction and NO liberation.33  As is typical for 
NONOate-based silica particles,28, 35 the real-time NO release profiles exhibited a maximum 
instantaneous NO concentration ([NO]max) that was achieved shortly after the particles were 
introduced into the solution.  The unmodified AHAP/NO and methylQA/NO were 
characterized as having similar [NO]max values (1388±161 and 1034±32 ppb/mg, 
respectively), whereas  butylQA/NO, octylQA/NO, and dodecyl/NO had lower [NO]max 
(882±36, 791±52, 617±68 ppb/mg, respectively).  The decrease in [NO]max with increasing 
alkyl chain may be attributed to the increased surface hydrophobicity that slows the rate of 
water diffusion into the particle scaffold.  Such behavior was further demonstrated by an 
increase in the time to reach [NO]max (i.e., tmax) with increasing QA alkyl chain length.  The 
NO payloads for each particle system were completely depleted by 24 h. 
 
5.3.3 Bactericidal efficacy 
S. aureus and P. aeruginosa are two of the most commonly isolated species in 
chronic wounds and were therefore selected as the test microbes to evaluate the efficacy of 
the QA-functionalized nanoparticles presented herein.42  We sought to test our nanoparticles 
against both Gram-positive (S. aureus) and Gram-negative (P. aeruginosa) bacteria strains as 
previous work has shown that the potency of both NO- and QA-based
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Table 5.2  Nitric oxide release properties of unmodified and QA-modified silica 
nanoparticles, including total NO release ([NO]T), maximum instantaneous concentration of 
NO ([NO]max), and time to reach [NO]max (tmax). 
 
 
[NO]T 
(µmol/mg) 
[NO]max 
(ppb/mg) 
tmax 
(min) 
AHAP/NO  0.27±0.04 1388±161 1.5±0.2 
MethylQA/NO  0.30±0.03 1034±32 1.8±0.3 
ButylQA/NO  0.27±0.03 882±36 2.3±0.2 
OctylQA/NO  0.28±0.04 791±52 2.9±0.6 
DodecylQA/NO  0.27±0.04 617±68 4.3±0.8 
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antimicrobials depend greatly on the bacterial membrane composition.14, 43  Prior to 
evaluating the bactericidal activity of the dually functional nanoparticles, the efficacy of the 
monofunctional formulations alone (i.e., NO-releasing or QA-functionalized) were evaluated 
to fully understand the benefit of designing a combination approach.   
The AHAP/NO particles proved to be significantly more effective against P. 
aeruginosa compared to S. aureus with MBC24h of 1.5 and 3.5 mg/mL, respectively (Figure 
5.4).  These results are consistent with previously reported N-diazeniumdiolate-based NO-
releasing nanoparticles.21  Conversely, the antimicrobial activity of the QA-functionalized 
particles was greater against S. aureus than P. aeruginosa (Figure 5.4).  Chen et al. also 
reported greater sensitivity of Gram-positive bacteria to QA-based antimicrobials compared 
to Gram-negative bacteria.14  As shown in Figure 5.4, the methylQA particles did not present 
appreciable toxicity to either of the microbes tested.  As expected, the bactericidal efficacy of 
QA-modified particles exhibited a strong dependence on alkyl chain length.  Increasing the 
alkyl chain length from methyl to butyl, octyl and dodecyl resulted in a decrease in MBC24h 
from 4.0, 3.0 and 1.5 mg/mL against S. aureus, respectively.  OctylQA and dodecylQA 
particles were equally effective against P. aeruginosa and more effective than the butylQA 
scaffolds.  Antimicrobial activity of short chained QAs results from the positively charged 
ammonium group complexing with the negatively charged bacterial cell membrane to disrupt 
membrane functions, alter the balance of essential ions (i.e., K+, Na+, Ca2+, and Mg2+), 
interrupt protein activity, and damage bacterial DNA.44  Long alkyl chain QAs can exert 
additional antimicrobial activity by inserting into the bacterial membrane, resulting in 
physical disruption.44  Indeed, longer alkyl chains have been shown to be more effective due 
to deeper penetration into the membrane and concomitant disruption.9, 36, 37     
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Figure 5.4  Minimum bactericidal concentrations (MBC24h) against (A) S. aureus and (B) P. 
aeruginosa for non-NO-releasing (solid) and NO-releasing (hashed) AHAP (red), methylQA 
(green), butylQA (blue), octylQA (magenta), dodecylQA (cyan). Treatment with a 50:50 
(w/w) mixture of dodecylQA and AHAP/NO particles is shown in yellow (hashed). 
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The advantages of combining antimicrobial strategies on the same scaffold have 
previously been demonstrated with QA-functionalized surfaces that release an antimicrobial 
agent, such as silver ion7, 17 or gentamicin.18  Although these releasable therapies are potent 
antimicrobials, resistance concerns plaque their wide-spread use.45, 46  The QA-functionalized 
particles described herein were designed to allow for the release of NO, a broad-spectrum 
antimicrobial with low risk of resistance.25  As shown in Figure 5.4, NO-releasing long chain 
(i.e., octyl and dodecyl) QA-functionalized particles exhibited increased toxicity against S. 
aureus compared to particles functionalized with short chain (i.e., methyl or butyl) QAs or 
NO release alone.  Nitric oxide-releasing AHAP/NO, methylQA/NO, and butylQA/NO were 
equally effective against S. aureus with an MBC24h of 3.5 mg/mL.  Increasing the alkyl chain 
length of NO-releasing QA particles to octyl and dodecyl improved the antimicrobial activity 
with a substantial decrease in MBC24h to 1.5 and 1.0 mg/mL, respectively.  Disruption of the 
bacterial membrane by the long chain QAs may allow for greater oxidative stress due to 
increased intracellular NO levels compared to treatment with AHAP/NO.43  The combination 
of NO release and QA modification (i.e., NO-releasing QA-functionalized particles) did not 
alter the antimicrobial efficacy against P. aeruginosa compared to unfunctionalized NO-
releasing particles (i.e., AHAP/NO).  These results reflect those of the monofunctional 
particles, where the MBC24h of dodecylQA was much greater than that of AHAP/NO against 
P. aeruginosa.   
To prove the advantage of co-treatment with QA-functionalized NO-releasing 
particles, we treated S. aureus and P. aeruginosa to 25% of the MBC24h values of dodecylQA
and AHAP/NO either simultaneous or at 30 min intervals.  Sublethal doses were used to 
avoid complete killing and allow for viable enumeration, and short exposure intervals were 
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used to inhibit the production of new or repaired cells.43  As shown in Figure 5.5, the 
simultaneous addition of the two separate antimicrobial particles resulted in greater 
antimicrobial action against S. aureus than when the microbes were exposed to one agent 
(e.g., AHAP/NO or dodecylQA) followed by the second 30 min later.  In comparison, the 
decrease in P. aeruginosa viability was the same for all combination treatments regardless of 
the addition order.  These latter results were not surprising as the antimicrobial activity of 
NO-releasing dodecylQA was equal to that of NO-releasing AHAP/NO against P. 
aeruginosa.   
Confocal microscopy was used to study the antimicrobial mechanisms of NO-
releasing dodecylQA/NO particles against S. aureus.  DAF-2, a green fluorescent marker for 
intracellular NO, and PI, a red fluorescent marker for a compromised membrane, were used 
to visualize the effects of the NO-release scaffolds on the bacteria.  As shown in Figure 5.7, 
treatment with dodecylQA/NO resulted in red fluorescence and weak green fluorescence 
after 60 min.  Conversely, treatment with AHAP/NO for the same time period resulted in 
strong green fluorescence due to DAF without the presence of red fluorescence.  Thus, the 
QA-functionalities were observed to cause membrane disruption, even before significant 
intracellular NO concentrations were achieved.  As expected, the intensity of the green 
fluorescence increased with incubation time, indicating elevation of the intracellular NO 
concentrations.  Moreover, the faster release kinetics of AHAP/NO compared to 
dodecylQA/NO resulted in greater intracellular NO concentrations at shorter exposure times.  
Small differences in the physical and chemical properties of nanomaterials have been 
shown to greatly influence nanoparticle-cell interactions,47 suggesting that the use of dual 
function nanoparticles may be more favorable than co-administering two different
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Figure 5.5  Change in bacterial viability of (A) S. aureus and (B) P. aeruginosa following 
exposure to sublethal doses of dodecylQA and/or AHAP/NO nanoparticles either 
simultaneously or at 30 min intervals. 
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Figure 5.6  Confocal microscopy images of S. aureus exposed to (A) dodecylQA/NO and 
(B) AHAP/NO particles exhibit green fluorescence due to intracellular NO (DAF) and red 
fluorescence due to compromised membrane (PI). Scale bar = 1 µm. 
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monofunctional nanoparticles.  To investigate the validity of this hypothesis, the MBC24h of a 
mixture of dodecylQA and AHAP/NO (50:50 w/w) particles was also determined.  The 
MBC24h of the dodecylQA+AHAP/NO particle mixture was 2.0 and 3.0 mg/mL against S. 
aureus and P. aeruginosa, respectively.  The NO and QA concentrations of the 50:50 
dodecylQA+AHAP/NO mixture correspond to the same NO and QA concentrations 
delivered from the MBC24h doses of dodecylQA/NO (i.e., 1.0 and 1.5 mg/mL, respectively).  
Thus, combining NO release and QA-functionalities on the same scaffold proved 
advantageous as a lower total dose of particles was required to induce bactericidal efficacy 
compared to treatment with a mixture of two monofunctional particles.   
 
5.3.4 In vitro cytotoxicity 
The ultimate utility of next generation antimicrobials is often governed by their 
toxicity to mammalian cells, assuming adequate microbial killing.  Although long chain 
quaternary ammonium salts have long been used clinically, they are mostly restricted to 
topical applications due to their toxicity against mammalian cells.37, 48  However, tethering 
QAs to a macromolecular scaffold has been shown to decrease their toxicity toward 
eukaryotic cells.48  We thus evaluated the toxicity of QA- and NO-releasing QA-
functionalized particles against L929 fibroblasts cells (Figure 5.7).  Fibroblast cells represent 
the standard for cytotoxicity screening of new antimicrobials due to their involvement in 
wound healing and the immune response.49, 50  The viability of fibroblasts cells was 
monitored via the MTS assay following 24 h exposure to the MBC24h against both S. aureus 
and P. aeruginosa.  Control AHAP particles exhibited significant toxicity at the high particle 
dose of 6.0 mg/mL due to the presence of primary amines.21, 51  Conversion of the primary
 188 
amines to trimethylQA groups caused a significant decrease in the observed cytotoxicity, as 8 
mg/mL of methylQA particles only decreased viability by 40%.  The cytotoxicity of QA-
functionalized particles against fibroblasts at their MBC increased with increasing alkyl 
chain length.  For example, 4.0 mg/mL butylQA, octylQA or dodecylQA-modified particles 
resulted in a 45, 60, and 94% decrease in viability, respectively.   
Due to the lower concentrations of particles required for microbial killing with NO 
release, the cytotoxicity of NO-releasing QA-particles against fibroblast was notably less.  
For example, the 94% decrease in fibroblast viability for 4.0 mg/mL dodecylQA (MBC24h 
against P. aeruginosa) was reduced to only 31% for dodecylQA/NO (MBC24h of 1.5 
mg/mL).  Unexpectedly, the addition of NO release resulted in an increase in cytotoxicity for 
the short-chained QAs, suggesting that lower fluxes of NO may be more biocompatible to 
mammalian cells.  In combination, the decreased cytotoxicity and increased bactericidal 
efficacy of NO-releasing long chain QA-functionalized particles indicate their advantage 
over QA-functionalized particles alone.   
 
5.4 Conclusions 
Quaternary ammonium (QA)-functionalized particles exhibited antimicrobial action 
against both S. aureus and P. aeruginosa, with long alkyl-chain QAs (e.g., octyl and dodecyl) 
proving more potent than short alkyl-chain QAs (e.g., methyl and butyl).  The 
functionalization of particles with both QA groups and NO donors resulted in particles with 
even more favorable antimicrobial activity against S. aureus compared to monofunctional 
QA-functionalized or NO-releasing particles alone.  Conversely, the antimicrobial activity of 
the hybrid particles against P. aeruginosa was unchanged relative to the NO-releasing only
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Figure 5.7  Percent viability of L929 mouse fibroblasts cells following 24 h exposure to non-
NO-releasing (solid) and NO-releasing (hashed) AHAP (red), methylQA (green), butylQA 
(blue), octylQA (magenta), and dodecylQA (cyan) particles compared to control (untreated) 
cells with the numbers corresponding to the MBC24h against S. aureus and P. aeruginosa (in 
mg/mL dose).  
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particles.  Overall, S. aureus was more sensitive to QA particle treatment, while the inverse 
was true for P. aeruginosa (greater sensitivity to NO).  In addition, hybrid NO release/QA-
functionalized particles proved to be more effective at microbial killing than mixtures of NO-
releasing and QA-functionalized particles. The design of scaffolds expressing multiple 
antimicrobial mechanisms of action may represent an important strategy for lowering the 
concentration of therapy required and reducing the risk of potential resistance.  
  
 191 
References
1. Coates, A.; Hu, Y. M.; Bax, R.; Page, C. "The future challenges facing the 
development of new antimicrobial drugs." Nat. Rev. Drug Discov. 2002, 1, 895-910. 
2. Fischbach, M. A. "Combination therapies for combating antimicrobial resistance." 
Curr. Opin. Microbiol. 2011, 14, 519-523. 
3. Allahverdiyev, A. M.; Kon, K. V.; Abamor, E. S.; Bagirova, M.; Rafailovich, M. 
"Coping with antibiotic resistance: Combining nanoparticles with antibiotics and 
other antimicrobial agents." Exp. Rev. Anti. Infect. Ther. 2011, 9, 1035-1052. 
4. Mintzer, M. A.; Dane, E. L.; O'Toole, G. A.; Grinstaff, M. W. "Exploiting dendrimer 
multivalency to combat emerging and re-emerging infectious diseases." Mol. 
Pharmaceut. 2012, 9, 342-354. 
5. Huh, A. J.; Kwon, Y. J. ""Nanoantibiotics": A new paradigm for treating infectious 
diseases using nanomaterials in the antibiotics resistant era." J. Control. Release 
2011, 156, 128-145. 
6. Tashiro, T. "Antibacterial and bacterium adsorbing macromolecules." Macromol. 
Mater. Eng. 2001, 286, 63-87. 
7. Li, Z.; Lee, D.; Sheng, X.; Cohen, R. E.; Rubner, M. F. "Two-level antibacterial 
coating with both release-killing and contact-killing capabilities." Langmuir 2006, 22, 
9820-9823. 
8. Dong, H.; Huang, J.; Koepsel, R. R.; Ye, P.; Russell, A. J.; Matyjaszewski, K. 
"Recyclable antibacterial magnetic nanoparticles grafted with quaternized poly(2-
(dimethylamino)ethyl methacrylate) brushes." Biomacromolecules 2011, 12, 1305-
1311. 
9. Jiang, S.; Wang, L.; Yu, H.; Chen, Y. "Preparation of crosslinked polystryenes with 
quaternary ammonium and their antibacterial behavior." React. Funct. Polym. 2005, 
62, 209-213. 
10. Yao, C.; Li, X.; Neoh, K. G.; Shi, Z.; Kang, E. T. "Surface modification and 
antibacterial activity of electrospun polyurethane fibrous membranes with quaternary 
ammonium moieties." J. Membr. Sci. 2008, 320, 259-267. 
11. Huang, J.; Koepsel, R. R.; Murata, H.; Wu, W.; Lee, S. B.; Kowalewski, T.; Russell, 
A. J.; Matyjaszweski, K. "Nonleaching antibacterial glass surface via "Grafting onto": 
The effect of the number of quaternary ammonium groups on biocidal activity." 
Langmuir 2008, 24, 6785-6795. 
12. Oosterhof, J. J. H.; Buijssen, K. J. D. A.; Busscher, H. J.; van der Laan, B. F. A. M.; 
van der Mei, J. C. "Effects of quaternary ammonium silane coatings on mixed fungal 
and bacterial biofilms on tracheoesophageal shunt prostheses." Appl. Environ. 
Microbiol. 2006, 72, 3673-3677. 
 192 
13. Majumdar, P.; Crowley, E.; Htet, M.; Stafslien, S. J.; Daniels, J.; VanderWal, L.; 
Chisholm, B. J. "Combinatorial materials research applied to the development of new 
surface coatings XV: An investigation of polysiloxane anti-fouling/fouling-release 
coatings containing tethered quaternary ammonium salt groups." ACS Comb. Sci 
2011, 13, 298-309. 
14. Chen, C. Z.; Beck-Tan, N. C.; Dhurjati, P.; van Dyk, T. K.; LaRossa, R. A.; Cooper, 
S. L. "Quaternary ammonium functionalized poly(propylene imine) dendrimers as 
effective antimicrobials: Structure-activity studies." Biomacromolecules 2000, 1, 473-
480. 
15. Song, J.; Kong, H.; Jang, J. "Bacterial adhesion inhibition of the quaternary 
ammonium functionalized silica nanoparticles." Colloids Surf. B 2011, 82, 651-656. 
16. Beyth, N.; Yudovin-Farber, I.; Perez-Davidi, M.; Domb, A. J.; Weiss, E. I. 
"Polyethyleneimine nanoparticles incorporated into resin composite cause cell death 
and trigger biofilm stress in vivo." Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 22038-
22043. 
17. Song, J.; Kang, H.; Lee, C.; Hwang, S. H.; Jang, J. "Aqueous synthesis of silver 
nanoparticle embedded cationic polymer nanofibers and their antibacterial activity." 
ACS Appl. Mater. Interfaces 2012, 4, 460-465. 
18. Wong, S. Y.; Moskowitz, J. S.; Veselinovic, J.; Rosario, R. A.; Timachova, K.; 
Blaisse, M. R.; Fuller, R. C.; Klibanov, A. M.; Hammond, P. T. "Dual functional 
polyelectrolyte multilayer coatings for implants: Permanent microbicidal base with 
controlled release of therapeutic agents." J. Am. Chem. Soc. 2010, 132, 17840-17848. 
19. Lee, J. E.; Lee, N.; Kim, T.; Kim, J.; Hyeon, T. "Multifunctional mesoporous silica 
nanocomposite nanoparticles for theranostic applications." Acc. Chem. Res. 2011, 44, 
893-902. 
20. Hetrick, E. M.; Shin, J. H.; Stasko, N. A.; Johnson, C. B.; Wespe, D. A.; 
Holmuhamedov, E.; Schoenfisch, M. H. "Bactericidal efficacy of nitric oxide-
releasing silica nanoparticles." ACS Nano 2008, 2, 235-246. 
21. Hetrick, E. M.; Shin, J. H.; Paul, H. S.; Schoenfisch, M. H. "Anti-biofilm efficacy of 
nitric oxide-releasing silica nanoparticles." Biomaterials 2009, 30, 2782-2789. 
22. Carpenter, A. W.; Slomberg, D. L.; Rao, K. S.; Schoenfisch, M. H. "Influence of 
scaffold size on bactericidal activity of nitric oxide-releasing silica nanoparticles." 
ACS Nano 2011, 5, 7235-7244. 
23. Jones, M. L.; Ganopolsky, J. G.; Labbe, A.; Wahl, C.; Prakash, S. "Antimicrobial 
properties of nitric oxide and its application in antimicrobial formulations and 
medical devices." Appl. Microbiol. Biotechnol. 2010, 88, 401-407. 
24. Ghaffari, A.; Miller, C. C.; McMullin, B.; Ghahary, A. "Potential application of 
gaseous nitric oxide as a topical antimicrobial agent." Nitric Oxide 2006, 14, 21-29. 
 193 
25. Privett, B. J.; Broadnax, A. D.; Bauman, S. J.; Riccio, D. A.; Schoenfisch, M. H. 
"Examination of bacterial resistance to exogenous nitric oxide." Nitric Oxide-Biol. 
Chem. 2012, 26, 169-173. 
26. Riccio, D. A.; Schoenfisch, M. H. "Nitric oxide release: Part I. Macromolecular 
scaffolds." Chem. Soc. Rev. 2012. 
27. Carpenter, A. W.; Schoenfisch, M. H. "Nitric oxide release: Part II. Therapeutic 
applications." Chem. Soc. Rev. 2012, 41, 3742-3752. 
28. Shin, J. H.; Metzger, S. K.; Schoenfisch, M. H. "Synthesis of nitric oxide-releasing 
silica nanoparticles." J. Am. Chem. Soc. 2007, 129, 4612-4619. 
29. Koh, A.; Riccio, D. A.; Sun, B.; Carpenter, A. W.; Nichols, S. P.; Schoenfisch, M. H. 
"Fabrication of nitric oxide-releasing polyurethane glucose sensor membranes." 
Biosens. Bioelectron. 2011, 28, 17-24. 
30. DeRosa, F.; Keefer, L. K.; Hrabie, J. A. "Nitric oxide reacts with methoxide." J. Org. 
Chem. 2008, 73, 1139-1142. 
31. Reynolds, M. M.; Saavedra, J. E.; Showalter, B. M.; Valdez, C. A.; Shanklin, A. P.; 
Oh, B. K.; Keefer, L. K.; Meyerhoff, M. E. "Tailored synthesis of nitric oxide-
releasing polyurethanes using O2-protected diazeniumdiolate chain extenders." J. 
Mater. Chem. 2010, 20, 3107-3114. 
32. Riccio, D. A.; Nugent, J. L.; Schoenfisch, M. H. "Stober synthesis of nitric oxide-
releasing S-nitrosothiol-modified silica particles." Chem. Mater. 2010, 23, 1727-
1735. 
33. Coneski, P. N.; Schoenfisch, M. H. "Nitric oxide release: Part II. Measurement and 
reporting." Chem. Soc. Rev. 2012. 
34. Clogston, J. D., Ncl method pcc-2: Measuring zeta potential of nanoparticles. 
Nanotechnology Characterization Laboratory, N. C. I., Ed. Frederick, MD, 2009. 
35. Shin, J. H.; Schoenfisch, M. H. "Inorganic/organic hybrid silica nanoparticles as a 
nitric oxide delivery scaffold." Chem. Mater. 2008, 20, 239-249. 
36. Majumdar, P.; Lee, E.; Gubbins, N.; Christianson, D. A.; Stafslien, S. J.; Daniels, J.; 
VanderWal, L.; Bahr, J.; Chisholm, B. J. "Combinatorial materials research applied to 
the development of new surface coatings XIII: An investigation of polysiloxane 
antimicrobial coatings containing tethered quaternary ammonium salt groups." J. 
Combin. Chem. 2009, 11, 1115-1127. 
37. Thorsteinsson, T.; Masson, M.; Kristinsson, K. G.; Hjalmarsdottir, M. A.; 
Hilmarsson, H.; Loftsson, T. "Soft antimicrobial agents: Synthesis and activity of 
labile environmentally friendly long chain quaternary ammonium compounds." J. 
Med. Chem. 2003, 46, 4173-4181. 
38. Beyth, N.; Houri-Haddad, Y.; Baraness-Hadar, L.; Yudovin-Farber, I.; Domb, A. J.; 
 194 
 Weiss, E. I. "Surface antimicrobial activity and biocompatibility of incorporated 
polyethylenimine nanoparticles." Biomaterials 2008, 29, 4157-4163. 
39. Shi, Z.; Neoh, K. G.; Kang, E. T.; Wang, W. "Antibacterial and mechanical properties 
of bone cement impregnated with chitosan nanoparticles." Biomaterials 2006, 27, 
2440-2449. 
40. Malvern Zetasizer nano series user manual. Malvern Instruments, Ltd.: 
Worcestershire, 2007. 
41. Coneski, P. N.; Schoenfisch, M. H. "Competitive formation of N-diazeniumdiolates 
and N-nitrosamines via anaerobic reactions of polyamines with nitric oxide." Org. 
Lett. 2009, 11, 5462-5465. 
42. Bjarnsholt, T.; Kirketerp-Møller, K.; Jensen, P. Ø.; Madsen, K. G.; Phipps, R.; 
Krogfelt, K.; Høiby, N.; Givskov, M. "Why chronic wounds will not heal: A novel 
hypothesis." Wound Repair Regen. 2008, 16, 2-10. 
43. Privett, B. J.; Deupree, S. M.; Backlund, C. J.; Rao, K. S.; Johnson, C. B.; Coneski, P. 
N.; Schoenfisch, M. H. "Synergy of nitric oxide and silver sulfadiazine against gram-
negative, gram-positive, and antibiotic-resistant pathogens." Mol. Pharmaceut. 2010, 
7, 2289-2296. 
44. Simoncic, B.; Tomsic, B. "Structures of novel antimicrobial agents for textiles - a 
review." Text. Res. J. 2010, 80, 1721-1737. 
45. Silver, S. "Bacterial silver resistance: Molecular biology and uses and misuses of 
silver compounds." FEMS Microbiol. Rev. 2003, 27, 341-353. 
46. Mohamed, A. F.; Nielsen, E. I.; Cars, O.; Friberg, L. E. "Pharmacokinetic-
pharmacodynamic model for gentamicin and its adaptive resistance with predictions 
of dosing schedules in newborn infants." Antimicrob. Agents Chemother. 2012, 56, 
179-188. 
47. Wang, J.; Byrne, J. D.; Napier, M. E.; DeSimone, J. M. "More effective 
nanomedicines through particle design." Small 2011, 7, 1919-1931. 
48. Lv, H.; Zhang, S. W.; Wang, B.; Cui, S.; Yan, J. "Toxicity of cationic lipids and 
cationic polymers in gene delivery." J. Control. Release 2006, 114, 100-109. 
49. Lineaweaver, W.; McMorris, S.; Soucy, D.; Howard, R. "Cellular and bacterial 
toxicities of topical antimicrobials." Plast. Reconstr. Surg. 1985, 75, 394-396. 
50. Thelestam, M.; Mollby, R. "Cultured human-fibroblasts as a model for evaluation of 
potential in vivo toxicity of membrane damaging antibiotics." Chem. Biol. Interact. 
1980, 29, 315-325. 
51. Stasko, N. A.; Johnson, C. B.; Schoenfisch, M. H.; Johnson, T. A.; Holmuhamedov, 
E. L. "Cytotoxicity of polypropylenimine dendrimer conjugates on cultured 
endothelial cells." Biomacromolecules 2007, 8, 3853-3859. 
  
Chapter 6: 
Summary and Future Directions 
6.1  Summary 
 The synthesis of NO-releasing silica nanoparticles of various physical and chemical 
properties was thoroughly evaluated and found to impact both NO release properties and 
therapeutic potential.  Chapter 1 reviewed reported methods for designing and synthesizing 
functionalized silica nanoparticles for biomedical applications, with a focus on their use as 
nitric oxide delivery scaffolds.  The introduction served to instruct on the importance of 
specific particle properties on therapeutic outcome and to provide methods for varying 
physical and chemical characteristics of nanoparticles.  In Chapter 2, physical properties 
(e.g., size) of NO-releasing silica nanoparticles was found to greatly influence their 
bactericidal efficacy.  A reverse microemulsion technique was used to achieve particles of 
specific sizes (diameter= 50, 100 and 200 nm) and monodisperse populations (PDI<0.2), 
while maintaining constant chemical composition (i.e., amine content and NO donors).  The 
role of scaffold size on bactericidal efficacy against P. aeruginosa could thus be evaluated by 
delivering equal NO release payloads.  Minimum bactericidal concentrations improved with 
decreasing particle size, while cytotoxicity of both control and NO-releasing particles against 
L929 mouse fibroblasts was not influenced.  Using fluorescently tagged particles, scaffold-
dependent particle-bacterium interactions were observed via confocal microscopy.  Particles 
with smaller diameters associated with bacteria at a faster rate and to a greater
 196 
extent than particles of larger diameters 
 In Chapter 3, methods for achieving tunable NO release kinetics from silica particles 
were described.  The incorporation of hydrophobic groups onto the particle surface resulted 
in prolonged NO release rates due to the slowed diffusion of water into the scaffold.  The 
surface-modified particles exhibited NO release half-lives ranging from 0.3–2.7 h.  
Increasing   the   particles’   surface   hydrophobicity   also   improved their utility as dopants in 
electrospun polyurethane fibers for NO-releasing porous membranes.  Fibers doped with 
ethyl- and isobutyl-modified particles were characterized by 15 and 11% particle leaching, 
compared to the 40% particle leaching observed from fibers doped with unmodified particles.   
 Chapter 4 described an alternative method for achieving NO-releasing silica particles 
with significantly extended NO release kinetics by directly modifying the N-
diazeniumdiolate NO donor structure.  An O2-protected NONOate-based silane was 
synthesized by coupling iodopropyltrimethoxysilane with O2-methoxymethyl 1-(piperazin-1-
yl)diazen-1-ium-1,2-diolate (MOM-Pip/NO).  The MOM-Pip/NO silane was then surface grafted 
onto mesoporous silica particles to yield macromolecular NO release scaffolds with a total 
NO payload of 2.5 µmol NO/mg and an NO release half-life of 23 d.  These particles 
represent the longest NO-releasing silica particles to date.  Nitric oxide-releasing dental 
composites were prepared by doping MOM-Pip/NO particles into polymer resin composites.  
The MOM-Pip/NO-doped composites resulted in a 3-log reduction in viability of adhered 
Streptococcus mutans compared to composites doped with faster NO-releasing AHAP/NO 
particles and undoped controls following 24 h exposure in nutrient conditions. 
 In Chapter 5, a dually functional antimicrobial silica nanoparticle was described with 
both NO release capabilities and quaternary ammonium functionalities.  Quaternary 
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ammoniums were tethered to the surface of AHAP particles through a ring opening reaction 
between synthesized QA-epoxides and primary amines present on the particle surface.  The 
alkyl chain of the QA group was varied to evaluate structure-dependent bactericidal efficacy.  
Butyl-, octyl-, and dodecylQA-functionalized particles induced a 3-log reduction in S. aureus 
at 4.0, 3.0 and 1.5 mg/mL, respectively.  For P. aeruginosa, octyl- and dodecylQA-
functionalized particles caused a 3-log reduction in viability at 4.0 mg/mL, while butylQA-
functionalized required 8 mg/mL.  Imparting NO release from the QA-functionalized 
particles resulted in a decrease in the MBC against S. aureus compared to NO-releasing or 
QA-functionalized particles alone.  The combination of NO and QA on a single particle did 
not result in improved killing against P. aeruginosa.  Confocal microscopy with fluorescent 
markers for intracellular NO (DAF-2) and compromised membranes (propidium iodide) 
indicated the increased efficacy of QA-functionalized NO-releasing particles against S. 
aureus was due to their ability to cause membrane damage followed by delivery of 
intracellular NO.  
 
6.2 Future Directions 
 The first report of N-diazeniumdiolate-modified silica nanoparticles was established 
only 9 years ago.1  Since then, much work has proven the efficacy of these materials as 
cardiovascular, antimicrobial, anticancer, and wound-healing therapies.1-6  Yet, further 
optimization remains to achieve ideal NO-releasing characteristics as different applications 
require specific NO release totals and kinetics.  Our laboratory and others have advanced the 
synthesis of hybrid silica particles to achieve control over both NO release and particle 
characteristics (i.e., size, shape, composition and surface chemistries).  Translation of the 
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silica scaffolds from research laboratories to the clinic will require the efforts of many, 
including those that specialize in the NO chemistry and nanoparticle synthesis and those that 
specialize in the NO biology of particle-cell interactions.  The results described herein still 
represent the beginning steps toward developing fully optimized NO-releasing 
macromolecules for biomedical applications. 
 
6.2.1  Studies to further investigate the role of nanoparticle size 
 In Chapter 1, smaller particles were shown to be more effective against bacteria.  The 
next logical step is to further decrease particle size below 50 nm to determine the optimal 
scaffold size using constant NO loading and release kinetics.  Since prokaryotic cells do not 
express an endocytotic mechanism, the extent of association of the particles to the bacterial 
surface will govern their efficacy and therefore must be understood.  Nanoparticle-bacterium 
interactions could be quantified using flow cytometry or ICP-OES where the amount of silica 
adhered to the cell is determined and translated to the number of associated particles.7  In 
order to use these methods, careful experimental design will be required to ensure non-
adhered particles are washed from the cells prior to analysis.  Atomic force microscopy may 
also be useful to observe nanoparticle-cell interactions, although quantitative analysis would 
be difficult.  Particle size not only governs the rate of an interaction (i.e., diffusion), but also 
the number of particles that can adhere to a particular microbe and the relative percentage of 
those particles’ surfaces that are directly in contact with the bacterium.  Unfortunately, the 
synthesis of monodisperse nanoparticles with diameters less than 50 nm and large organic 
content (i.e., NO loading) is difficult.  As an alternative approach, a surface grafting method 
may be used to incorporate aminosilanes onto commercially available 14 nm TEOS particles 
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(Nissan Chemical Industries, Ltd, Tokyo, Japan).  The exponential relationship between 
nanoparticle surface area and volume suggests that surface-grafted particles of small sizes 
may be capable of releasing NO payloads similar to an equivalent mass of larger particles.   
 To achieve NO release scaffolds of smaller sizes, future work should focus on NO-
releasing dendrimers, which are extremely monodisperse and have diameters as low as 2 nm.  
Sun et al. has recently observed that the MBCs of NO-releasing dendrimers are significantly 
lower than that of NO-releasing particles, albeit with increased toxicity toward mammalian 
cells.8  Confocal microscopy with DAF/PI fluorescent probes indicate that the dendrimers 
result in greater intracellular NO at a faster rate and to a greater extent than the 50 nm 
AHAP/TEOS particles presented in Chapter 2.  In addition to planktonic cultures, the role of 
particle size and shape in the ability of NO-releasing particles to penetrate into biofilms is an 
equally appealing future direction.  Microbial biofilms are difficult to treat due to their 
protective exopolysaccharide matrix.9  The extent to which NO-releasing scaffolds (silica or 
dendrimers) may penetrate the dense network and deliver NO within the biofilm interior 
should be determined to fully understand their antimicrobial efficacy in more clinically 
relevant environments. 
 
6.2.2   Tuning NO release properties 
 For many applications, the short NO release kinetics typically exhibited by 
NONOate-based silica particles is insufficient.  Methods such as those discussed in Chapters 
3 and 4 are thus desirable for increasing the duration of NO release.  While modifying the 
surface of particles with groups of varied hydrophobicity allowed for tunable release kinetics, 
the decreased conversion efficiency of amines to NONOates resulted in low NO payloads.  
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Conversely, greater NO payloads were achieved using MOM-protected NONOates, but the 
release kinetics were not tunable.  While surface modifying particles pre-loaded with 
NONOates may result in formulations with tunable release kinetics and sufficient NO 
payloads, the labile nature of the NONOate groups limits the opportunities for chemical 
modifications on NO-loaded scaffolds.  Other O2-protecting groups have been designed that 
are stable in acidic conditions and labile in basic conditions.10, 11  Thus, particles could be 
loaded with base-labile O2-protected-NONOates, surface modified with hydrophobic 
functionalities, and then deprotected under basic conditions.  This approach would allow for 
greater NO payloads and tunability of NO release kinetics.     
 Lastly, bimodal NO release may be advantageous for wound healing applications 
where high initial doses are necessary to inhibit microbial colonization, while low NO 
concentrations over extended durations are necessary to facilitate proper wound healing (i.e., 
collagen deposition, reepithelialization, etc.).12  To this end, particles modified with 
NONOate stabilized by different methods (i.e., cation and O2-protected) should be 
investigated.  The use of cation-stabilized (i.e., unprotected) NONOates would provide high 
initial NO fluxes, while the inclusion of protected NONOates would deliver low NO fluxes 
for long durations.  As discussed in Section 1.4.1, MSN are excellent candidates for these 
efforts as they contain two separate functionalizable surfaces.  The outer surface can be 
modified prior to surfactant removal, then the inner surfaces can be modified following 
removal of the surfactant from the pores.  Moreover, the silica network comprising the MSN 
may be formed by co-condensing an organosilane with a tetraalkosilane as a means to add a  
third type of  NONOate.  
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6.2.3 Combination therapies 
 Combination strategies are particularly effective for antimicrobial applications as 
exposure to two agents that act via different mechanisms drastically decreases the probability 
for resistance and often results in synergistic activity.13, 14  In Chapter 5, NO release was 
combined with QAs on the same particle scaffold. While QA-functionalization increased the 
bactericidal efficacy of the silica scaffolds, it also resulted in an increase in toxicity towards 
mammalian cells.  The cytotoxicity of long chain QAs is well reported, thus most current 
applications for QA-based materials are topical or non-biomedical (e.g., anti-biofouling 
surfaces for ship hulls).  To decrease the cytotoxic effects, QA-functionalized particles may 
be doped into polymers or resins to impart antimicrobial properties to biomedically relevant 
matrices.  For example, Beyth et al. prepared resins doped with 1 wt% quaternized 
poly(ethylene imine)  nanoparticles and found that their use as dental composites 
significantly decreased the viability of bacteria within biofilm communities with no observed 
impact on biocompatibility in vivo.15  Polymers or resins doped with NO-releasing QA-
functionalized particles would likely still exhibit beneficial antimicrobial properties superior 
to polymers doped with NO-releasing particles alone.  Nitric oxide release from the surface 
would decrease bacterial adhesion, and the presence of QA functionalities may ensure 
decreased viability of those bacteria that did manage to adhere.  As illustrated in Chapter 3, 
leaching of noncovalently incorporated particles may be decreased due to van der Waals 
interactions between the alkyl chains and hydrophobic polymers.   
 Future work should also investigate the design of macromolecular scaffolds that 
combine NO release with other releasable therapies.  Our laboratory previously reported the 
synergistic effects of co-administering ionic silver (Ag+) with a LMW NO donor, 
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PROLI/NO.16 This work suggests that hybrid NO-releasing nanoparticles containing Ag+ or 
silver nanoparticles embedded within the NO-releasing silica nanoparticle may also exhibit 
synergy. Other metallic nanoparticles with proven antimicrobial activity should also be 
investigated, including copper,17-19 zinc oxide,20-24 and titanium dioxide.20, 25, 26  The 
bactericidal properties of metallic nanoparticles arise from the release of metal ions from the 
particle surface, thus their entrapment within a silica network may decrease their efficacy.  If 
this proves to be true, the metallic particles should be tethered to the surface of the silica 
particle.27  In aerobic conditions, NO reacts with O2 to form NOx species that may react with 
the metallic nanoparticles.  X-ray photoelectron spectroscopy could be used to investigate the 
oxidation states present in the metallic nanoparticles initially and after exposure to relevant 
concentrations of NO.  Additionally, the use of combination therapies has been shown to 
increase the sensitivity of microbes to antibiotics to which they had previously developed a 
resistance toward.14  Future work should investigate the efficacy of nanoparticles that release 
both NO and vancomycin against vancomycin-resistant S. aureus, or nanoparticles that 
release NO and methicillin against methicillin-resistant S. aureus.   
 
6.2.4  Improving the anticancer potential of NO-releasing nanoparticles 
Nitric oxide has an intricate role in cancer biology, serving as a tumor regressor at 
high concentrations and a tumor progressor at low concentrations.28  As discussed in Chapter 
1, nanoparticle-derived NO was observed to inhibit the growth of ovarian cancer cells while 
exhibiting low toxicity to normal (i.e., non-tumor) cells.4  While these results are promising, 
the ultimate utility of NO-releasing particles for cancer therapy remains hindered by 
uncontrolled NO release and the undesirable effects that result from the low levels of NO 
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release (i.e., angiogenesis and tumor growth).  For NONOate-based particles, release of the 
NO payload begins immediately upon introduction into aqueous media, limiting the amount 
of NO that can be delivered directly to the cell.  Methods to target the delivery of the NO-
releasing scaffold would significantly increase the percentage of the NO payload delivered 
directly to the tumor site, and in turn improve their efficacy.  Future work in this area should 
involve designing strategies for targeted delivery and triggered NO release.  
The use of magnetic nanoparticles, such as iron oxide, to actively target nanoparticle-
based therapies was discussed in Section 1.1.4.  This technique could be used to target the 
delivery of NO-releasing silica nanoparticles to specific locations in vivo.  Preliminary 
experiments were conducted to prepare magnetic NO-releasing silica nanoparticles by 
forming a hybrid (i.e., aminosilane and tetraalkoxysilane) silica shell around an iron oxide 
core particle.  Iron oxide nanoparticles were synthesized by a thermal degradation method 
according to a previously reported procedure.29  Briefly, iron pentacarbonyl (1.52 mmol) was 
mixed with dioctyl ether (10 mL ) and oleic acid (4.56 mmol).  The translucent yellow 
reaction was heated to reflux, and the formation of the iron-oleate complex as indicated by a 
black color change and confirmed by an absorption maximum at 330 nm.  After formation of 
the iron-oleate complex, the reaction was cooled to room temperature, and 4.56 mmol of 
dehydrated trimethylamine N-oxide was added to control oxidation.  The temperature was 
increased to 240 °C to induce nucleation and further increased to 320 °C to promote 
nanoparticle growth.  The resulting magnetic particles were monodisperse and characterized 
by a diameter of 7 nm particles (Figure 6.1).  X-ray photoelectron spectroscopy (XPS) 
analysis confirmed that the particles were composed of maghemite (Fe2O3) as indicated by 
binding energies of 710.9 eV and 724.7 eV for the Fe 2p3/2 and 2p1/2 electrons,  respectively.30
 204 
 
 
 
 
 
 
 
 
 
Figure 5 TEM micrograph of 7
nm Fe2O3 nanocrytals.
 
 
Figure 6.1  Transmission electron micrograph of Fe2O3 nanocrystals (diameter = 7 nm) 
synthesized via the thermal degradation of iron pentacarbonyl in dioctyl ether and oleic acid.  
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 The presence of a small satellite peak at 719 eV and the absence of a shoulder on the 2p1/2 
peak further supported the identification.   
As synthesized, the iron oxide nanocrystals are capped with hydrophobic oleate 
groups.  However, encapsulation of the Fe2O3 nanoparticles in silica required their dispersion 
in aqueous solution (i.e., interior of micelles or Stöber conditions).  Thus, the surface of the 
nanocrystals was noncovalently modified with a long-chain alkylsilane, as shown in Figure 
6.2.  The non-polar alkyl chains of the silane associate with the oleate chains on Fe2O3 
through van der Waals interactions, leaving the hydrolyzable methoxy groups oriented 
outward.  The resulting n-octyltrimethoxysilane-capped Fe2O3 nanoparticles were then 
suspended in water and added to a reverse microemulsion composed of pentane (organic 
phase), Triton X-100 (surfactant), hexanol (cosurfactant), and water (aqueous phase).  
Subsequent addition of TEOS and 3-butylaminopropyltrimethoxysilane (BAP) to the reverse 
microemulsion resulted in the formation of ~60 nm amine-containing silica particles with 
Fe2O3 cores (Figure 6.3).  Of note, use of other water-miscible aminosilanes, such as MAP 
and AHAP, resulted in a disruption of the emulsion likely because the silanes diffused too 
quickly into the water droplet.   
The amines on the BAP/TEOS-coated Fe2O3 nanoparticles were converted to N-
diazeniumdiolates as described by Shin et al.31  The total NO released was 3.81 nmol/mg, 
indicating that only a low amount of BAP was incorporated into the silica particle.  Greater 
amine incorporation may be achieved with increased aminosilane concentrations or the 
sequential silane addition that was discussed in Chapter 2.  Alternatively, the Stöber method 
could be used to form a silica shell around the Fe2O3 nanocrystals.  By suspending the n-
octyltrimethoxysilane-capped Fe2O3 nanocrystals in a basic aqueous solution under dilute 
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Figure 6.2  The addition of n-octyltrimethoxysilane to the surface of oleic acid-capped Fe2O3 
nanocrystals via van der Waals interactions allows for their stability in aqueous media and promotes 
the formation of a silica shell. 
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Figure 6.3 Transmission electron micrograph of magnetic NO-releasing silica particles composed of 
Fe2O3 core and a BAP/TEOS shell (diameter = 67 nm). 
Figure 7. TEM image of
BAP3/TEOS coated Fe2O3
nanocrystals. d= 66.5 5.1nm.
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 conditions, a silica shell can be added by sequential addition of small amounts of silane 
precursors.  These dilute reaction conditions are required to inhibit nucleation sites that 
would result in the growth of silica particles without an Fe2O3 core.   
While the inclusion of a magnetic particle addresses the need for targeted delivery, 
methods to delay NO release prior to the particle arriving at the tumor site are also necessary.  
One possible method for achieving delayed NO release would be to encapsulate the 
NONOate-based particle within a liposome.  The lipophilic region of the lipid bilayers would 
inhibit diffusion of water to the particle, limiting the decomposition of the NONOate.  Once 
taken up within the cell, the liposome would be ruptured, and the NO would be released to 
the cellular interior.  Modifications to the NO donor moiety may also be studied to prevent 
premature NO release.  Protected O2-NONOates are excellent candidates, especially those 
with protecting groups that are labile in the acidic and/or reducing environments common to 
intracellular compartments.  For example, the MOM protecting group described in Chapter 3 
is labile at low pH.  Other O2-protecting groups are cleaved selectively by intracellular 
species.  For example, O2-[2,4-dinitro-5-[4-(N-methylamino)-benzoyloxy]phenyl]-1-(N,N-
dimethylamino)diazen-1-ium-1,2-diolate (PABA/NO) is a LMW NO donor that features a 
protecting group cleaved upon nucleophilic aromatic substitution by glutathione, allowing for 
intracellular NO release.32 Alternatively, nanoparticles containing tertiary nitrosothiols or 
metal nitrosyls may be promising for antitumor applications as their NO payload would only 
be released upon irradiation with light.33, 34  Triggerable NO release is most ideal to avoid 
extended periods where low levels of NO are released, which might enable in cell
proliferation and tumor growth. 
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6.2.5  Next generation NO-releasing macromolecular scaffolds 
The two primary NO-releasing scaffolds discussed in this dissertation are silica 
nanoparticles and dendrimers.  The main advantage of silica nanoparticles is their relatively 
low toxicity to mammalian cells.35  When normalized by mass however, the NO release from 
silica particles is restricted by the large relative concentration of Si and O that account for 
most of the particle mass.  Larger particle doses (per mg) are thus required to achieve NO 
levels necessary for the intended therapeutic response compared to LMW donors.  
Undesirable cytotoxicity often arises as a result of these large particle doses, negating the 
motivation for employing silica nanoparticles.  Alternative macromolecular scaffolds, such as 
dendrimers, provide greater NO loading per unit mass, but their ultimate success is hindered 
by toxicity to mammalian cells.36   
Next generation NO-releasing scaffolds should incorporate dendrimers within a 
mesoporous silica particle to take advantage of each  scaffold’s positive properties (i.e., high 
NO loading of dendrimers and low toxicity of silica) while minimizing the negative 
properties.  As such, dendrimer-loaded MSNs may be characterized by larger localized NO 
delivery than silica alone and lower toxicity than dendrimers alone.   
Covalently binding dendrimers to mesoporous silica particles has been reported for 
the purpose of gene transfection carriers.37  For these materials, the dendrimers were bound 
to the outer surface of the MSNs to allow for complexing with plasmid DNA.  In future 
work, the dendrimers should also be loaded within the pores of the MSNs to maximize NO 
storage and delivery.  Binding of dendrimers to the particle surface may result in undesirable 
cytotoxicity, in which case the surface of the MSNs could be passivated with an inert 
functionality.  The dendrimers should be restricted to the particle interior following 
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surfactant removal.  Primary amine-terminated dendrimers, such as poly(amido amine) 
(PAMAM) and poly(ethylene imine) (PEI), could be covalently bound to a MSN 
functionalized with glycidylpropyltrimethoxysilane through ring opening reactions similar to 
those used in Chapter 5.  Lower generation dendrimers would provide greater NO release per 
unit mass and may prove easier to load into the mesopores due to their smaller diameter. 
 
6.3 Conclusions 
 The work presented here illustrates the versatility available when employing silica 
nanoparticles for the delivery of nitric oxide for therapeutic applications.  The preceding 
chapters have described methods for tuning both physical and chemical properties of NO-
releasing silica particles.  Although most of the materials described herein were evaluated for 
their antimicrobial efficacy, the broad therapeutic utility of NO suggests NO-releasing silica 
nanoparticles hold potential in other areas including cardiovascular dysfunctions, cancer 
treatment, and wound healing.  Moreover, NO-releasing silica particles may be doped in 
polymer matrices to prepare biocompatible coatings that improve the fate of biomedical 
implants.  The true success of NO-releasing silica particles for any one of these applications 
will require tuning of specific particle and NO release properties.  Thus, the synthetic 
techniques described herein will greatly impact future developments of NO-releasing silica 
nanoparticles. 
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Supplemental Information of Chapter 4 
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Appendix B:  
Supplemental Information of Chapter 5 
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1H NMR of glycidyldimethylbutylammonium chloride.  
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13C NMR of glycidyldimethylbutylammonium chloride 
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1H NMR of glycidyldimethyloctylammonium chloride 
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13C NMR of glycidyldimethyloctylammonium chloride 
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1H NMR of glycidyldimethyldodecylammonium chloride 
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13C NMR of glycidyldimethyldodecylammonium chloride 
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1H NMR of glycidyltridodecylammonium chloride 
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FT-IR spectra of QA-epoxides. 
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Xray photoelectron spectrum of Cl 2p peak for the five particle systems indicating the 
presence of the chloride counter ion in the QA-modified particles.  
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Dynamic light scattering size distribution spectrum for AHAP silica nanoparticles.  
 
 
 
 
Raw correlation data spectra for dynamic light analysis of AHAP (red), methylQA (green), 
butylQA(blue), octylQA (black), dodecylQA (pink) silica nanoparticles at 0.5 mg/mL in 
phosphate buffered saline.  
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Zeta potential distribution spectra of AHAP (pink), methylQA (red), butylQA (green), 
octylQA (blue) and dodecylQA (black) in (A) 10 mM NaOH and (B) 10 mM phosphate 
buffer at 0.5 mg/mL.  
A 
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Phase plots from zeta potential analysis of  AHAP (pink), methylQA (red), butylQA (green), 
octylQA (blue) and dodecylQA (black) in (A) 10 mM NaOH and (B) 10 mM phosphate 
buffer at 0.5 mg/mL. 
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